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PREFACE 
Adrenaline may facilitate platelet reactions in the 
normal haemostatic response and, if increased platelet 
reactivity leads to atherosclerosis, adrenaline could 
thereby contribute to atherogenesis. Adrenaline levels 
rise during stress, and in other risk factor conditions for 
coronary artery desease. The action of adrenaline by 
itself on platelets can be inhibited by cyclooxygenase 
inhibitors, but the ability of adrenaline to potentiate the 
response to other agonists is not completely inhibitable by 
these drugs. The mechanisms of potentiation of platelet 
responses by adrenaline is the subject of this thesis. 
Chapter 1 emphasises the platelet as a subject of 
greater interest in the pathogenesis of atherosclerosis and 
its complications and outlines its structure and functions 
in relation to this. The known effects of adrenaline on 
the platelet, together with current understanding of 
pathways of platelet activation are discussed. Chapter 2 
describes the materials and methods employed in the course 
of the investigations carried out. 
Chapters 3-7 describe the experimental work undertaken 
to investigate some aspects of adrenaline-platelet 
interaction. The exploration of the effects of multiple 
agonists, including adrenaline and noradrenaline, is 
described in Chapter 3. Investigation of the mechanism ( s ) 
of potentiation by adrenaline is commenced by the 
verification in Chapter 4 of previously published evidence 
vi 
that adrenaline stimulates both a prostaglandin-independent 
and a prostaglandin-dependent pathway. 
Chapter 5 reports the unexpected finding of stimulated 
thromboxane formation, by adrenaline, in the presence of 
the phospholipase A2 inhibitors, BPB and TPCK, suggesting 
involvement of adrenaline in arachidonic acid release by a 
pathway not involving phospholipase A2 enzymes. The 
hypothesis is put forward that adrenaline in the presence 
of other agonists stimulates the release of arachidonic 
acid from diacylglycerol by diacylglycerol lipase. 
Chapter 6 examines the characteristics of platelet 
aggregation, release of nucleotide, thromboxane formation 
and phospholipid changes due to exogenous phospholipase C. 
In the presence of BPB, exogenous phospholipase C is 
apparently more active as indicated by the increased 
breakdown of PC, but does not result in further PA 
production, indicating that perhaps diacylglcerol lipase is 
more active in these circumstances. Thrombin-stimulated 
endogenous phospholipase C did not, however, behave in this 
manner in the presence of BPB. 
The possibility was considered that adrenaline 
influences PI turnover and thereby achieves potentiation. 
Studies of phospholipid metabolism were therefore 
undertaken. The effects of adrenaline on ADP- and 
thrombin-induced changes in phospholipids is the subject of 
Chapter 7. The development of a paper chromatographic 
technique for the estimation of PI and PA turnover and 
amounts is reported. 
vii 
Chapter 8 reviews and discusses the findings of 
Chapters 3-7 and attempts to establish hypotheses for the 
mechanism(s) by which adrenaline influences platelets to 
ensure that they respond more effectively to other 
agonists. Phospholipid changes due to adrenaline proved 
difficult to demonstrate. Calcium redistribution was not 
explored in this thesis and there obviously remains, many 
aspects of the adrenaline-platelet interaction which need 
to be investigated. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 HISTORICAL BACKGROUND 
The study of blood platelets commenced over one 
hundred years ago. In the early nineteenth century, as 
microscopes improved, so did the observations of blood 
components. / In 1842, Donne reported smaller 'globules' 
1 
than the red and white elements, although he erroneously 
placed their origins in the lymph. At about the same time, 
two independent English medical practitioners, Gulliver and 
Addison noted minute spherules in the blood. Both these 
men also reported the association of these particles with 
fibrin, and made the first drawings of a platelet-fibrin 
clot. There was still confusion over the existence of 
platelets for several years however, with the result that 
only red and white cells were investigated for involvement 
in coagulation and inflammation. 
With the use of anticoagulants, platelets were more 
easily observed. Zimmerman (1846) repeated the work of 
Simon (1842) to establish the presence of colourless 
bodies, 2-5µ in size but thought they came from the 
lymphatic system and were the origin of the red cell. 
In 1850, Wharton Jones described colourless corpuscles 
incorporated in a mass which adhered to blood vessel walls 
and blocked flow of blood in the web of a frog's foot. 
Through the remainder of the nineteenth century there were 
several more developments concerning the role of platelets 
in clot formation. Osler (1874) illustrated single 
elements in the circulating blood which had the capacity to 
aggregate when the blood escaped from the blood vessel. 
Hayem (1878) added another function for platelets, namely 
'regenerating' the blood after haemorrhage. Bizzozero 
(1882) seems to be the first to have observed circulating 
platelets in living animals, and demonstrated conclusively 
that t_he white portion of thrombi consisted almost 
exclusively of platelets, then called "petites plaques". 
These observations were later confirmed and extended by 
Eberth and Schimmelbusch (1885) and Laker (1889). 
2 
In 1906, Wright determined the genetic relationship of 
the platelet to the megakaryocyte, denying all theories of 
platelets originating from the white cell or as an early 
stage of the red cell. There was still doubt about the 
validity of these early observations, however, until the 
mid-twentieth century. 
Even before the participation of platelets in thrombus 
or haemostatic plug formation was established, mural 
thrombi were thought to be involved in the development of 
atherosclerosis. In 1852, von Rokitansky proposed that 
atheroma resulted from the degeneration of a deposit of 
blood products, largely fibrin. Virchow (1856) and later, 
Hogerstedt and Nemser (1897) proposed that thrombi might 
contribute to the development of atherosclerosis, a theory 
revived in 1936 by Clark, Graef and Chasis and by Duguid 
in 1948. A large part of current work on platelets is 
directed towards determining the mechanism whereby 
platelets and thrombi contribute to the inception and 
progression of atherosclerosis. 
1.2 PLATELET STRUCTURE 
The platelet is normally discoid, 2-4µ in diameter, 
and is formed by the fragmentation of megakaryocyte 
cytoplasm. The circulating platelet count in man is about 
2x10 8 /ml with a turnover rate of about 3.Sx10 7 /ml/day 
(Harker and Finch, 1969). Its structure is far from 
simple. 
1.2.1 The Platelet Surface 
3 
The platelet surface consists of the plasmatic 
atmosphere, an ill-defined cloud of plasma proteins, and 
the plasma membrane proper which resembles that of other 
cells. This membrane possesses several exceptional features 
enabling the platelet to carry out its unique functions. 
The plasmatic atmosphere has not been well characterized 
but it has been proposed as the cause of the observed 
differences in behaviour between platelets in plasma and 
washed platelets in in vitro studies(Ardlie and Han,1974). 
The glycoproteins of the outermost membrane layer, the 
glycocalyx, contribute largely to the responsiveness of the 
platelet. While more than 30 electrophoretically different 
glycoprotein bands have been identified (Berndt and 
Phillips, 1981a) only five have become the subject of 
detailed investigation. The glycoproteins Ib,Ilb,III and IV 
are present in particularly high concentrations. 
Several lines of evidence are consistent with glycoprotein 
Ib/glycocalicin being the thrombin receptor on human 
platelets (Okumura and Jamieson,1976; Okumura et al.,1978 ; 
Ganguly, 1977; Ganguly and Gould, 1979). There is 
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considerable evidence that glycoproteins IIb and III are 
subunits of a single glycoprotein, and together may 
participate in the aggregation process (Phillips et al., 
1980). No biological function has yet been ascribed to 
glycoprotein IV. The distinguishing feature of the single 
chain polypeptide, glycoprotein Vis that it is the sole 
thrombin substrate on the surface of intact, washed human 
platelets (Berndt and Phillips, 1981a,b). Purified 
glycoprotein V behaves as a thrombin substrate equally with 
that on intact platelets (Berndt and Phillips, 1981b,c). 
The plasma membrane is similar to other cell plasma 
membranes in having an apparent trilaminar structure of 
protein and lipid. It differs from oth~r cells in 
possessing many invaginations and 'knobs' (Feagler et al., 
1974) as seen in freeze-etched fixed platelets. The 
membrane extends into the open canalicular system or 
surface connecting system and the inner surface of the 
membrane contains numerous fibrillar structures. 
Compositional analysis of the isolated plasma membrane 
indicates it is composed of 52% lipid, 36% protein and 7% 
carbohydrate which can be divided into two lipoglycoprotein 
subfractions of two different densities (Barber and 
Jamieson, 1970). The 52% lipid is further divided into 42% 
phospholipid and 10% cholesterol. The carbohydrate 
consists of glucose, galactose, mannose, hexosamine, sialic 
acid and fucose. The sialic acid contributes to the 
negative charge on the platelet surface (Seaman and Vassar, 
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1966) and the removal of terminal sialic acid residues fr6m 
membrane glycoproteins and glycolipids by neuraminidase 
slightly enhances platelet responses to aggregating agents 
(Greenberg et al., 1975). 
Phospholipids of platelet membranes include: 
sphingomyelin(SM), phosphatidylcholine(PC), 
phosphatidylethanolamine(PE), phosphatidylserine(PS) and 
phosphatidylinositol(PI). Platelet membranes( including 
outer plasma membrane and membrane from intracellular 
structures such as dense tubular system) contain, relative 
to other phospholipids, more PI and PC than does the 
granule fraction (Marcus et al.,1969). Only minor amounts 
of PS and PE are present at the exterior of the plasma 
membrane, but platelet activation may increase 
accessibility of PE(Schick et al.,1976; Rittenhouse-Simmons 
et al.,1976). Exposure of phophatidylserine by collagen or 
thrombin increases the procoagulant activity of the 
platelet (Bevers et al.,1983) and enhances the conversion 
prothrombin to thrombin. Perret et aL.(1979) published the 
proportions of the phospholipids in the exterior of the 
oµter membrane to be: PC 23%, PE 11%, PI 10%, PS 4.5% and 
SM 70%, using enzymes which hydrolyzed phospholipids 
without causing lysis of the platelets. Phospholipid 
metabolism and its role in platelet function will be 
discussed later (1.5.4). 
Procoagulant activities of platelets, reside in the 
membrane. One of these activities has been termed platelet 
factor 3, and this activity resides in phospholipids(mainly 
6 
phosphatidylserine) on the inside leaf of the bilayer 
membrane(Hemker et al.,1983). Because platelet lipids have 
this role in blood coagulation, and because phospholipids 
have been shown to participate in the aggregation and 
secretion process, platelet lipids are an important subject 
of research in the platelet field. Platelet lipids are 
indeed closely linked to platelet reactivity. The role of 
arachidonic acid metabolism in platelet activation, in 
particular, will be discussed (1.5.3). 
Platelet cholesterol content reflects the initial 
composition of the megakaryocyte from which platelets are 
derived, but there can also be some exchange with 
lipoprotein-cholesterol in the platelet environment 
(Derksen and Cohen, 1973). Platelets cannot synthesize 
cholesterol. Carvalho et al. (1973) found that patients 
with Type II hyperbetalipoproteinemia have enhanced 
platelet responses to adrenaline, collagen and ADP but the 
mechanism for this cholesterol influence has not been 
established. Shattil et al. (1975) found that incubation 
of platelets with cholesterol-rich liposomes raised the 
membrane cholesterol level and increased 35-fold the 
sensitivity of platelets to adrenaline and ADP. 
Correspondingly, a reduction in membrane cholesterol was 
associated with an 18-fold reduction in platelet 
sensitivity to adrenaline. 
Of further interest are the findings of Hassall et 
al.(1983) who established a correlation between low density 
lipoproteins and total cholesterol concentrations with 
sensitivity to aggregation by adrenaline but no other 
agonists. A possible mechanism for the influence of 
cholesterol has been suggested by Kramer et al.(1982) who 
found that elevated platelet cholesterol content affected 
thrombin-induced changes in platelet phospholipids with an 
increased metabolism of [ 3H]arachidonic acid from 
phosphatidylcholine. It is proposed that cholesterol 
affects lipid organization and thus affects phospholipase 
activity for the liberation of arachidonic acid. 
The role of platelet membrane glycolipids in platelet 
function is unknown. Gangliosides and ceramides have only 
been the subject of limited experimentation to date. 
1.2.2. Microfilaments and Microtubules 
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The fibre system of the platelets in the cytoplasm 
supports the discoid shape of unstimulated platelets. 
Electron micrographs show the circumferential band of 
microtubules as marginal bundles with long straight 
sections, possibly under tension (Behnke, 1965; Haydon and 
Taylor, 1965). The bundle of microtubules never directly 
contacts the cell wall of the platelet but forces necessary 
to maintain the discoid shape can be transmitted through 
submembrane filaments (White, 1972a). The discoid shape is 
also regulated by intrinsic properties of the surface 
membrane, by cyclic nucleotides, and by the maintenance of 
high levels of ATP as will be discussed later (1.5.1). 
Platelet stimulation inducing a shape change, is 
accompanied by a contraction of the ring of microtubules 
and microfilaments around tightly packed central organelles 
(White, 1968). In addition, the dense tubular system is a 
calcium sequestering site in platelets, resembling the 
sarcotubules of muscle cells. The channels of the ope~ 
canalicular system, with their specialized microfilaments, 
are similar to the transverse tubules of muscle (White, 
1972b). The platelet therefore has all the contractile 
elements necessary to undergo shape change when required. 
The microtubules and microfilaments are also involved in 
the release reaction of platelets (MacIntyre, 1976). 
1.2.3 Platelet Organelles 
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The cytoplasm of platelets also contains mitochondria, 
a-granules, dense bodies, lysosomes, occasional Golgi 
apparatus and glycogen granules (White and Gerrard, 1978). 
The number of mitochondria in platelets,however, are 
comparatively low. 
Dense bodies contain serotonin, ADP, calcium and 
phosphorus; the last two constituents contribute to the 
electron dense properties of dense bodies (Skaer, 1975). 
The phosphorus is only partially accounted for by ATP and 
ADP. Dense bodies also contain large amounts of 
phospholipid,probably rich in arachidonic acid (Skaer et 
al., 1976). This was suggested by the finding of 
arachidonic acid by autoradiography in a structure regarded 
as a stage in the discharge of dense bodies (Skaer and 
Skaer, 1979). Some of the dense body contents promote 
growth of platelet aggregates, and are released from the 
dense bodies into the platelet environment. Skaer (1981) 
proposed a mechanism involving movement of dense bodies to 
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the surface of the platelet where they distort the 
membrane, fusing with it and then enlarging. The resultant 
spheroid then releases its contents, leaving behind an 
empty shell. 
The a-granules also participate in the release 
reaction. Holme et al. (1973) observed the presence of 
fibrin, and White (1972b) observed nucleoids which 
originated from the a-granules, in the canalicular system 
and concluded that fusion of the a-granule membranes with 
the inner surface of the open canalicular system occurs, 
allowing the contents to diffuse out. The contents include 
fibrinogen, platelet factor 4 (anti-heparin factor), beta-
thromboglobulin and platelet derived growth factor(PDGF). 
Lysosomes contain enzymes including cathepsins, 
glycosidases, a chemotactic factor for leucocytes and a 
cationic protein which increases vascular permeability and 
induces histamine release from mast cells. Lysosomal 
degranulation is a fairly slow process(Holmsen et al.,1969) 
and the mechanism is unclear. These diverse inclusions of 
the platelet and its complex structure enable this cell to 
have many functions. 
1.3 PLATELET FUNCTION 
The smallness of the platelet with respect to the 
other blood cells should not lead to an underestimation of 
its importance. 
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1.3.1 Maintenance of Integrity of the Vasculature 
Gimbrone et al. (1969) found that capillary 
integrity, in isolated perfused organs, was better 
preserved when the perfusate contained intact viable 
platelets in addition to plasma proteins and the necessary 
ions. Thrombocytopenia is associated with an increase in 
capillary fragility. Evidence for the close association of 
platelets with endothelial cells lining capillaries was 
obtained by Johnson (1971) in transfusion studies in 
thrombocytopenic _animals. She found that the transfusion 
of radioactively labelled platelets labelled the 
capillaries of many organs whereas labelled platelet-poor 
plasma did not. Ultrastructural studies confirmed the 
association but could not explain the interaction of 
platelets with endothelial cells. 
The endothelial lining depends on circulating 
platelets for sustained normal functioning, while the 
endothelium protects platelets from activation and 
subsequent aggregation. Tissue culture studies of 
endothelial cells indicate that a platelet factor promotes 
replacement of a partial removal of endothelial cells from 
monolayers. Migration of endothelial cells into the 
damaged area is enhanced by platelet-rich serum (Wall 
et al., 1978) though smooth muscle cell migration is more 
enhanced by platelet factors (Thorgeirsson et al., 1979). 
Mitogenic responses, as determined by tritiated thymidine 
incorporation were increased by platelet-rich serum added 
to pre-confluent monolayers of endothelial cells (Fratkin 
1 1 
et al., 1980). On the other hand, confluent monolayers did 
not respond in agreement with the work of Thorgiersson and 
Robertson (1978). Smooth muscle cells again differed from 
endothelial cells in that they exhibited a mitogenic 
response whilst confluent. The mitogenic factor found in 
serum is the platelet derived growth factor from the a-
granules (Antoniades et al., 1975; Busch et al., 1976; 
Antoniades and Scher, 1977). Platelets probably assist in 
the repair of injured blood vessels by regulating 
endothelial cell and smooth muscle cell growth. This 
facility forms the basis of the response to injury 
hypothesis for atherogenesis( see Section 1 .3.4). 
1.3.2 Inflammation 
Platelets accumulate at sites of tissue damage and 
aid in the inflammatory response by increasing vascular 
permeability and by being chemotactic for leucocytes. 
Nachman et al •... ( 1972) found a permeability factor in the 
lysosomes ass~ciated with histamine release. Chemotaxis 
of leukocytes could be brought about by several possible 
candidates. Weksler and Coupal (1973) found that a 
cationic protein from the lysosomes liberated a chemotactic 
factor from the fifth component of complement. The 
lipoxygenase product, 12L-hydroxy-S,8,10,14-
eicosatetraenoic acid (HETE) was shown by Turner et al. 
(1975) to induce leukocyte chemotaxis and Kitchen et al. 
(1978) showed some chemotactic activity of thromboxane B2 
(TXB 2). 
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Through the action of proteolytic enzymes, platelets 
also have the potential to participate in the destruction 
of connective tissue in the chronic inflammatory disease 
state (Zucker, 1974). Thrombin releases a considerable 
proportion of platelet 8-gluceronidase, 8-N-
acetylglucosaminidase and cathepsin, hydrolytic enzymes of 
lysosomes. Further, antigen-antibody complexes interact 
with the platelet Fe-receptor and thereby induce the 
release reaction (Humphrey and Jacques, 1955). 
1.3.3 Haemostasis 
The most important role of platelets is in the 
haemostatic process. Platelets initiate the formation of a 
haemostatic plug by accumulating at the site of vascular 
injury. These adherent and stimulated platelets then 
release factors (eg. ADP, TXA 2 ) promoting aggregation and 
coagulation. The membrane of the platelet also acts as a 
cofactor in the clotting cascade. 
In order to plug a wound in a blood vessel wall, the 
platelets have to adhere to the tissue of the wound. 
Artificial surfaces, (Friedman _et al., 1970) and natural 
vascular surfaces (Baumgartner, 1973) both have the 
capacity to cause adherence of platelets. Removal of the 
endothelium of the blood vessel wall exposes the 
subendothelium collagenous layer. In animal studies, where 
the endothelial layer is removed artificially, platelets 
adhere within minutes (Baumgartner and Spaet, 1970; 
Stemerman and Ross, 1972; Nam et al., 1973). Electron 
micrographs (Baumgartner et al., 1967; Baumgartner, 1977) 
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illustrate the adhesion of platelets to the subendothelium. 
Degranulation of adherent platelets bringsabout the 
formation of a platelet plug by the process of platelet 
aggregation. An electron micrograph taken 10 minutes after 
removal of the rabbit endothelium shows platelets which 
have undergone a shape change. Pseudopodia interlink 
platelets and those platelets closest to the subendothelial 
surface show a loss of alpha granules and serotonin storage 
granules. After forty minutes, all that remains is a thin 
covering of flattened, degranulated platelets. 
Exposed subendothelium also activates coagulation 
factor XII. The intrinsic pathway of coagulation is 
further promoted by platelets at several steps when they 
accumulate at sites of vascular injury (Walsh, 1974). The 
ADP-stimulated platelet membrane surface provides a 
suitable surface for the activation of factor XII. The 
collagen-stimulated platelet membrane activates factor XI. 
Phospholipids norm.ally found on the interior of the 
platelet membrane may be exposed by disruption of the 
platelet or by a specific mechanism called flip-flop where 
different phospholipids are swapped from inside to outside 
and vice versa. This mechanism is stimulated by the 
simultaneous presence of small amounts of collagen and 
thrombin (Hemker et al., 1983). Exposed platelet membrane 
procoagulant phospholipids bind factors IXa and VIIIa to 
form the factor X converting enzyme. They also provide for 
the interaction of factor Xa and factor Va to form 
prothrombinase which forms thrombin. Fibrin formation is 
thus promoted and the haemostatic plug is consolidated. 
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White cell accumulation occurs secondarily to platelet 
adhesion, probably as a result of release of chemotactic 
substances as mentioned before. These cells could serve to 
phagocytize cellular debris. 
When a blood vessel is intact, the endothelium may 
counteract platelet activity in several ways. Moncada et 
al.(1977) found that prostacyclin(PGI 2 ) production by the 
arterial wall was highest in the intimal region. Martin 
et al. (1980) found that PGI 2 prevents platelet aggregation 
in vivo and possibly promotes disaggregation. PGI 2 has 
been shown to increase c'AMP levels in platelets which 
inhibits aggregation (Gorman _et al., 1977a). Use of PGI 2 -
neutralizing antibodies by Steer et al. (1980) indicated 
that _circulating levels of the hormone are insufficient to 
prevent in vitro aggregation. This may mean that PGI 2 acts 
in cooperation with other anti-aggregatory factors in vivo. 
Other means by which the endothelium may be anti-
aggregatory are the production of plasminogen activator 
activitr, heparin-like activity (heparan sulphate), ADP-ase 
activity and thrombin-binding activity. These factors in 
addition to the endothelium being a physical barrier 
between the blood and the underlying connective tissue and 
smooth muscle cells, make the endothelial lining an 
important protective organ (Nalbandian et al., 1979 ) . 
1.3.4 Aberrant Haemostasis: Thrombosis and 
Atherosclerosis. 
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Haemostasis, as summarized above, involves the 
interaction of platelets, the vessel wall and plasma 
coagulation factors. Thrombosis may be considered as an 
aberrant form of the haemostatic process. Atherosclerosis 
can be ·considered als.o as an undesirable reactive response 
of the blood vessel wall to injury, although there is still 
controversy over the mechanism of atherogenesis. 
The characteristics of atherosclerosis are: localized 
lesions of the arterial intima which contain smooth muscle 
cells, fibrous tissue and acculumated lipid, associated 
with a narrowing of the arterial lumen (Wis.sler. 1976). The 
lesion commences in· the intima mainly around vessel 
orifices and branches. The intimal thickenings are rich in 
smooth muscle cells, connective tissue and proteoglycans 
(Geer and Haust, 1972; Strong and McGill, 1962). Within, 
and between cells, lipids collect, particularly low density 
lipoproteins (LDL) and cholesterol crystals. A fibrous 
cap overlies the resultant plaque. 
No single theory of atherogenesis has been proven. It 
is, however, undisputed that advanced atherosclerotic 
lesions often have thrombi associated with their surfaces. 
Histological and morphological evidence indicates that 
intimal thickenings have incorporated thrombus material 
(Mustard and Packham, 1975). The platelet-endothelial 
interaction is therefore of considerable importance in the 
development of atherosclerosis, be it biochemical or 
biophysical. 
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The response to injury hypothesis of Ross and Glomset 
(1976) postulates that injury to the endothelium gives rise 
to events which, if they occur repeatedly, cause an 
atherosclerotic lesion. The injury to the endothelium may 
take the form of desquamation, lysis or changes in the 
permeability characteristics of the cells. There could 
then be a focal adherence of platelets at the injured site, 
followed by release of platelet granule contents including 
PDGF which enhances proliferation of arterial smooth muscle 
cells(Section 1 .3.1). If there is also platelet 
aggregation, there would be even further release. This 
hypothesis is not entirely new, but rather a modification 
of that documented by Duguid (1949) who followed the line 
of thinking from several workers as previously mentioned 
(Section 1.1). 
According to the response to injury hypothesis, PDGF 
provides a stimulus for focal migration and proliferation 
of smooth muscle cells. These cells may be derived either 
from the media of the artery wall or from pre-existing 
cells within the intima. These proliferative cells are 
stimulated to also synthesize connective tissue, including 
collagen, elastic fibre proteins and glycosaminoglycans. 
Lipids accumulate both inside and outside cells, 
particularly if plasma lipoprotein levels are raised, or 
the endothelium is damaged. 
An important feature of the response to injury hypothesis 
is that the 'injury' must occur on a chronic or recurrent 
basis. The response to single injury is a normal 
haemostatic response, such lesions regressing and 
disappearing once repair is complete (Ross and 
Harker, 1976). Repetition of such injuries could 
conceivably occur in the presence of several known risk 
factors for coronary heart disease. Major risk factors 
include smoking, hypertension and hypercholesterolaemia. 
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Hypertension could lead to chronic damage of 
endothelial cells at bifurcations of arteries where also, 
platelet reactivity may be increased. Lipoproteins have 
been shown to have some ability to stimulate proliferation 
of smooth muscle cells (Fisher-Dzog_a et al., 1974) and to 
inhibit PGI 2 production (Nordoy et al.,1978). Lipoproteins 
are also incorporated into the atherosclerotic plaque, the 
consequences of which are uncertain. Hypercholesterolaemia 
was shown by Ross and Harker(1976) to decrease platelet 
survival, probably by loss of endothelium sustained by 
chronic hypercholesterolaemia. Also, platelet reactivity 
is increased by increased cholesterol incorporation 
(Shattil et al., 1975) and by increased saturated fats in 
the diet (Jakubowski and Ardlie, 1978). Smoking, which is 
another risk factor, has been found to affect the 
haemostatic system in several and complex ways. For 
example, it increases the sensitivity of platelets to ADP 
(Hawkins, 1972). Aryl hydrocarbons (premutagens) from 
cigarettes are taken up and carried by the same fractions 
in the p_la_sma as cholesterol, namely the lipoproteins 
(Benditt, 1976). This would provide a mechanism for 
introduction to the vessel wall of a mutagen respons ible 
for induction of proliferation." Also, Mustard and Murphy 
(1963) proposed that cigarette smoke damages the 
endothelium. 
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Another hypothesis of major interest in atherogenesis 
is the monoclonal hypothesis. Benditt and Benditt (1973) 
discovered that the cellular composition of 
atherosclerotic plaques is monoclonal, with only a small 
percentage polyclonal, as characterized by enzyme analysis. 
Similar findings have been described by Pearson et al. 
(1977). According to this hypothesis atherosclerosis is 
initiated by a mutation caused by chemicals, possibly 
cigarette smoke, radiation or viruses. The cells with a 
selective advantage then proliferate. Further development 
of the disease can occur when platelets then form thrombi 
on these thickened regions. This hypothesis also proposes 
'injury' as an initiator and includes platelet involvement 
in its development. 
The earlier theories concentrated on the lipid nature 
of the lesions, rather than their cellular nature. In most 
of the current theories, lipid accumulation is regarded 
more as a secondary event. More emphasis is placed on the 
origin of cellular proliferative stimuli. Research is 
concentrated on the possible biochemical alterations in the 
endothelium and the stimuli responsible for modification of 
the smooth muscle cells. The importance of platelets in 
atherogenesis lies in their relationship to endothelial and 
smooth muscle cell behaviour. 
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The work reported in this thesis concentrates on the 
mechanisms of platelet activation keeping in mind the 
involvement of platelets in thrombosis and atherosclerosis. 
1.4 PLATELET INTERACTIONS 
The studies of platelet interactions with various 
blood and vessel wall components, have been mostly carried 
out, for convenience, in vitro. Biogenic amines, thrombin, 
connective tissue and ADP are in vivo compounds which are 
known to interact with platelets. 
1.4.1 Catecholamines 
~aseline plasma levels of catecholamines have been 
estimated at 3.4nM for noradrenaline and 0.64nM for 
adrenaline (Dimsdale and Moss, 1980). During public 
speaking, adrenaline levels increase twofold, and during 
moderate physical excercise, noradrenaline levels increase 
threefold (Dimsdale and Moss, 1980). Roizen et al. (1975) 
found catecholamine levels to change dramatically with 
changes in body temperature in rats. Catecholamine levels 
are ~apable of changing rapidly to meet acute body 
reactions to environmental and activity changes. 
Catecholamines accumulate in pig platelets (Born 
et al., 1958) against a concentration gradient, but the 
affinity of this transport system is unknown. 
Interpretation of data on the subject is difficult. 
Experiments performed on plasma without pH control may have 
artificially affected uptake results. Similarly, data on 
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washed platelets for accumulation of catecholamines may be 
artifactual. 
The stimulation of platelets by catecholamines 
produces a series of reactions. It is difficult to 
separate pure catecholamine responses from those which may 
be induced via secondary stimulation by, for example, ADP. 
Adrenaline has been shown, however, to interact with its 
own specific cellular receptor (Scrutton and Wallis, 1981), 
whereas released ADP may mediate secondary aggregation. 
Studies using selective agonists and antagonists have 
demonstrated that stimulation of an a-adrenoceptor is 
responsible for initiation of aggregation and secretory 
responses of human platelets to adrenaline. Radioligand 
and physiological response studies suggest that both the 
aggregatory and pro-aggregatory responses of human 
platelets to adrenaline are mediated by a 2-adrenoceptors 
(Grant and Scrutton, 1980b; Clare et al., 1984). More 
recent studies, however, suggest that the present 
understanding of the relationship between receptor 
occupation and functional responses of platelets may be 
incorrect (Swart et al.,1984). Although inhibition of 
adenylate cyclase is widely accepted as the typical 
stimulus-response coupling mechanism for a 2-adrenoceptors, 
this cannot explain induction of platelet aggregation by 
adrenaline and therefore unique a 2 -adrenoceptors ma y be involve d 
in the aggregatory response to adr e na li ne (Clare et al ., 1984) . 
There has been some disagreement as to whether 
adrenaline causes platelets to change shape. Mills (1973) 
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based on observations on ATP consumption in combination 
with aggregation tracings, found no shape change-associated 
decrease in the platelet adenylate energy charge and 
concluded that adrenaline does not induce a shape change in 
human platelets. Patscheke (1980) observed an adrenaline 
shape change in recordings for washed platelets suspended 
in a medium containing 1mM calcium. The so-called shape 
change due to adrenaline certainly differs from that caused 
by ADP. 
Adrenaline, when capable of causing aggregation 
1n vitro, induces two waves of aggregation in human 
platelets: a primary and a secondary response. The 
secondary response is associated with the release reaction 
and a minimal amount of thromboxane production. 
Arachidonic acid, released from phospholipids, is 
metabolized via the endoperoxides to thromboxanes and 
several other products. Thromboxane A2 is a potent 
aggregating compound. Arachidonic acid is also metabolized 
by the enzyme lipoxygenase but the roles for the products 
of this pathway are uncertain. There are several questions 
so far unanswered in regard to the mechanism of induction 
of these responses to adrenaline, and the connections 
between the two phases. 
One point of confusion arises from the choice of 
anticoagulant for blood collection for the preparation of 
the platelets. Primary aggregation occurs in both citrated 
and heparinized plasma, while it is increased in the latter 
(O'Brien et al., 1969). Secondary aggregation is the 
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predominant response to adrenaline in citrated plasma, and 
is dependent on arachidonic acid metabolism by cyclo-
oxygenase to form thromboxane A2 (Best et al., 1980). Both 
secretion of serotonin (5-hydroxytryptamine) and 
thromboxane B 2 (TXB 2), the stable end-product of TXA 2 , are 
inhibited by 100µM acetylsalicylic acid (aspirin) which 
irreversibly acetylates cyclooxygenase. The second phase 
of the adrenaline response is therefore totally abolished 
by aspirin while the small primary response remains 
unaffected. 
It is not known whether this secondary aggregation is 
important in vivo as it could be purely an artifact of 
citrated plasma (see 2.1 .1.2.). (See Chapter 3 for a 
comparison of platelet reactivity in heparin vs. citrate.) 
The involvement of adrenaline and noradrenaline in the 
reactivity of platelets and thus thrombosis and 
atherosclerosis is an important area of investigation. It 
is possible that the major importance of adrenaline lies in 
its preparation of platelets to respond to other agonists. 
Adrenaline and noradrenaline are known to potentiate the 
aggregation response to other agonists in vitro. Ardlie 
et al. (1966) first demonstrated this and it was studied in 
detail by Mills and Roberts (1967). In particular they 
studied adrenaline potentiation of the response to 
nucleotides. Since then, several authors have observed 
adrenaline potentiation of ~he response to thrombin, 
collagen, serotonin and vasopressin (Baumgartner and Born, 
1968; Thomas, 1967; Grant and Scrutton, 1980a). 
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Of further interest is the inability of aspirin to 
prevent adrenaline potentiaton of ADP-induced aggregation. 
(Rao et al., 1980a). The alteration of the platelet 
involved in potentiation is at the receptor-membrane level 
(Rao et al., 1980b; Rao et al., 1981a). It was thought 
that the effects may be due to changes in calcium 
mobilization because adrenaline potentiation was inhibited 
by verapamil,a calcium 'antagonist' (Owen and Le Breton, 
1980). It has subsequently been shown, however, that 
verapamil is an a-adrenergic antagonist(Barnathan et al., 
1982) with no receptor sub-type specificity as studied in 
other tissues(Motulsky et al., 1983). Adrenaline and 
noradrenaline ~epress the basal activity of adenylate 
cyclase in human platelet lysates (Moskowitz et al., 1971; 
Salzman and Levine, 1971) and lower prostaglandin E1-
induced increases in cyclic AMP in intact platelets 
(Harwood et al., 1972; Haslam and Taylor, 1971; Robinson 
et al., 1969) _ b~t a~renaline does not depress the level of 
cyclic AMP in resting platelets nor can the adrenaline 
response be enhanced by addition of an inhibitor of 
adenylate cyclase (Haslam et al., 1978a,b). An alternative 
mechanism of adrenaline potentiation in vitro must be 
sought. 
Adrenaline is also of interest because platelets from 
human donors exhibit _wide variability in their response to 
this agonist. Sensitivity to adrenaline could conceivably 
be related to thrombotic tendencies, but such a correlation 
needs to be established. There is also a need to establish 
the physiological role of adrenaline in platelet 
reactivity. Detailed reviews of recent work on the 
mechanisms of adrenaline action will be given in later 
chapters, appropriate to the particular study undertaken. 
See also Section 1.5 for discussion on calcium,c'AMP and 
phospholipids in relation to mechanisms of platelet 
responses. 
1.4.2. Serotonin (5-hydroxytryptamine, 5HT) 
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Ser~ton_i~ i _s __ actively and passively taken up by 
platelets and stored in the dense granules, where it is 
inaccessible to the destructive enzyme monoamine oxidase, 
in preparation for release (Paasonen, 1965). These 
granules also contain ADP, ATP, magnesium, calcium and 
other biogenic amines. The interaction of platelets in 
vitro with serotonin commences with a shape change, first 
observed by O'Brien and Heywood (1966) although aggregation 
is not necessarily a consequence of this event. 
Human platelets, prepared in either citrate or 
heparin, can be aggregated by micromolar concentrations of 
serotonin (O'Brien et al., 1969). This aggregation is 
generally small and reversible, and high concentrations are 
self-inhibitory (Baumgartner and Born, 1968). Variations 
in ionized calcium levels can, under certain conditions 
have dramatic effects on the platelet responsiveness to 
serotonin. Addition of calcium to citrated human platelets 
increases the initial velocity of serotonin-induced 
aggregation but does not affect the maximal response 
(O'Brien et al., 1969). Aggregation to serotonin is 
calcium dependent to this extent. 
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A small percentage of human donors is found to exhibit 
a secondary response to serotonin with an associated 
release of adenine nucleotides. Some donors have serotonin 
-insensitive platelets. 
Serotonin, like adrenaline, can potentiate the 
platelet response to other agonists (Baumgartner and Born, 
1968). There are serotonin receptors on the platelet of 
heterogeneous _ types, either related to shape change or 
serotonin uptake (Drummond, 1976). 
1.4.3. Thrombin 
Since only a few platelets would be in contact with 
collagen at a wound surface, other agents are expected to 
be involved in consolidating a platelet mass in the 
formation of a haemostatic plug. Thrombin is formed at the 
sites of injury in blood vessels. Thrombin is therefore of 
interest in in vitro studies. 
The effects of thrombin on platelets include an 
increase in phosphatidylinositol (PI) turnover and an 
increase in protein phosphorylation (Lyons et al., 1975). 
Diacylglycerol production from PI hydrolysis has been 
reported to be coupled to a protein kinase thought to 
participate in the release reaction through phosphorylation 
of a 40,000dalton M.W. polypeptide (Kawahara et al., 1980). 
Breakdown of phosphatidylinositol by phospholipase C due to 
thrombin stimulation, is associated with arachidonate 
release (Rittenhouse-Simmons, 1979; Bell et al., 1979). If 
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the metabolism of this arachidonic acid is blocked by 
indomethacin, aggregation induced by thrombin still occurs 
but with an increased production of phosphatidic acid, an 
intermediary in the phosphatidylinositol cycle (Lapetina 
et al., 1978). Indomethacin also inhibits diglyceride 
lipase responsible for arachidonic acid release 
(Rittenhouse-Simmons, 1980). Thrombin also stimulates 
arachidonic acid release from phosphatidylcholine via the 
activity of phospholipase A2 (Bills et al., 1977) so that 
there are two potential sources of arachidonic acid release 
due to thrombin. Prostaglandin synthesis occurs subsequent 
to thrombin activation of arachidonate release (Hamberg 
et al., 1974). 
Thrombin inhibits adenylate cyclase by three 
concurrent mechanisms: by interaction with its receptor, by 
mediation via thromboxanes or endoperoxides and by an 
increase in the level of free calcium in the 
cytosol(Feinstein et al., 1981). Thrombin binding to its 
receptor _behaves more like a hormone than an enzyme, 
expressing negative cooperativity for further binding 
(Majerus et al., 1976). These highly specific receptors 
bind thrombin with high affinity, ensuring platelet 
involvement in clot formation. In addition, some thrombin-
induced responses, aggregation and dense granule secretion 
do not require the continuing presence of thrombin on its 
receptor (Holmsen et al., 1981). 
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1.4.4. Connective Tissue 
A wound in a blood vessel exposes tissues not normally 
in contact with the blood. Platelets have been found to 
adhere to connective tissue underlying the endothelium, the 
first step in haemostatic plug formation. The major 
components of the connective tissue are collagen, elastin, 
glycoprotein and proteoglycan. Collagen achieves 
aggregation of platelets in vitro while elastin has been 
found not _to induce aggregation (Hoffman, 1975). 
Glycosaminoglycans may enhance aggregation (Muir and 
Mustard, 1968). The enormous amount of work on platelet-
collagen adhesion and aggregation will not be included in 
this introduction. 
1.4.5. Adenine Nucleotides 
Adenosine diphosphate (ADP) and adenosine triphosphate 
(ATP) are stored within the platelet in dense granules for 
release during the release reaction. ADP and ATP located 
elsewhere in mitochondria, the cytosol and membranes are 
available for metabolic processes. Platelets challenged 
with radioactive adenosine, exhibit the label in this 
metabolic pool, while no label is found in the releasable 
nucleotides (Holmsen et al., 1969). 
There is a critical level of metabolic ATP required 
for the platelet shape change, aggregation and the release 
reaction (Holmsen et al., 1974; Holmsen, 1975). Stimulated 
platelets have an increase in the activity of key enzymes 
of glycolysis and oxidative phosphorylation as energy is 
consumed. 
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The release of nucleotides serves to consolidate a 
thrombus, as new platelets are challenged and activated by 
ADP. Studies using ADP in vitro show that platelets 
undergo a shape change almost immediately in response to 
ADP (Born, 1970) and in the absence of external calcium. 
The platelets are then able to aggregate, with the release 
reaction occuring secondarily. 
Little is known of the mechanism of induction of shape 
change, aggregation and release due to ADP. In vitro 
studies illustrate that the shape change is immediate and 
rapid, with a maximum change occurring in less than thirty 
seconds. The contractile elements of the platelet 
immediately beneath the plasma membrane can be rapidly 
activated following calcium loss from the dense tubular 
system or other membranes (Behnke, 1970). The work of 
Lloyd et al. (1973a,b) indicates that ADP-induced shape 
change is associated with phosphatidic acid production. 
Calcium is mobilized during shape change, a process 
which includes psuedopod formation and granule 
centralization (Le Breton et al., 1976). The calcium may 
control contraction in platelets through calcium-dependent 
myosin phosphorylation reactions (Hathaway and Adelstein, 
1979) involving ATP bound to actin (Crawford, 1976). The 
concentric ring of microtubules becomes disorganized, but 
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can become prominent again, extending into the pseudopodia 
which form during activation. The platelet is then ready 
for platelet-platelet adhesion. 
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ADP can induce the release reaction and prostaglandin 
production but it is not clear whether these events occur 
in parallel with secondary aggregation, or are the cause of 
secondary aggregation. Experiments with platelets from 
patients with storage pool deficiency, deficient in dense 
granule ADP, show that secondary aggregation is abolished 
in the absence of endogenous ADP (Weiss, 1975). Lages and 
Weiss (1980) reported two patients with storage pool 
deficiency who exhibited biphasic aggregation responses to 
ADP and adrenaline but these patients could also secrete 
ADP, despite the deficiency. These authors suggested that 
secondary aggregation responses may be mediated by both 
thromboxanes and ADP secreted f r-0m platelets. 
1.5 MECHANISMS OF PLATELET RESPONSES 
1.5.1. The Necessity for Calcium 
Platelet activation involves a shape change, the 
release reaction, prostaglandin metabolism and aggregation. 
These steps require _energy, membrane changes and 
contractile function, all of which have been thought to 
be calcium-dependent processes. The manner in which 
calcium is utilized is less certain. 
The platelet shape change induced by ADP or the 
ionophore A23187 (an agent known to facilitate divalent 
cation transport across membranes) is associated with a 
redistribution of intraplatelet divalent cations, as s hown 
by the use of a fluorescent-chlortetracycline probe (Le 
30 
Breton et al., 1976). The contractile mechanism involved 
in constric~ing the band of microfilaments during the shape 
change is activated by calcium (Hanson et al., 1973). 
Calcium is thought t~ participate in the disappearance of 
the equatorial bundle of microtubules. Calcium controls 
the platelet contractile protein, thrombasthenin, through 
its effect on ATPase activity in a similar way to muscle 
proteins. 
Calcium ionophores also stimulate aggregation and 
release (~~te et al., 1974). The regulation of 
cytoplasmic calcium is thought to control release of 
arachidonic acid from phospholipid substrates by 
phospholipase A2 and thus calcium governs the generation of 
endoperoxides and thromboxanes from these sources 
(Rittenhouse-Simmons and Deykin, 1978; Gerrard et al., 
1978a). On the other hand, phospholipase C does not have 
the same requirement for calcium (Billah et al., 1980). 
The phosphatidate specific phospholipase A2 described by 
Billah et al. (1981) requires calcium for the release of 
arachidonic acid but not to the same extent as the 
phospholipase A2 which degrades phosphatidylethanolamine 
and phosphatidylcholine. 
Rittenhouse (1984) concluded that phospholipase C is 
not activated by calcium and suggested that stimulation is 
totally dependent upon a receptor-coupled event, possibly 
via cyclooxygenase products and ADP. The subsequent events 
of this calcium-independent pathway of platelet activation 
involves protein kinase C (Simon et al.,1984). Calcium may 
influence the phosphatidylinositol cycle initiated by 
phospholipase C by inhibiting the resynthesis of 
phosphatidylinositol, causing the accumulation of 
phosphatidic acid (Lapetina et al., 1981b). Cyclic AMP 
directly opposes this action. 
Dibutyryl cyclic-AMP(Bt 2c'AMP) and 8-(N,N-
diethylaminooctyl-3,4,5-trimethoxybenzoate (TMB-8) oppose 
arachidonate release. Bt 2 c'AMP is thought to 
compartmentalize calcium and TMB-8 to immobilize calcium, 
both restricting the availability of calcium for enzyme 
activation, the latter's specificity albeit doubtful 
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(Simpson et al., 1984). These agents also cause inhibition 
of thrombin-induced release of serotonin, which can be 
overcome by the addition of calcium. Perhaps the enzymes of 
arachidonic acid conversion to thromboxanes are also 
calcium-dependent since they are inhibited by TMB-8 (Shaw,1981). 
The work of White et al.(1981) demonstrated a calcium-
dependent calcium-binding regulator protein, calmodulin, in 
platelets. Localization using immunofluorescence was 
inconclusive, giving general staining. It has been 
suggested that calmodulin controls phospholipase A2 
activity, and thus arachidonate release (Rao et al., 1980b; 
Vanderhoek and Feinstein, 1979) but the phenothiazines used 
as a basis for these studies inhibit other enzymes 
(Schatzman et al., 1981) and may be u-receptor blocking 
agents (Cocks et al., 1981). More recent evidence 
indicates that calcium regulation of phospholipase A2 is 
independent of calmodulin (Withnall et al., 1984). 
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The development of the fluorescent intracellular 
calcium indicator, quin 2, has provided an important tool 
to examine in detail the role of calcium in platelet 
responses to stimuli (Tsien et al.,1982). Quin 2 is added 
as an ester that readily penetrates platelets, is 
hydrolized intracellularly and binds calcium. The 
fluorescence of quin 2 increases when it is complexed with 
calcium. Studies with quin 2 show that several natural 
agonists, in the presence of 1mM external calcium, cause 
cytoplasmic free calcium to increase by both stimulated 
calcium entry across the plasma membrane and discharge of 
calcium from intracellular stores (Rink et al., 1982; 
Hallam et al., 1983a; Feinstein et al., 1983; Kawahara et 
al., 1983a; Hallam et al., 1984a; Hallam et al., 1984b). 
When calcium was omitted from the suspending medium, 
thrombin and other agonists evoke responses when the 
cytoplasmic free calcium remains near basal levels (Rink et 
al., 1982; Hallam et al., 1984a; Hallam et al., 1984b). 
The occurrence of shape change and secretion at basal 
levels of calcium has been attributed to the ability of 
diacylglycerol,_ a product of phosphoinositide hydrolysis, 
to initiate responses in platelets (Rink et al., 1983) (see 
1.5.4). More recently, the photoprotein, aequorin, has 
been utilized to measure ionized calcium in platelets 
(Johnson et al., 1985) and this has drawn attention to some 
potential problems with quin 2 which nonetheless remains a 
useful indicator of calcium elevation in platelets. 
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Calcium modulation at the membrane level has been 
suggested as the means by which adrenaline acts as a 
potentiator of platelet reactions (Rao et al., 1981a). It 
has been proposed that calcium participates 1n the 
initiating events of adrenaline stimulation of platelets 
(Owen et al., 1980). With the 45Ca-assay technique, Owen 
and LeBreton (1980) found that low concentrations of ADP 
promote the ability of adrenaline to stimulate an increase 
in membrane permeability to calcium. If, on the other 
hand, adrenaline is added to the platelets first, no 
increased calcium uptake is measured. These workers then 
proposed that some kind of calcium involvement in the 
potentiated ADP-response on the basis of inhibition of the 
response by verapamil. As has been mentioned, however, 
verapamil also acts as a a 2-adrenoceptor inhibitor 
(Barnathan et al.,1982). (See Section 1 .4.1) 
Clare and Scrutton(1984) concluded that calcium uptake 
did occur but as a consequence of secretion due to 
adrenaline and other agonists. They found that blockade of 
secretion by aspirin prevented radioactively labelled calcium 
uptake. Hallam et al. (1983b) also found that adrenaline 
induces no increase in cytosolic calcium concentration in 
platelets treated with aspirin. On the other hand, Brass 
and Shattil(1982) did find that both ADP and adrenaline 
increased the amount of calcium bound to the platelet 
surface membrane, despite no net influx of calcium, and 
without the occurrence of secretion. Hence, there is 
conflicting evidence as to whether adrenaline induces an 
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aggregatory response by enhancing calcium influx into human 
platelets. The involvement of calcium in the pro-
aggregatory response to adrenaline has not been 
investigated in any detail. 
1.5.2. Control by c'AMP(cyclic adenosine 3' ,5'-
monophosphate) 
The actions of several inhibitors of platelet 
aggregatio~ and release are mediated by c'AMP (Haslam 
et al., 1978a). c'AMP is thought to decrease the 
concentration of calcium ions in the platelet cytosol, 
probably by activation of a calcium pump. Kaser-Glanzman 
et al.(1977) reported that under certain conditions, 
addition of c'AMP with platelet c'AMP-d~pendent protein 
kinase, can increase the initial uptake of calcium by a 
platelet membrane fraction containing both plasma and 
intracellular membranes. c'AMP promotes movement of 
calcium ions into the dense tubular system or across the 
plasma membrane or both, and this can be mimicked by 
dibutyryl cyclic AMP(Bt 2 c'AMP). 
Both PGE 1 and PGD 2 were used in early studies to 
increase adenylate cyclase activity, but PGI 2 has 
subsequently been found to be far more potent, inhibiting 
platelet aggregation at nanomolar concentrations (Moncada 
et al., 1976). As PGI 2 is produced by the endothelial 
lining of blood vessels, it is thought to be a major 
regulatory component of the haemostatic process. 
Isoproterenol causes increased adenylate cyclase 
activity by a weak e-adrenergic effect. Platelet 
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aggregation 1s further inhibited by c'AMP phosphodiesterase 
inhibitors e.g. papaver1ne, which prevent breakdown of 
c 'AMP (Mills et al., 1970). 
Adenylate cyclase activity 1s itself modulated by 
released calcium (Kume and Kariya, 1980). Thus, the 
attenuation by ADP and adrenaline of increased c'AMP by 
PGE 1 , is likely to be due, not only to receptor-mediated 
inhibition, but also to calcium-mediated inhibition of 
adenylate cyclase. 
Cyclic guanosine 3' ,5'-monophosphate (c'GMP) has been 
found to increase during platelet activation by adrenaline 
(Jakobs et al.,1974) and by other agonists(Haslam et al., 
1978b). Kume and Kariya (1980) found c'GMP had an 
inhibitory effect on c'AMP-dependent phosphorylation of 
platelet proteins which could regulate platelet function. 
Takai et al.(1981) suggested that increased c'GMP levels, 
caused by thrombin stimulation, lead to feedback inhibition 
of phosphatidylinositol hydrolysis, presumably through 
protein phosphorylation. 
The interrelationships of the cyclic nucleotides are 
obviously complex. For example, Steer and Wood (1979) 
suggested from their observations, that guanine nucleotides 
mediate either stimulation or inhibition of adenylate 
cyclase, depending on which binding site is involved. One 
of these guanine nucleotide sites is thought to interact 
with the a-receptor to result in enzyme inhibition, while 
the other interacts with the PGE1-receptor to cause 
stimulation. Steer and Wood (1979) also found while 
adrenaline and GTP individually inhibited 
adenylate cyclase slightly in isolated membranes, 
adrenaline and GTP together act synergistically to cause 
50% inhibition of cyclase activity. 
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Membrane phospholipids may also be involved. In 
hamster adipocytes, phosphatidic acid, a product of 
phosphatidylinositol turnover, inhibited methyl xanthine-
stimulated c'AMP formation (Schimmel et al., 1980). 
Phosphatidic acid is formed in platelet membranes upon 
stimulation by thrombin (Rittenhouse-Simmons, 1979) and is 
perhaps a means by which thrombin inhibits adenylate 
cyclase. It is 1n this area of assigning roles to 
phospholipids in platelets that attention is currently 
focussed (See 1.5.4). 
1.5.3. Prostaglandins (PG) and the Release Reaction 
Secondary aggregation is associated with both the 
secretion of dense and a-granule constituents, including 
the aggregating agents 5HT and ADP, and the activation of a 
pathway for conversion of arachidonic acid to 
prostagl~ndins (Smith et al., 1973). Cyclooxygenase 
converts arachidonic acid to endoperoxides which form 
thromboxanes (Fig 1.1). The precise role of endoperoxides 
and thromboxanes so formed is still a matter of 
controversy. Thrombin and collagen may cause secretion in 
the absence of thromboxane synthresis whereas ADP induced 
secretion is dependent on thromboxane synthesis. 
Best et al. (1980) concluded that the aggregation 
process can occur independently of secretion, depending on 
ARACHIDONIC ACID METABOLISM 
lipoxygenase 
HPETE 
HETE 
arachidonic acid 
aspirin 
indomethocin 
8W755C 
cyclooxyg en as e 
endoperoxides 
imiclazole 
n-butyl imidazole 
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PGI 2 (prostacyclin) 
malondi aldehyde 
+ HHT 
thromboxane 
synthetase 
thromboxane A 2 
thromboxane 8 2 
(stable) 
Figure 1.1 Arachidonic acid metabolism. 
6-keto-PGF 1 a 
The combined activity of cyclooxygenase and thromboxane 
synthetase to produce endoperoxides and thromboxane A 2 , a 
potent platelet aggregator is thought to be the most 
important pathway of arachidonic acid metabolism in 
platelets. The reactions are controlled by calcium and 
c'AMP: calcium (Ca 2 +) promotes the formation of 
thromboxanes, while c'AMP has the reverse effect, largely 
through their respective effects on arachidonic acid 
release. 
PG= prostaglandin HHT = heptadecatrienioc acid 
HETE c 12L-hydroxy-5,8,10,14-eicosatetraenoic acid 
'¢ c inhibition. 
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the stimulus used. Thrombin and collagen each appear to 
activate platelets by two possibly independent mechanisms. 
If this were so, this would mean that thromboxane synthesis 
could be stimulated coincidently with, but separately from, 
platelet activation by a thromboxane-independent pathway. 
Stimulation by ADP or adrenaline of thromboxane 
biosynthesis occurs as a consequence of the primary events 
in aggregation. The major aggregation response to 
adrenaline, which is of the secondary type, can be blocked 
by inhibitors of thromboxane production, and is therefore 
dependent on the small amount of thromboxane found. Meyers 
et al. (1979) demonstrated that secondary aggregation in 
cat platelets can be mediated through thromboxane formation 
but without participation of secreted ADP. The evidence 
from studies on blood from patients with storage pool 
disease (see 1.4.5) indicates that some ADP is necessary 
for the human platelet release reaction. It appears that 
the products _of secretion may amplify aggregation, but for 
some agonists, an alternate pathway may obviate the need 
for such stimulation. 
Best et al. (1980) also showed with the thromboxane 
synthetase inhibitor, 1-N-butyl imidazole, that 
prostaglandin endoperoxides alone contribute little toward 
platelet activation. Contrary to this, Flower and Cardinal 
(1979) found 1-N-butyl imidazole only partially effective 
in blocking platelet aggregation, and suggested that 
endoperoxides have significant activity. The advantage of 
endoperoxide formation as an intermediary could be in the 
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facility for transformation to alternative prostaglandins, 
depending on the enzyme stimulated (Samuelsson, 1977). 
Endoperoxides have been found to inhibit PGE 1-induced 
increases in c'AMP but not as effectively as thromboxanes 
(Gorman et al., 1978). Through the use of inhibitors of 
thromboxane synthase, it appears that the effect of the 
endoperoxides on c'AMP levels is due to their conversion to 
TXA 2 (Gorman et al., 1977b). 
Gerrard et al. (1978a;1978b) reported indirect 
evidence that endoperoxides and TXA 2 could act as 
intracellular calcium ionophores within platelets. 
Platelet activation induced by these prostaglandins is 
thought to be mediated by calcium mobilization from the 
dense tubular system (Gerrard and White, 1978) where 
thromboxane synthesis occurs (Gerrard et al., 1976). In 
this fashion, TXA 2 can act in direct opposition to the 
function of c'AMP which decreases calcium in the cytosol. 
Recently, however, Menashi et al.(1984) reported that 
neither thromboxanes, endoperoxides nor phosphatidic acid 
can act as ionophores. 
Siess et al.(1983) suggested that endoperoxides or 
thromboxane A2 are responsible for their finding that 
exogenous arachidonic acid stimulates the phospholipase C 
pathway. Formation of diacylglycerol and phosphatidic acid 
are important for platelet activation. Rittenhouse (1984) 
found also that phospholipase C activation by the ionophore 
A23187 was dependent on cyclooxygenase products and ADP. 
Inhibition of platelet aggregation by prostaglandins 
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may also occur, without measu~able increases in c'AMP 
levels, although this may represent the limit of 
discrimination of the assays. Sinha and Colman (1978) 
reported that PGE 1 induces an alteration or formation of an 
inhibitory macromolecule in plasma which can regulate 
platelet function independently of c'AMP. Rao et al. 
(1981a) used PGI 2 at levels which caused inhibition of 
arachidonate-induced aggregation without raising c'AMP 
levels. The inhibition was correctable with adrenaline, 
again independently of c'AMP. No inhibitors of adenylate 
cyclase were used to eliminate an effect of c'AMP. These 
workers were investigating the influence of catecholamines 
on prostaglandin receptors and concluded that stimulation 
of adrenergic receptors by adrenaline uncouples PG-receptor 
activity through close physical association of the two 
receptors. In experiments with washed platelets, where 
platelet receptors may be altered, small concentrations of 
PGI 2 were found to stimulate aggregation due to ADP and 
thrombin (Jorgensen et al., 1980). PG-receptor interaction 
is not a straightforward system leading to adenylate 
cyclase activation. 
1.5.4 Phospholipid Turnover 
Phospholipids were initially of interest as a source 
of arachidonic acid for thromboxane production but 
phospholipid breakdown has also been associated with 
platelet aggregation independently of arachidonic acid 
conversion (Lapetina et al., 1978). Arachidonic acid can 
be released from several phospholipid classes by the action 
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of phospholipase A2 , which cleaves the acyl group in the 2-
position. Phosphatidylcholine (PC), phosphatidyl-
ethanolamine (PE) and phosphatidylserine (PS) are the 
preferred substrates of phospholipase A2 and are present in 
the platelet membrane (see 1.2.1) (Billah et al., 1980). 
Phosphatidylinositol (PI) is broken down specifically by 
phospholipase C to diacylglycerol (Rittenhouse-Simmons, 
1979). By the action of a lipase, arachidonic acid can be 
released from diacylglycerol (Bell et al., 1979). 
Arachidonic acid release is not, however, necessary for 
platelet activation, and other products of membrane 
phospholipase activity could be important (Lapetina et al., 
1979). 
The action of thrombin on PI turnover in human 
platelets has been extensively studied. A recent report 
(Lapetina et al., 1981b) describes the conversion of PI to 
phosphatidic acid which cycles back to PI via four 
consecutive enzymes (Fig 1 .2). Calcium controls this 
cycle, in that it promotes the degrading enzymes and 
inhibits resynthesis, resulting in an accumulation of 
phosphatidic acid. c'AMP increases the resynthesis 
resulting in a decrease in phosphatidic acid. Lapetina et 
al. (1981a) conclude that arachidonic acid release occurs 
via conversion of phosphatidic acid to lysophosphatidic 
acid. They do not see the action of a lipase on the 
diglyceride as important, but rather platelet diglyceride 
kinase is more active, yielding phosphatidic acid. Again 
these studies are largely concerned with arachidonic acid 
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PHOSPHA TIDYLINOSITOL CYCLE 
40K protein 
phosphorylation 
1,2 diacylglycerol 
lipase 
arachidonic acid 
p hosp hati dyli nositol 
phospholipase C 
Ca 2 + 
1,2 diacylglycerol 
1,2 diacylgtycerol 
kinase 
phosphatidic acid 
phospholipase A 2 
lysophosphatidic acid 
+ arachidonic acid 
CDP,1,2 diacylglycerol inositol 
.:> phosphatidyl transferase 
. c .. 
~J) 
Co 2 + 
cytidine diphosphate 
diacylglycerol + Pi 
CTP phosphatidate 
cytidyl transferase 
Figure 1 .2 The phosphatidylinositol cycle. 
This four enzyme cycle is controlled by Ca 2 + and c'AMP. 
Increased Ca 2 ~ levels favour the production of phosphatidic 
acid, while increases in local c'AMP favours the 
reconversion to phosphatidylinositol. Diacylglycerol 
occupies a significant position in being able to 
participate in three possible reactions. 
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release, rather than focussing on agents responsible for an 
initial and cyclooxygenase-dependent reaction within the 
platelet. 
Much other work is concerned with the debate on the 
relative importance of phospholipase C or phospholipase Az 
as the enzyme responsible for arachidonate release. For 
example, McKean et al. ( 1981), using thin layer 
chromatography (TLC), measured increases in 
lysophosphatidylcholine in response to thrombin, indicating 
stimulation of phospholipase Az in preference to 
stimulation of phospholipase C. Also using TLC, Billah et 
al. (1980) claimed, however, that no lysophospholipid 
accumulated during platelet activation, but this study 
utilized deoxycholate treated horse platelets. Uncoupling 
of normal membrane structure with deoxycholate could lead 
to different substrate availabilities. Phospholipase 
activity would depend on which phospholipid was accessible 
as well as calcium concentration and pH. Billah et al. 
(1980) held the view that phospholipase C is 
calcium-sensitive but requires less calcium than 
phospholipase Az and could be stimulated immediately in the 
cytosol to act on exposed PI. Phosphatidic acid so 
produced could participate in the transfer of arachidonic 
acid to other phospholipids. There is also evidence for 
lysophosphatidic acids being able to act as calcium 
ionophores (Gerrard et al., 1979 ) . Kannagi et al. (1980) 
published evidence supporting the idea that arachidoni c 
acid needed to be mobilized within the 
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phospholipid classes during platelet aggregation. Rabbit 
platelets, after thrombin stimulation, exchanged arachidonic 
acid from the PE fraction to the PC fraction which is 
preferentially hydrolyzed. The idea of there being a store 
of arachidonic acid is attractive in terms of the benefits 
of control mechanisms for its release. Later work by 
Kannagi et al. (1981) modified their conclusions. They 
proposed domains of phospholipase-susceptible phospholipids, 
the mechanism of formation of which is unknown. 
Thus far, phosphatidic acid has been postulated to act 
as a substrate itself for arachidonic acid release, but has 
not yet been given a role in prostaglandin-independent 
reactions. Considerable recent evidence indicates that 
diacylglycerol formed from PI may be a transmembrane signal 
for protein phosphorylation necessary for the release 
reaction (Kawahara et al., 1980). Diacylglycerol activates 
protein kinase C which is then capable of phosphorylating 
specific cellular proteins, especially those required for 
calcium independent reactions or those requiring very low 
levels of calcium (Naka et al., 1983). The action of 
activated protein kinase C, therefore, provides a possible 
mechanism for stimulation of release without an increase in 
resting cytosolic [ca2+] . 
Michell (1975) interprets a role for PI-turnover in 
opening cell-surface calcium-gates based on work with guinea 
pig ileum smooth muscle cells. The 'gate' is an ill-defined 
physiological system but implies control of calcium 
availability, either from calcium uptake or release from 
membrane calcium-chelators. PI breakdown plays a role in 
the coupling between receptor-agonist interaction and the 
opening of the gates. It is of interest to note here, 
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also, that a 1-receptor activation is thought to involve PI 
turnover and the release of bound intracellular calcium as 
well as the entry of extracellular calcium (Fain and 
Garcia-Sainz, 1980). This conclusion is based on 
examination of various tissues but not platelets which may 
not possess a 1-receptors (see Chapter 4). It would 
certainly be of interest to associate catecholamine activity 
and PI turnover even though this would be unusual. 
There are three species of phosphoinositide found in 
cell membranes: phosphatidylinositol and two 
polyphosphoinositols. The actual levels of any of these 
lipids may be small but their interconversion enzymes may be 
quite active. Broekman (1983) observed that the 
thrombin-induced loss of phosphatidylinositol-4,5-
bisphosphate in platelets coincides with a decline of 
membrane-found calcium as monitored by chlortetracycline 
fluorescence. Hydrolysis of phosphatidylinositol-4,5-
bisphosphate yields inositol-1,4,5-trisphosphate which seems 
to act by mobilizing intracellular calcium (Berridge,1984). 
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A simple measurement of increased PI-turnover does not 
indicate which phospholipid products are formed, nor which 
would be responsible for specific activities within the 
platelet. A study of the action of one agonist, thrombin, 
does not allow for the possibility of alternate actions by 
other agonists on the platelet membrane. Billah and 
Lapetina (1982a) found that thrombin induces a rapid loss 
of phosphatidylinositol-4,5-bisphosphate but not 
phosphatidylinositol-4-monophosphate. This thrombin-
stimulated loss is linked to receptor activation and is 
insensitive to calcium mobilization as shown by 
independence from calcium inhibitors (Billah and Lapetina, 
1982b). In contrast to thrombin, activation by the 
ionophore, A23187, is totally dependent on the formation of 
cyclooxygenase products and ADP which form as a consequence 
of a receptor coupled event(Rittenhouse, 1984). The 
addition of A23187 to human platelets induces a transient 
drop in the amount of phosphatidylinositol-4,5-
bisphosphate, a decrease in the amount of PI, and the 
formation of diacylglycerol and phosphatidic acid, 
producing lysophosphatidylinositol and free arachidonic 
acid. 
The current understanding of the mechanism of 
activation of platelets via phosphatidylinositol turnover 
involves, therefore, the combined activities of two second 
messengers, diacylglycerol and inositol-1,4,5-
• 
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trisphosphate. Agonist receptor interaction induces the 
formation of these messengers from the hydrolysis of 
phosphatidylinositol-4,5-bisphosphate formed from part of 
the pool of PI (Berridge, 1984). Inositol-1 ,4,5-
trisphosphate mobilizes calcium which then promotes protein 
phosphorylation via a calmodulin-dependent kinase. Diacyl-
glycerol, in addition to forming phosphatidic acid and free 
arachidonic acid, may also be involved in calcium-
independent phosphorylation via protein kinase C. Either 
protein phosphorylation may lead independently to the 
platelet physiological response of shape change and 
secretion, but a synergistic interaction between the two 
may be involved in the full physiological response(Kaibuchi 
et al., 1983) • 
1.5.S. Platelet Activating Factor 
~late 1 et act iv a~ i ng factor ( PAF) , __ is a 
glycerophospholipid with the proposed structure of 1-0-
alkyl-2-acetyl-sn-glyceryl-3-phoshorylcholine (Demopoulos 
et al., 1979). PAF is released from various cells, 
including basophils, macrophages and p~~telets upon immune 
and non-immune challenge (Vargaftig et al., 1980a). It is 
one of the mo~t potent aggregating substances, since 
concentrations as low as 1nM activate washed rabbit 
platelets. Plasma reduces its activity and human platelets 
are less sensitive. 
Cazenave et al. (1979) studied the type of aggregation 
induced in rabbit platelets by PAF. They found the 
aggregation to be cyclooxygenase-independent and to occur 
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independently of serotonin release. PAF-induced 
aggregation can be inhibited by the prostaglandins, PGE 1 
and PGI 2 , possibly via c'AMP-induced reduction in available 
calcium ions. The strongest inhibitors of PAF-induced 
platelet aggregation are drugs that are known to be lipid 
soluble, and therefore membrane soluble. The mechanism of 
this inhibition is unknown and the drugs used are not 
specific. 
PAF will induce aggregation in thrombin-degranulated 
platelets and in previously PAF-degranulated 
platelets(Cazenave et al.,1979). Thrombin can also 
activate PAF-degranulated platelets. A23187, thrombin and 
collagen cause release of PAF from rabbit platelets but ADP 
and arachidonic acid do not (Chigna~d et al., 1979; 1980). 
This indicates that PAF formation is not a general 
consequence of platelet activation but rather is part of a 
specifically induced pathway. 
Kloprogge et al.(1983) found that the first wave of 
aggregation due to PAF is independent of cyclooxygenase 
products and ADP, but the second wave, accompanied by 
secretion was sensitive to cyclooxygenase inhibition and 
ADP removal. Despite several conflicting reports on the 
importance of platelet PAF, these authors suggest it plays 
only a minor role, if any, in aggregation. 
Investigations of a mechanism for PAF induced 
aggregation have revealed that it stimulates PI turnover in 
human platelets (MacIntyre and Pollock, 1983), stimulates 
metabolism of phosphoinositides in horse platelets (Billah 
and Lapetina, 1983) and that PAF promotes an early 
degradation of phosphatidylinositol-4,5-bisphosphate in 
rabbit platelets (Mauco et al., 1983). 
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1 .6 AIMS OF THIS PROJECT IN RELATION TO PRESENT MODELS OF 
PLATELET AGGREGATION • 
.. - - . . - -----------
Mechanisms of platelet aggregation can be viewed in 
terms of p~thways. A pathway is a series of events which 
lead to the same outcome in the platelet, such as 
aggregation or secretion. Since ADP can induce aggregation 
independentl_y of thromboxane production and further 
release, ADP has been seen as having its own pathway for 
aggregation. Thromboxane mediated aggregation by collagen, 
thrombin, A23187 and adrenaline has been seen as another 
pathway. Since aggregation is still possible in the 
presence of both prostaglandin synthesis inhibitors and ADP 
degrading enzymes, a third pathway was proposed. 
Platelet activating factor was thought to be the mediator 
of this third pathway, but seems to have been excluded. 
Activation of protein kinase C by diacylglycerol may occur 
independently of both ADP and calcium. Formation of ADP 
and release of calcium augment the platelet response. 
Calcium may stimulate phosphorylation of contractile 
proteins and thromboxane formation which in turn may 
stimulate phospholipase C. 
This thesis is concerned with examining further, 
various aspects of the enhancememt of human platelet 
responses by adrenaline. Adrenaline may participate in 
platelet activation as a potentiator for other agonists. 
so 
As mentioned (1.4.1), it is possible that the importance of 
adrenaline, in vivo, is in its sensitization of platelets 
·to respond more effectively to other agents. Adrenaline 
needs to be considered when studying platelet reactivity, 
since psychological and other forms of stress may be risk 
factors for coronary artery disease, and can produce raised 
levels of this catecholamine. For example, even in the 
mildly stressful situation of public speaking, adrenaline 
levels have been reported to rise 3-fold (Dimsdale and 
Moss, 1980). 
The mechanism of adrenaline potentiation has been 
investigated by others but not yet clarified. Although 
adrenaline-induced secondary aggregation depends on the 
cyclooxygenase pathway of arachidonic acid metabolism, 
adrenaline potentiation of ADP- and arachidonate-induced 
aggregation is not prevented by cyclooxygenase inhibitors 
(Rao et al., 1980a) and neither is the first phase. It has 
been sugge~ted, particularly with the initial stimulation 
by ADP,that adrenaline increases calcium uptake from plasma 
(Owen and Le Breton, 1980), that adrenaline releases 
membrane-associated calcium, or that it directly promotes 
deacylation of phospholipids (Rao et al., 1980b). There 
is, however, no evidence that adrenaline increases 
intracellular calcium prior to secretion, although Brass 
and Shattil(1982) found that adrenaline can increase the 
amount of calcium bound to the platelet surface membrane. 
With the use of the chlortetracyline fluorescent probe, 
Owen and Le Breton(1981) found that adrenaline induced 
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significant mobilization of intracellular calcium but this 
was reduced in the presence of EDTA. Adrenergic 
involvement in phospholipid turnover has been reported in 
other tissues (Abdel-Latif, 1974; Michell, 1975; Fain and 
Garcia-Sainz, 1980). The mechanism of adrenaline 
potentiation warrants closer study. In particular, the 
phospholipids of membranes which could lead to calcium ion 
mobilization or redistribution across membranes, 
independently of thromboxane synthesis are of interest in 
relation to adrenergic interaction. 
No one has been able to associate phospholipid changes 
with the initiating events of adrenaline activation 
whereas changes have been associated with the later event, 
secretion (Deykin and Snyder, 1973). Adrenergic effects on 
phospholipid turnover are usually associated with 
receptor activation(Fain and Garcia-Sainz, 1980). 
a -l 
a -1 
receptors have been reported to be present on human 
platelets(Grant and Scrutton, 1979) but only with a 
frequency of 20%(Scrutton, 1981). a 1-receptors are less 
effective in inducing aggregation than are a 2 -
receptors(Grant and Scrutton, 1979), the a 2 -receptor being 
the primary mediator of the proaggregatory response to 
adrenaline (Grant and Scrutton, 1980b). 
The expected response following a 2 -receptor 
interaction is inhibition of adenylate cyclase(Fain and 
Garcia-Sainz, 1980). Primary aggregation is dependent on 
stimulus-response coupling following a 2 -receptor activation 
by adrenaline(Grant and Scrutton, 1979) but the events of 
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this coupling are not precisely known. No one has been 
able to show that adrenaline inhibits adenylate cyclase in 
resting, intact platelets. 
ADP-induced aggregation can be potentiated by 
subthreshold concentrations of several agonists, including 
adrenaline, and this is examined in Chapter 3. ADP-induced 
aggregation provides a thromboxane-independent system when 
cyclooxygenase or thromboxane synthetase inhibitors are 
used. ADP does not release PAF (Chignard et al., 1980), 
but does cause an increase in membrane phosphatidic acid 
(Lloyd et al., 1972; Lapetina and Cuatrecasas, 1979). The 
possibility of a-adrenergic activity also leading to 
increased phospholipid turnover suggests a mechanism for 
adrenaline potentiation of ADP-induced aggregation. 
Adrenaline potentiation of ADP-induced aggregation was 
therefore studied in the presence of various inhibitors. 
Cyclooxygenase inhibitors are the subject of Chapter 
4. Adrenaline potentiation without arachidonic acid 
metabolism is compared with adrenaline potentiation when 
arachidonic acid metabolism is stimulated, both subsequent 
to ADP-activation and as a result of exogenous arachidonic 
acid. This aspect of the project highlights the 
involvement of adrenaline in non-thromboxane initiated 
events under conditions of potentiation, even though the 
usual response to threshold levels of adrenaline results in 
thromboxane-dependent aggregation and release. An attempt 
was also made to examine adrenaline potentiation at stages 
-prior to cyclooxygenase activation by blocking post-
receptor events with different types of inhibitors. 
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In Chapter 5 a study is reported of the use of 
putative inhibitors of phospholipase A2 which inhibit the 
release of arachidonic acid. The aim was to observe 
aggregation in the absence of phospholipid changes arising 
from the action of phospholipase A2 • The results suggest 
that adrenaline affects the phospholipase C pathway 
of phosphatidylinositol turnover. To explore this further, 
the direct effects of these inhibitors on exogenous 
phospholipase C were studied and compared with their 
effects on adrenaline potentiation (Chapter 6). 
The first studies were based on observations of 
aggregation, release of ATP and thromboxane B2 production. 
To answer questions on associated phospholipid turnover, 
phospholipid analysis by Whatman SG-81 paper chromatography 
was undertaken (Chapter 7). With this method, preliminary 
observations of phospholipid metabolism were made in 
relation to a-receptor activation. 
With these combined studies a model for the mechanism 
of adrenaline potentiation has been examined. This model 
includes the interaction of adrenaline with a-receptors, 
and subsequent events at the membrane level involving 
phospholipid turnover, which lead to protein 
phosphorylation and calcium movement. Subsequently, 
thromboxane synthesis occurs and serves to amplify the 
original signal. 
CHAPTER 2 _ 
METHODS AND MATERIALS 
2. 1 METHODS 
2.1.1. Aggregation Studies 
2.1.1.1 Advantages and Disadvantages of Studying Platelet 
Aggregation in vitro. 
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Platelet aggregation studies are performed in vitro 
since it is much easier to obtain a blood sample from a 
human donor than it is to examine blood and vascular 
tissue, interactions in situ. Setting up a system in the 
laborato_ry en~bl~s parameters to be defined and 
standardized. Several different environmental factors can 
be controlled simultaneously. There is the additional 
advantage that potentially toxic substances can be used in 
vitro. 
There are, of course, several disadvantages in 
attempting to simulate the physiological environment. 
Platelets studied in isolation, are not influenced by 
vascular tissue which is multifactorial. Anticoagulants 
have to be used in the preparation of platelets from blood. 
These compounds very likely affect the reactivity of the 
platelets. Platelet responsivness alters with time once 
blood is removed from the circulation. Blood flow dynamics 
are reproduced by a simple procedure only, that of stirring 
magnetically. 
The physical handling of platelets gives rise to major 
problems, particularly if washed platelets are requi red. 
Release of granular products, if not actual aggregation, 
occurs. Extraordinary lengths have to be taken to en sur e 
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no release of PF 4 and aTG and other products from the a-
granules. The washing process may also remove a necessary 
platelet atmosphere containing fibrinogen, thrombin and 
calcium. All conclusions based on in vitro studies should 
therefore be made with an awareness of these differences 
from the in vivo situation. 
2.1.1.2 Platelet Preparation in Citrated Blood Versus 
Heparinized Blood. 
The choice of anticoagulant best suited to aggregation 
studies of platelets has been a matter of controversy for 
some years. It has been claimed that the release reaction 
induced by ADP is an artifact in citrated plasma brought 
about by the reduction in available calcium but is 
independent of such a reduction in magnesium (Mustard et 
al., 1975; Macfarlane et al ,., 1975). According to their 
reports platelets in plasma which is anticoagulated by 
heparin or hirudin, or_ platelets washed and suspended in a 
medium which contains 1-2mM Ca 2+ do not undergo the release 
reaction when they are aggregated by ADP. The 
concentration of calcium in the circulation is about 1mM 
(Hansen and Theodorsen, 1971), but the optimum 
concentration of calcium for aggregation is below this 
(Heptinstall, 1976). 
EGTA (ethylene-glycol-bis (a-amino-ethyl ether) N,N'-
tetra-acetic acid) behaves in the same manner as citrate in 
its effect on aggregation due to ADP, confirming that a 
reduction in calcium ions promotes the release reaction 
(Huzoor-Akbar and Ardlie, 1978). A direct effect of 
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citrate is therefore not the cause of secondary 
aggregation. ADP-induced biphasic platelet aggregation 
will occur in the absence of citrate. Huzoor-Akbar and 
Ardlie (1976; 1977; 1978) proposed that thrombin is 
necessary for the release reaction which would explain the 
inhibitory effect of heparin and hirudin. 
Recently a detailed comparison was made of the 
reactivity of platelets in plasma anticoagulated with 
citrate, heparin or hirudin (Lages and Weiss, 1981). 
Variable responses between different donors were observed 
for heparinized platelet-rich plasma, with respect to 
secretion, but not the extent of aggregation by ADP. 
Adrenaline-induced aggregation showed variability in both 
secretion and extent of aggregation in heparin compared to 
citrate. Hirudin consistently prevented the release 
reaction which supports earli-er evidence that thrombin is 
involved in platelet reactions caused by ADP, adrenaline 
and collagen (Ardlie and Han, 1974; Huzoor-Akbar and 
Ardlie, 1976; 1978). 
Hwang and Le Blanc (1981) proposed that heparin has 
aspirin-like activity in that it inhibits formation of 
endoperoxide metabolites. If this were so, lack of 
thromboxane formation and secondary aggregation could be an 
artifact of heparinized plasma. Heparin, added to citrated 
plasma inhibited thromboxane production. Collagen 
stimulation of thromboxane production was reduced i n 
heparinized plasma compared to citrated plasma. 
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Heparin itself is reputedly an aggregating agent in some 
circumstances but the effects are variable and inconsistent 
(Wissler and Gitel, 1976). Heparin was shown to induce 
aggregation at 4°C and at 37°C of washed platelets derived 
from patients exposed to severe stress (Mims et al., 1977). 
Other authors claimed that storage at 37°C protects the 
platelets from aggregation due to heparin (Han and Ardlie, 
1974). Heparin has also been reported to potentiate the 
platelet response to ADP (Thomson et al., 1973). Lages and 
Weiss (1981) could induce aggregation with 2.SU/ml to 
1000/ml heparin. 
Reches et al. (1979) showed that heparin (0.4-
1.620/ml) inhibits by 50%, PGE 1-sensitive adenylate cyclase 
and antagonizes PGE 1 antiaggregating effects on platelets. 
These authors claim that their observations demonstrate 
that heparin induces a secondary phase of aggregation but 
neither release of serotonin, nor ATP, nor thromboxane 
production was investigated in their study. Their 
definition of secondary phase seems to depend only on the 
lack of reversal of aggregation. 
Certainly. the anticoagulant has to be specified to 
enable any interpretation to be made of an aggregation 
study. For one of the studies in this thesis, low 
concentrations of heparin were chosen in order to more 
closely reflect the situation in circulating blood. This 
practice incurred several difficulties, including 
insufficient anticoagulation of the blood from some donors. 
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For other aggregation studies, where maximal platelet 
sensitivity was not required, and a stable system was 
desired for comparisons to be made between experiments, 
citrate was used as the anticoagulant. Although trisodium 
citrate (10mM) chelates calcium ions, it does not, unlike 
EGTA, leach calcium out of the platelets. 
2.1 .1.3 Preparation of Platelet-Rich and Platelet-Poor 
Plasma from Fresh Whole Blood. 
Blood donors were healthy human volunteers who had not 
taken any aspirin-containing drugs in the previous 
fortnight. Donors taking steroids, antihypertensive drugs 
or antiasthmatic drugs were also avoided. 
Anticoagulant was mixed gently with the blood which 
was then contrifuged at 100g for 15 mins. The platelet-
rich plasma (PRP) was aspirated off, avoiding the layer 
near the white cells, using a siliconized-glass Pasteur 
pipette. This plasma was pooled in a polypropylene vessel, 
then taken up in a syringe from which air was subsequently 
expelled. The syringe was tightly capped and placed in a 
37°C water bath for the duration of the experiment. Under 
these storage conditions the aggregation response remains 
constant for 2.5-3 hours. The platelets were not used 
during the first ten minutes of storage. Platelet counts 
were determined using a Coulter Counter, Model ZF. 
A sample of PRP was spun in an Eppendorf 
microcentrifuge at 8000g for 2 mins. to sediment the 
platelets. The platelet-poor plasma (PPP) so formed was 
then used to establish 100% light transmission using an 
aggregometer. 
2.1.1 .4 Preparation of Washed Platelets. 
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Method A. PRP was prepared from blood anticoagulated 
with acid citrate. The PRP was centrifuged at 1100g for 
lSmin to form a platelet pellet. The plasma was poured 
off, the tube allowed to drain and washing fluid (pH6.5) 
was added. The platelets were resuspended in this washing 
fluid by pipetting up and down and a further 2ml of acid-
citrate dextrose was added per 8ml fluid prior to further 
centrifugation. The platelets were resuspended in 
suspending fluid (pH7.4)(see below) and stored in an air-
tight syringe at 37°C. 
Method B. PRP was obtained from the Red Cross Blood 
Bank, derived from a unit of blood. The PRP was spun at 
100g in the presence of 2ng/ml prostacyclin (PGI 2 ) to 
remove more red blood cells. The supernatant PRP was then 
centrifuged with 300ng PGI 2 /ml at 1100g for lSmin to form a 
platelet pellet. These platelets were resuspended in 
washing fluid (pH7.4) with 150ng PGI 2 /ml and apyrase 
(1ml/50ml plasma)(see below for preparation of apyrase). 
The platelets were again centrifuged at1100g for lSmin and 
the resultant pellet resuspended in suspending fluid 
(pH7.4). The platelets were stored in an airtight syringe 
at 37°C. A recovery time of 30min was allowed to reverse 
the effects of the PGI 2 • This method is a modification of 
Vargas et al.(1982). 
2.1 .1 .5 Observation of Aggregation using an Aggregometer 
and Lumi-aggregometer. 
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A turbidometric method for observation of platelet 
aggregation was devised by Born in 1962. This widely 
accepted technique was adopted, using a Payton dual channel 
Aggregation Module to measure changes in light transmission 
through stirred samples of PRP in siliconized glass 
cuvettes. 
Changes in light transmission were recorded with a 
Riken-Denshi SP-H6P recorder with a paper speed of 
600mm/hour. A baseline was established for unstimulated 
swirling platelet-rich plasma (zero transmission) and 100% 
transmission was set for PPP. This system allowed for 
observation of shape change when the turbidity increased 
slightly and subsequent aggregation associated with an 
increase in light transmission. 
A Chrono-Log Lumi-Aggregometer was used to measure the 
release of ATP associated with platelet aggregation 
Firefly lantern extracts were prepared by homogenizing 30mg 
Sigma FFT in 1ml of 100mM HCl, filtering through gauze and 
finally centrifuging at 1 ,OOOg for 5 mins. 25µ1 of this 
preparation was added to 500µ1 PRP containing 20µ1 of 154mM 
MgC1 2 • 
Standard solutions of ATP were prepared freshly on the 
day of the experiment in Reagent Diluent (RD, see Section 
2.2). One test for each of a range of concentrations o f 
ATP was used to determine the number of divisions of 
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recorder deflection for that concentration. In this manner 
the ATP assay was semi-quantitative. 
2.1 .2 _Radioimmunoassay of Thromboxane B2 
2.1.2.1 Antibody Binding and Crossreactivity 
TXB 2 antiserum (#280 D21) was a kind gift from Dr L. 
Levine, Waltham, Mass. USA. With the number of counts of 
the tracer set at 4,000 cpm per 100µ1, 50% binding was 
achieved with a final dilution of antiserum of 1 in 20,000. 
A dilution of 1 in 10,000 shifted the standard curve to the 
right for no increase in binding. As binding displacement 
was required for standards in the lower range and, of 
course for conservation of antibody, the 1 in 20,000 
dilution was chosen. There was less than 1% cross-
reactivity with PGF 1 a and PGF 2 a. 
2.1 .2.2. 3H-TXB 2 Characteristics 
The radioactive tracer, 3H-TXB 2 , was obtained from New 
England Nuclear in different lots which varied in 
radiochemical purity, as assessed by thin layer 
chromatography, between 98 and 98.5%. Each lot had a 
different specific activity but was counted prior to use 
and diluted to achieve a final dilution of approximately 
4,000 cpm per incubation tube. 
2.1.2.3 The Assay 
In polystyrene, Wasserman tubes, the radioimmunoassay 
was set up with each incubate consisting of 100µ1 each of 
sample or standard antibody and tracer, added in that 
order. The tubes were incubated at 4°C for at least 18 hrs 
and no longer than 2 days. An intra-assay control 
consisted of placing standard TXB 2 at various positions 
throughout the one assay set of tubes. Inter-assay 
variability was controlled by placing in each assay a 
standard set of tubes from a batch kept frozen. 
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The standard curve was formed with the dilution from a 
2µg aliquot to make a series of 8 standards from 8pg to 
1000pg/100µl. The samples assayed contained plasma which 
was found to interfere with antibody binding so each 
incubate contained 10µ1 of sample only. Consequently each 
standard TXB 2 tube had 10µ1 PRP (inactivated with 100µM 
indomethacin) added. Each tube was vortexed and then 
incubated. 
2.1.2.4 Separation, Counting and Calculations 
Separation of bound from unbound tracer was achieved 
by the addition of 300µ1 of dextran-coated charcoal. The 
mixture of charcoal, dextran and albumin was stirred for 10 
min. on ice and the aliquot was rapidly added to each tube 
which was immediately placed in a centrifuge carrier and 
shaken. 
5 mins after the addition of charcoal to the last tube 
centrifugation for 10 mins at 1500g on a MSE Coolspin was 
commenced. The supernatant fluid was decanted into a 
scintillation vial containing 5ml of Xylene/TritonX100 
scintillant. The vials were capped, shaken vigourously and 
counted in a Packard scintillation counter. 
Raw counts were converted to percentage binding by the 
formula %Bound= Counts - NSB 
Total Counts 
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NSB = non-specific binding, that is, the counts remaining 
in the supernatant fluid without the presence of antibody. 
A standard curve of percentage bound radioactivity versus 
amount of TXB 2 (pg) was plotted on semi-logarithmic paper. 
The unknown samples were then read from this curve and 
concentrations in pg/ml were converted to pmole/10 7 
platelets for each experiment. 
2.1.3 Phospholipid Analysis 
2.1.3.1 Extraction of Membrane Lipids 
Platelet reactions in a volume of 900µ1 were stopped 
by the addition of 1 .25ml CH 30H:10M HC1(50:l). The 
cuvette was rinsed out with 3.1ml CHC1 30H (25:32) and added 
to reaction mixture. This was partioned using 1.4ml CHC1 3 
and 1 .4ml water which was mixed and the mixture centrifuged 
at 1000g for 10min. The lower layer was dried under 
nitrogen at 45°C. The phospholipids were redisolved in 
CHC1 3 :CH 30H:10M HCl (200:100:0.1) containing 0.05% 
butylated hydroxytoluene (BHT) and stored at -20°C prior to 
chromatographing. This method is modified from Bligh and 
Dyer (1959) as used by Lloyd et al.(1972). 
2.1.3.2 Paper Chromatography 
The lipid extract was separated into different polar 
lipids in a two dimensional system on Whatman SG-81 
chromatography paper. Two different solvent systems were 
tried with the second one being adopted for experiments. 
Both were taken from Wuthier (1976). 
System A. 
1st dimension (long) chloroform: diisobutylketone: 
methanol: acetic acid: water (45:30:15:20:4) 
2nd dimension (short) chloroform: diisobutylketone: 
pyridine: methanol: water (30:25 : 35:25:8). 
System B. 
1st dimension (short) chloroform: methanol: SM NH 4 0H 
(64:34:4). 
2nd dimension (long) chloroform: diisobutylketone: 
pyridine: methanol: water: acetic acid: formic acid 
(23:20:25:20:3:8:1). 
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46x57cm sheets of paper were cut into 9 equal-sized 
sheets 15.3xl9.0cm and stored in a dessicator. 
Diisobutylketone was vacuum distilled prior to use. 
Solvent mixtures were prepared fresh daily and 100ml added 
to each tank at least 10min prior to introduction of the 
paper. TLC tanks were used into which four rolled 
cylinders of paper could stand side by side. 
A spot of lipid extract was made in the lower left 
hand corner, applying 20-30µg Pin about 20µ1. The spot 
was made in the form of a streak about 3x7mm in the 
direction of the first run. The spot and labels were 
marked with a pencil. The paper was rolled and hand-sewn 
with a whip-stitch to form a cylinder. The paper was then 
placed in the chromatography tank after no longer than 
fifteen minutes. 
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The solvents were allowed to run to about 1cm from the top 
which took 2 hr for the first dimension (short) and 3 hr 
for the 2nd dimension (long). The paper was dried for 
30min between the two runs by hanging in a fume cupboard. 
The cylinder was then cut open and resewn at right angles 
to the first. 
After the second run, the paper was thoroughly dried 
again in the fume cupboard and prepared for staining which 
was done in a metal tray. The chromatogram was washed with 
distilled water and rinsed with 0.5M acetic acid. The 
staining was then achieved by soaking in rhodamine 6G 
(0.0012%) for 10min with gently rocking to ensure uniform 
contact. 
The stained chromatogram was viewed under UV while 
still wet and the spots marked with a dull pencil. When 
the chromatogram had dried, it was again viewed under UV 
and the spots checked for colour changes. Lysolipids were 
detected by a change from pale yellow to blue on drying. 
2.1.3.3 Phospholipid Estimation by Phosphorus Analysis. 
(Rouser et al., 1966) 
Each spot was cut out, weighed and placed in a 15x1cm 
pyrex test tube. To each tube was added 750µ1 70% 
perchloric acid containing 1ml/litre of 10% ammonium 
molybdate. The tubes were heated in a radiant heat 
apparatus at 180-200°C until the colour disappeared. To 
the cooled tubes 3ml of water was added and mixed. Next, 
0.5ml 2.5% ammonium molybdate then 0.5ml 10% ascorbic acid 
was added to each tube, mixing between additions. The 
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tubes were incubated at 56°C for 30min. The silica was 
removed by centrifugation and the supernatant fluid read on 
a Beckman DU-8 spectrophotometer. A zero standard was used 
as a blank for the instrument. A standard curve was 
prepared using standard inorganic phosphorus solutions in 
the range 0.1 to 10µg/ml. Each unknown phosphorus was 
estimated from the standard curve allowing for the 
phosphorus content of the paper itself. The paper 
phosphorus was calculated from non-stained areas of the 
chromatogram which were weighed and digested as were the 
lipid spots. The estimation of phosphorus per mg paper 
allowed an estimation of phosphorus due to the paper alone 
from the weight of the spot. 
true µgP/spot - (totalP/spot)-(mgpaper/spot X µgP/mg 
paper in blank areas) 
2.1.3.4 Phospholipid Turnover as Indicated by 3H-arachi-
donic Acid Incorporation 
3H-arachidonic acid was incorporated in the membranes 
of platelets by incubating at 37°C for 1 hr with Sµl 3H-
arachidonic acid (Amersham), specific activity 137Ci/m mol 
per 100ml of original PRP volume. (Sµl=SµCi). The 
incubation was done in washing fluid, ensuring prostacyclin 
150µg/ml was added for the incubation and again immediately 
prior to centrifugation. The platelets were then 
resuspended as usual and allowed to recover for 15min at 
37°c. 
Platelet reactions, extraction of lipids and 
chromatography were carried out as described above. The 
67 
spots were cut out and placed in scintillation vials to 
which 5ml of scintillant was added. The vials were counted 
in a Packard Tri-carb 460 scintillation counter which 
recorded counts as disintegrations per min. Different 
quenching due to the different sizes of stained paper was 
found to be insignificant. 
2.2 MATERIALS 
2.2.1 Buffers and Solutions. 
Reagent Diluent (RD) is a modified Tyrode's solution 
with the following composition:8.0g/1 NaCl, 0.2g/l KCl., 
1 .0g/1 NaHC0 3 , 0.0Sg/1 NaH 2 PO 4 at pH 7.4. This solution 
was prepared weekly and stored at 4°C. It was used to 
dilute reagents used in aggregation studies. 
Washing fluid was prepared on the day required to give 
a final composition of: NaCl 8.0g/1,KCl 0.2g/l,NaHCO 3 
1.0g/l,NaH 2PO 4 0.0Sg/1, albumin 3.Sg/1, glucose1g/l; pH7.4 
or 6.5 at 37°c. Apyrase was added (Ardlie et al., 1970; 
1971) immediately prior to addition to platelets or 2ml 
extra ACD was added per 8ml fluid. The solutions were kept 
at 37-°C prior to use. ACD = acid citrate dextrose which 
consists of 25g trisodium citrate, 14g citric acid and 20g 
dextrose per litre. 
Suspending fluid was prepared on the day required and 
differed from the washing fluid in containing, in addition, 
MgC1 2 0.009g/l and CaC1 2 0.022g/l;pH7.4,37°C. 
Stock fibrinogen for adding to washed platelets 
in order that adrenaline and ADP may cause aggregation. It 
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was prepared from Kabi human fibrinogen, 1g was dissolved 
in 20ml normal saline, and placed on gentle agitation. 2ml 
of 20% Al(0H) 3 was added when fibrinogen dissolved. The 
solution was left for 10min at room temperature for 
adsorption and centrifuged at 2000g for 10min. The 
adsorption was repeated with another 2ml of 20% Al(0H) 3 • 
The fibrinogen solution was then dialyzed against normal 
saline at room temperature with four changes overnight. 
The dialyzed solution was ultracentrifuged at 37,000g for 
20min ambient temperature on a Beckman J2-21 centrifuge. 
The protein concentration was estimated by a modified Lowry 
method (Peterson, 1977). Aliquots of 100~1 were stored at 
-20°C and thawed on the day required. 
The stock solution was estimated to be 1 .2g%. An 
aliquot was thawed by warming and used at 20µ1 per 750µ1 
platelet suspension. This gave a final concentration of 
approximately 0.3mg/ml. 
Apyrase was prepared from potatoes and stored in 1ml 
aliquots at -20°C. Peeled, sliced potatoes were 
homogenized in a Waring blender (10kg/litre d.H 20). The 
suspension was stirred a further 30min at room temperature 
and then pressed through 6 layers of cheese cloth. The 
effluent was centrifuged at 900g R.T. for 10min. The 
supernatant fluid was refiltered and centrifuged. Further 
steps were carried out at 0-10°C. The supernatant fluid 
was brought to 25mM CaC1 2 and stirred 15min at 4°C. The 
solution was allowed to settle for 1 hr at 4°C, then 
centrifuged 3500g for 20min at 4°C. The precipitate was 
resuspended in 1 .OM CaC1 2 , stirred 60min 0-4°C and 
centrifuged as before. The supernatant fluid was then 
dialyzed against 201 0.1M KCl for 24hr 4°C. The 
supernatant fluid was combined with saturated ammonium 
sulphate and stirred for 40min, then again centrifuged. 
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The precipitate was redissolved in 25ml distilled water and 
dialyzed twice against normal saline overnight. 
For platelet counting, 5~1 of platelets were added to 
15 mls of Isoton II (azide free) balanced electrolyte 
solution. 
TRIS-gel buffer for radioiminunoassay was a lSmM TRIS-
base (Sigma) solution with SOOmg/1 gelatin (Ajax) added. A 
stock solution of lSOmM TRIS-HCl, pH 7.4 was kept at 4°C. 
As required this was diluted one-tenth, gelatine dissolved 
in it by warming, then adjusted to pH 7.4 at 4°c. 
2.2.2 Aggregating Agents 
Adenosine diphosphate (ADP)(Sigma) was made up in 
100~~ aliquots of 10- 2M and stored at -20°C. Just prior to 
an experiment this solution was further diluted with RD. 
Adrenaline bitartrate (Calbiochem San Diego, CA, USA) 
was prepared and stored the same way as ADP, except that 
adrenaline was kept in the dark. 
Arachidonic acid was converted to the potassium salt 
by dissolving 100mg in 11 .2Sml ethanol containing 18.42mg 
KOH. This was stored in 1ml aliquots in the dark at -20°C. 
Immediately prior to each experiment, the potassium 
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arachidonate was dried down under nitrogen and redissovled 
in RD. 
5 hydroxytryptamine (serotonin) from Sigma was 
prepared as required. 
A 20O/ml ampoule of Vasopressin (Pitressin(R), Parke-
Davis) was opened for each experiment and diluted as 
required in RD. 
Noradrenaline (Sigma) was prepared and stored the same 
way as adrenaline. 
Clonidine (Catapres pure substance) a gift from 
Boehringer Ingelheim, was prepared and stored the same way 
as adrenaline. 
Phenylephrine-HCl(Sigma) was kept dry at 4°C and 
prepared as required. 
Phospholipase C (Sigma) of specific activity 20U/mg 
protein or 8O/mg solid was stored at -20°C and prepared in 
RD as required. 
Thrombin (Parke Davis, bovine origin) was diluted in 
RD to 1000U/mland stored in 100µ1 aliquots at -20°c. 
2.2.3 Inhibitors 
Acetysalicylic acid, aspirin (ASA) (BDH,general 
purpose reagent) S0mM was made freshly each day with 90mg 
per 10ml. It was dissolved by stirring and adding NaOH 
until the pH was approx. 7.3. This solution was diluted as 
required and used at one-tenth volume of PRP. 
Indomethacin (Sigma) was prepared in absolute ethanol 
at a concentration of 10mM to be used at one-hundredth the 
volume of PRP at a final concentration of 100µM. 
BW75SC; 3-Amino-1-[M-(trifluoromethyl)-phenyl]-2-
pyrazoline, a gift from Burroughs-Wellcome, was dissolved 
at a concentration of 100µg/ml (380µM) in RD and used at 
one-tenth volume in PRP. 
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n-butyl-imidazole (Koch-Light), a liquid stored at 4°C 
was freshly diluted in RD to obtain a concentration of S0mM 
and was used at one-tenth volume in PRP. p-Bromophenacyl 
bromide, BPB (Koch-Light) was made freshly in 
dimethylsulphoxide (DMSO) at a concentration of SmM to be 
used at one-hundredth volume in PRP. 
Tosylphenylalaninechloromethylketone (TPCK) (Sigma) 
was also dissolved in DMSO. 
Dibenamine and phenoxybenzamine were both gifts from 
Smith, Kline and French, Frenchs Forrest, NSW. Both were 
prepared freshly in ethanol and added at one-hundredth 
volume or diluted further in saline. 
Hirudin (Sigma Chemical Co.) was dissolved freshly in 
RD. 
Isoptin (verapamil)(Knoll, 2.5/ml ampoules) was stored 
at 4°C and diluted in RD as required. 
Largactil (chlorpromazine)(May and Baker, 25mg/ml 
ampoules) was stored at 4°C and diluted as required. This 
preparation also contained sodium sulphite, sodium 
metabisulphite and sodium citrate. 
Phenergan (promethazine)(May and Baker, 25mg/ml 
ampoules) was stored at 4°C and diluted as required as was 
trifluoperazine. 
Mepacrine(quinacrine)(May and Baker) was prepared freshly 
in DMSO. 
Prostacyclin, a gift from the Upjohn Company, 
Kalamazoo, Michigan, U.S.A. was prepared in O.OSM TRIS 
buffer, pH9.3 freshly each week. 
Trimetoquinol (S-TMQ)was a kind gift from Yoshio 
Iwasawa, Tanabe Sekako Co.Ltd.Japan. and was stored at -
20°C dissolved in DMSO as required 
Spermine (N,N-bis[3-aminopropyl]-1 ,4 butanediamine) 
Sigma was dissolved in RD. 
2.2.4 Anticoagulants. 
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Citrate, (trisodium salt) was kept as a stock solution 
of 100mM and used in a ratio of 1ml to 9ml of blood, giving 
a final concentration of 10mM. 
Heparin (Injection B.P., Allen and Hanburys) was used 
freshly from an unopened ampoule, diluted in RD to give 
desired concentration from a one-in-ten dilution. Dried 
sodium heparin (mucous) from Commonwealth Serum 
Laboratories was dissolved freshly as required. Heparin 
from Evans Medical Ltd., Liverpool, England was used for 
some experiments. 
Acid citrate dextrose (ACD) was used as anticoagulant 
for some preparations of washed platelets. It was prepared 
from 25g trisodium citrate, 14g citric acid and 20g 
dextrose per litre. 
2.2.S RIA Reagents 
Antibody against thromboxane B2 #280 D21 courtesy Dr T. 
Levine, Waltham, Mass. U.S.A. was divided into 5µ1 aliquots 
which were freeze dried. As required, each aliquot was 
reconstituted to 1ml with TRIS-gel buffer pH 7.4 and 
diluted on the day of assay. Anything remaining of the 
reconstituted aliquot was stored at 4°C, not frozen, and 
discarded after one week if not used. 
3H-TXB 2 (New England Nuclear) was stored at -20°C 
with the addition of 5ml of ethanol. On the day of assay 
the appropriate volume was removed and diluted with TRIS-
gel buffer pH 7.4. 
Dried TXB 2 (U51541) for use as a standard was a gift 
from The Upjohn Companay, Kalamazoo, Michigan, USA. 
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0.569mg was weighed on a Perkin-Elmer Autobalance AD-27, 
weighed by difference. This sample was then dissolved in 
50ml water in a standard flask from which 200 aliquots were 
freeze dried and kept at -20°C. 
Dextran coated charcoal was prepared freshly by 
combining 10mg dextran T-10, 10mg bovine serum albumin and 
60mg charcoal (Norrit A) per 10ml TRIS-gel at 4°C. 
2.2.6 .. Solvents for Paper Chromatography 
The solvents used for the paper chromatograph were 
analyt~~al _reagents, except for diisobutylketone (2,6-
dimethyl-4-heptanone, Ega-Chemie) which was redistilled by 
vacuum distillation. The other solvents were chloroform AR 
(Ajax) .! methanol AR (Ajax), pyridine (Ajax), SN ammonia 
(NH 4 0H) _(Comm~nwealth Ammonia Co.), acetic acid (Ajax) 
formic acid (BDH) and nanopure distilled water. 
2.2.7 Reagents for Phosphorus Assay 
Digestions were performed in 70% perchloric acid (G. 
Frederick Smith Co., Columbus, Ohio). Colour development 
in the assay was produced by ammonium molybdate (Baker 
Chemical Co.) and ascorbic acid (Calbiochem). Nanopure 
distilled water was used for all solutions. 
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CHAPTER 3 
MULTIPLE AGONISTS IN VITRO 
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3.0 SUMMARY 
This study examined the interaction between several 
agonists of human platelet aggregation in blood collected 
into low concentrations of heparin, in an attempt to 
reproduce the in vivo situation. These conditions were 
chosen because _multiple agonist~ are present in circulating 
blood. Another characteristic of the haemostatic mechanism 
may be the physiologic regulation of blood coagulation by 
vascular endothelial heparan sulphate. Irreversible 
aggregation was observed in vitro at pathological levels of 
adrenaline, when used in combination with ADP and 
vasopressin. Even lower levels, in the physiological 
range, caused aggregation when four agonises were combined. 
In vivo aggregation might therefore be expected to occur 
under certain circumstances. Concentrations of adrenaline, 
vasopressin and ADP which together caused irreversible 
aggregation in heparinized PRP were insufficient to cause 
this response in citrated PRP from the same donor, in some 
cases, indicating a necessity for calcium in the 
potentiation mechanism. Any increase in aggregation in 
heparinized plasma was reduced by hirudin, indicating that 
thrombin can act as an additional agonist. It is suggested 
that the ability of adrenaline to potentiate platelet 
aggregation by physiological agents such as ADP and 
thrombin provides a mechanism for facilitating platelet 
activation at sites of vascular injury. 
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3.1. INTRODUCTION 
The s~udy of the effects of several different agonists 
on platelet aggregation is of interest because it reflects 
more closely the in vivo platelet environment in two 
aspects. Fir~tly, the circulating blood contains several 
agonists which can influence the platelet at any one time. 
Secondly, most of these agonists may not be raised above 
normal levels in the circulation in a given situation. Use 
of multiple agonists allows lower concentrations of each 
agonist to be tested for effects on platelet aggregation. 
In studies _using single agonists the concentrations 
required are well in excess of physiological 
concentrations. 
The phenomenon of positive interaction of low 
concentrations of agonists with platelets was first shown 
by O'Brien (1964). Ardlie et al.(1966) first described the 
ef~ect of prior exposure to catecholamines, adrenaline, 
noradrenaline and dopamine. Catecholamines potentiated the 
response to _ADP in vitro which suggested that the role of 
catecholamines in the initiation and subsequent development 
of thrombi deserv~d further investigation. 
Aggregating agents were studied further in paired 
combination by Niewiarowski and Thomas (1966), Mills and 
Roberts (1967), Baumgartner and Born (1968), Nakanishi et 
al.(1971), Packham et al.(1973), Michal and Motamed (1976) 
and G~ant and Scrutton (1980a). No multiple agonise 
studies have been undertaken. 
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The work of Huang and Detwiler (1981) contributed little to 
our understanding of the mechanisms of potentiation by 
particular agonists. Their work was based on varying the 
concentrations of different pairs of either weak or strong 
agonists. They concluded that the concentration of agonist 
determined the characteristics of the response regardless 
of the order of addition of the agonists. Their conclusion 
differed from Grant and Scrutton (1980a) and they claimed 
that this was due to the fact that the latter workers 
always added the higher concentration of agonist second. 
This was not, in fact, the case and where the concentration 
of the second agonist was lower than the first, the 
aggregation tracing still showed more of the 
characteristics of the second agonist. 
Further evidence that the order of addition is 
significant comes from Owen and Le Breton (1980) who showed 
that calcium uptake differed, depending on the order of 
addition of adrenaline and ADP. When ADP was added first 
there was measurable 45Ca uptake but not when adrenaline 
was added first. The concentrations of each agonist were 
kept constant and the final extent of aggregation was the 
same, regardless of order of addition. 
Two agonists investigated in the present study may be 
increased in the circulation under conditions of stress. 
Stress may be an important risk factor in coronary arteiy 
disease. Baseline levels of adrenaline reported by 
Dimsdale and Moss (1980) were 0.64nM (range 0.48-1.2nM) 
which could rise 3-fold during public speaking. 
Noradrenaline could rise 3-fold during vigorous exercise 
and increased 50% during public speaking from baseline 
levels of 3.4nM (range 2.2-4.3nM). Pathological stress 
could increase adrenaline levels to 10nM (Grant and 
Scrutton, 1980a). 
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Grant and Scrutton (1980a) reported that vasopressin 
increased 10-fold in adrenocortical insufficiency, from 
normal levels of O.lnM but Johnston et al.(1981) quote 
normal levels of 1-SpM. The level of 5-hydroxytryptamine 
in blood is 0.1-10µM (De Clerck and Herman, 1983) which 
would be locally increased once platelet release has been 
activated. ADP circulating levels are unknown and it is 
also not known what a pathological level of ADP would be. 
The work on positive interaction of platelet agonists has, 
so far, only reported effects at concentrations higher than 
pathological levels. The lowest concentrations at which 
adrenaline and vasopressin interacted postively were at 
least two orders of magnitude greater than the blood 
concentrations of these hormones achieved in pathological 
states (Grant and Scrutton, 1980a). To be able to achieve 
potentiation of aggregation with at least pathological 
levels would be a major step in accepting in vitro 
aggregation as a proper reflection of in vivo phenomena. 
The p~esent work extends the study of the interaction 
of aggregating agents by challenging platelets with up to 
four agonists in immediate succession. It was suspected 
that an additional agonist, thrombin, would be present as a 
very low concentration of heparin was used as 
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anticoagulant. In these ways, it was anticipated that the 
study approximate more closely the situation in circulating 
blood. Heparan sulphate associated with vascular 
endothelium may be a physiologic regulator of blood 
coagulation (Rosenberg, 1977) so that heparin can be 
regarded as a more 'natural' anticoagulant than citrate 
(see section 2.1.1.2 for a comparison of the use of heparin 
versus citrate). 
The study does not attempt to uncover a mechanism for 
the potentiation by any of the agonists. The aim of the 
study was to find out how low a concentration of an agonist 
can be used in vitro. In particular, a verification of the 
importance of circ~lating levels of catecholamines in 
platelet activation was sought. The lowest possible 
concentration of heparin was used to achieve anti-
coagulation. This might allow thrombin generation. The 
platelets sometimes showed increasing sensitivity during 
the course of a single experiment but each result was 
controlled by observing, simultaneously, the response 
obtained in the absence of the final agonist. 
3.2 METHODS AND MATERIALS 
Blood was obtained and plasma prepared as described 
in C~apter 2. 1.30/ml heparin was used as the 
anticoagulant for these experiments. The stress of 
venepuncture was minimized by allowing the donor to lie 
down and by the use of a winged infusion set (21Gx3/4") 
with a 12" (305mm) extension tube. The first two drops 
were discarded and withdrawal of the blood with a syringe 
was continued without a tourniquet. 
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Initially heparin (CSL) (161.8U/mg) was used but was 
found to allow microaggregates to form after centrifugation 
with some donors. This type of heparin was reported (Han 
and Ardlie, 1974) as being pro-aggregatory at 8.3U/ml when 
added to washed platelets. Thereafter, liquid heparin from 
Allen and Hanbury's was used in this study with more 
satisfactory anticoagulation. 
Since the stimulation by each agonist is not 
instantaneous and is only transitory, agonists were added 
at 15sec. intervals for an optimal rate of primary response 
for the range of concentrations used(Grant and Scrutton, 
1980). The order of addition of agonists was kept 
constant,firstly adrenaline, then serotonin(S-
hydroxytryptamine),noradrenaline or vasopressin and lastly 
ADP. 
Thrombin in PRP was determined using the chromogenic 
substrate Chromozym TH. 770µ1 TRIS imidazole buffer (pH 
8.4; 0.2M in 0.125M NaC1),10µl PRP (or thrombin) and 20µ1 
Chromozym TH (187.SµM) were incubated in a cuvette at 37°C 
and the absorption per min (at 405nm) was recorded. 
ADP, noradrenaline, adrenaline, 5-hydroxytryptamine 
(SHT), vasopressin, heparin and hirudin were obtained and 
stored as described in 2.2. 
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3.3 RESULTS 
3.3.1 The Use of Lower Concentrations of Heparin to Prepare 
Platelet Rich Plasma. 
As ~iscus~ed in Chapter 2, the characteristics of 
platelet aggregation induced in heparinized plasma have 
been found to differ by different authors. Observations 
were therefore made with different concentrations of 
heparin and these were compared with citrate. 
3.3.1.1 Effect of Heparin Concentration on Biphasic 
Aggregation due to ADP 
As the heparin concentration for anticoagulation was 
increased, so the threshold concentration of ADP required 
to cause a biphasic response increased(Fig 3.1). This 
reduced sensitivity to ADP was further illustrated when the 
concentration of heparin was increased such that only a 
single phase occurred in response to 5µM ADP(Fig 3.2). 
3.3.1.2 Comparison of Citrate and 1-2U/ml Heparin 
Heparinized platelet rich plasma was not always more 
sensitive to ADP than was citrated plasma. The pattern of 
response varied from donor to donor. Further, not all 
donors exhibited a biphasic ADP response in either citrate 
or heparin. Of those that did, the threshold concentration 
for induction of biphasic aggregation in response to ADP 
was often the same for citrate and 1-2U/ml heparin. Of 
eleven donors tested, four exhibited greater sensitivity in 
heparin (Table 3.1). For each of these donors, the exten t 
of primary aggregation in response to ADP was greater in 
PRP containing heparin (1-2 units/ml) than in PRP 
anticoagulated with citrate. Furthermore, · vasopressin 
(4µM) caused maximal aggregation in heparinized PRP, but 
almost no aggregation in citrated PRP. These differences 
could not be accounted for by differences in platelet 
count, since these were not significant. 
Table 3.1 Comparison Between Threshold Concentrations of 
ADP for Induction of Biphasic Aggregation in Citrated and 
Heparinized (1-2U/ml) PRP. 
Donor No 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
1 1 
citrated 
2.7 
1 • 8 
5.4 
7.2 
8. 1 
1 • 8 
3.6 
5.4 
4.5 
4.5 
4.5 
ADP threshold (µM) 
PRP Heparinized PRP 
1 • 8 
1 • 8 
5.4 
7.2 
7.2 
1 • 8 
1 • 8 
5.4 
4.5 
4.5 
2.7 
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% Light 
Transmission 
50 
1.3U Heparin 
t 
83 
4.0U Heparin 
t 0.9µM 
0.9µ.M 2JµM 
100_,__.__..__. __ ..._ ____ _._ ___________ _ 
1 2 Time(min) 
Figure 3.1 The effect of heparin concentration on ADP 
threshold. 
The biphasic aggregation responses to adenosine diphosphate 
(ADP) are shown. Platelet rich plasma (PRP) was anticoagu-
lated with 1.3U/ml and 4.0U/ml heparin, the latter 
concentration requiring more ADP to achieve the biphasic 
response. 
The arrow indicates the time of addition of the ADP. 
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Anticoagulant ADP cone 
% Light 
Transmission 
50 
A 5-lOU/ml 
heparin 
8 citrate lOmM 
C 2U/ml heparin 
D lU/ml heparin 
SµM 
"lµM 
O.BµM 
0.6µ.M 
100--.._ ..... ___. ___ _._ __ .__.__,,_.,_...J... _____ .,_ __ _ 
Time(min) 
Figure 3.2 High concentrations of heparin prevent 
biphasic aggregation. 
Platelet rich plasma from the same donor was anticoagulate
d 
with different concentrations of heparin (as shown) or 
citrate (10mM). ADP was added at increasing concentrations 
until biphasic aggregation was achieved. For 
concentrations of heparin of SU/ml and higher, biphasic 
aggregation was inhibited for ADP (S~M). 
The threshold heparin concentration for this inhibition 
varied between donors. Traces B, C and D were associated 
with release of ATP. The arrow indicates the time of 
addition of ADP. Platelet counts varied from 290,000-
330,000/~l. 
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3.3.1.3 Effect of Added Heparin on the Interaction between 
Adrenaline, Vasopressin and ADP. 
Plasma was anticoagulated with 1.3U/ml heparin, and 
aggregation was achieved with a combination of subthreshold 
concentrations of adrenaline, vasopressin and ADP. Heparin 
was added at two different concentrations three minutes 
prior to the addition of these agonists (Fig 3.3). 
Doubling the heparin concentration did not alter the 
response significantly and tripling the heparin 
concentration increased the response by only 5%. 
3.3.1.4 Thrombin as a Candidate for Explaining any 
Increased Sensitivity of Plasma Anticoagulated 
with 1.3U/ml Heparin. 
Thrombin was shown to potentiate the response to 
adrenaline and ADP in citrated plasma (Fig 3.4). 
Hirudin, a specific thrombin inhibitor, reduced the 
response to the combined addition of adrenaline, 
vasopressin and ADP to heparinized plasma (Fig 3.5). No 
significant differences were observed, however, in the 
thrombin levels (0-0.06U) using the chromogenic substrate, 
Chromozym TH in citrated or heparinized PRP from the same 
donor. 
3.3.1.5 Discussion on the Use of Heparin. 
Higher concentrations of heparin tend to increase the 
threshold for ADP which could be explained by inhibition of 
any thrombin which may be present. The low concentration 
of 1 .3U/ml heparin sometimes increased sensitivity when 
compared to responses in citrate, possibly due to a pro-
aggregatory effect. It is probable that citrate inhibits 
vasopressin by reducing the concentration of calcium ions 
0 
% Light 
T ronsmission 
so 
l Ht 
Hepa-ii 123 
or RD 
Time(min) 
A 
B 
C 
Figure 3.3 The effect of added hetarin on the response 
to the combined addition of adrena ine, vasopressin and 
ADP. 
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The platelet count was 295,000/~l in PRP anticoagulated 
with 1 .30/ml heparin. In another experiment 3.50/ml extra 
heparin did not alter the response at all. The arrows 
indicate the time of addition of : 
1. adrenaline (22nM) 
2. vasopressin (2nM) and 
3. ADP (435nM). 
A. no added heparin (RD). 
B. 1.70/ml extra heparin. 
C. 3.50/ml extra heparin. 
% Light 
Transmission 
0 
50 
Hl 
123 
A 
B 
C 
D 
Time(min) 
Figure 3.4 The potentiation of adrenaline and ADP by 
thrombin in PRP anticoagulated with 10mM citrate. 
A. RD+ 4nM adrenaline+ 0.35µM ADP 
B. RD+ 2.6mU/ml thrombin 
C. 2.6mU/ml thrombin +RD+ 0.35µM ADP 
D. 2.6mU/ml thrombin + 4nM adenaline + 0.3SµM ADP 
The arrows indicate the time of addition in the order : 
1. thrombin or RD 
2. adrenaline or RD 
3. ADP. 
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tll 
123 Hirudin 1 U/ml 
RD 
Time{min) 
Figure 3.5 The effect of ~re-incubation with hirudin 
(lU/ml), as ecific thrombin inhibitor, on the res onse to 
• 
PRP was anticoagulated with 1.3U/ml heparin. The arrows 
indicate the time of addition of: 
1. adrenaline 18nM 
2. vasopressin 0.8nM 
3. ADP O .18~M. 
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(Haslam and Rosson,1972). For most donors, 1.3U/ml heparin 
did not increase the sensitivity to ADP at all. When three 
agonists were used, added heparin at 3 times the 
anticoagulating concentration caused a small increase in 
response in one experiment. Heparin at low (1-1.3U/ml) 
concentrations was therefore considered to be the most 
suitable choice for a multiple agonist study where the 
lowest possible agonist concentrations of agonists was to 
be tested. It is clear that biphasic aggregation is not an 
artifact of citrated plasma and with most donors 1.3U/ml 
heparin did not inhibit the second phase with associated 
release caused by ADP~ 
3.3.2 Agonist Interactions Involving Adrenaline, ADP, 
Vasopressin, Noradrenaline and 5-Hydroxytryptamine. 
3.3.2.1 Interaction Between Two Agonists. 
The paired interaction of adrenaline and ADP or 
vasopressin and ADP resulted in irreversible aggregation 
for subthreshold concentrations of ea~~ _ag~nist (Fig 3.6) 
3.3.2.2 Interaction Between Three Agonists 
When three agonists were added in combination, lower 
concentrations of each agonist were required to achieve 
irreversible aggregation. Fig 3.7 illustrates an example 
of the re_sponses when 1 U/ml heparin ( CSL) was used, and 
Fig 3.8 illustrates an example of the responses when 
1.3U/ml heparin (Allen and Hanburys) was used. 
3.3.2.3 Interaction Between Four Agonists. 
Noradrenaline and SHT are also present in the 
circulation in addition to vasopressin, adrenaline and ADP. 
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With the addition of noradrenaline to the three agonists 
already used, even lower concentrations could achieve 
irreversible aggregation (Fig 3.9). The result was 
variable, however, and as much as 43nM noradrenaline was 
required for irreversible aggregation when using adrenaline 
(4.3nM), vasopressin (0.5 - 1nM) and ADP (0.2 - 0.4µM) in 
some donors. 
SHT added in combination with adrenaline, vasopressin 
and ADP also showed variable responses. For some donors 
aggregation was always reversible, no matter how much SHT 
added. The lowest concentration of SHT capable of causing 
irreversible aggregation in combination with the other 
three agonists was 120nM (Fig 3.10). The lowest 
concentrations of each agonist which interacted positively 
when combined with other agonists are shown, together with 
their physiological and pathological levels, where known, 
in Table 3.2. 
Table 3.2 Comparison of lowest concentration of agonist 
causing in vitro aggregation with reported physiological 
and pathological levels in circulating blood. 
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Agonist Physiological 
Level 
Pathological 
Level 
Level to cause 
in vitro 
aggregation 
in this study 
Adrenaline 1nM* 
(0.48-1.2nM)@ 
Noradren. 2.2-4.3nM@ 
Vasopressin 1-SpM# 
5-HT 
10nM* 
1nM* 
2.6nM 
4.3nM 
O.SnM 
120nM 
* Grant and Scrutton (1980). @ Dimsdale and Moss(l980). 
# Johnston et al. (1981). 0 De Clerck and Herman(1983) 
The levels given causing in vitro aggregation are those 
achieved by the addition of agonists. No assay was done on 
the existing levels in the blood. The stress of 
venepuncture was minimized as described. 
3.3.2.4 Effect of Citrate on the Response to Multiple 
Agonists. 
The response to multiple agonists was decreased in PRP 
obtained from blood anticoagulated with citrate compared 
with PRP obtained from blood anticoagulated with heparin in 
several donors. The concentration of adrenaline needed to 
enhance the aggregation response in citrated plasma was at 
least two orders of magnitude greater than the minimum 
concentration which achieved amplification in plasma 
containing a low concentration of heparin. Less adrenaline 
was required as the concentration of ADP was increased . 
% Light 
Transmission 
0 
50 
tt 
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B 
C 
Time(min) 
Figure 3.6 The positive interaction of adrenaline and 
ADP, vasopressin and ADP. 
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The PRP was anticoagulated with 1.2U/ml heparin. Neither 
18nM vasopressin nor 42nM adrenaline caused aggregation 
when added by themselves. These responses were obtained 
120 min after blood collection time. Platelet count was 
300,000/~1. Agonists were added at the times indicated by 
the arrows which are 15sec. apart. The order of addition 
was as indicated below. 
RD = reagent diluent 
A. 
B. 
C. 
Agonists 
1 • 
RD 
18nM vasopressin 
42nM adrenaline 
2. 
800nM ADP 
800nM ADP 
800nM ADP 
% Light 
Transmission 
0 
so 
ltt 
123 
A 
B 
Time(min) 
Figure 3.7 The positive interaction of adrenaline, 
vasopressin and ADP. 
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The PRP was anticoagulated with 1U/ml heparin (CSL) . 2.SnM 
adrenaline did not cause aggregation by itself. These 
responses were obtained 200 mins after blood collection. 
Platelet count was 277,000/~l. Agonists were added at the 
times indicated by the arrows which are 15sec . apar ta The 
order of addition was as indicated below. 
RD - reagent diluent 
A. 
B. 
1 • 
RD 
3.SnM adrenaline 
Agonists 
2. 
0.2nM vasopressin 
0.2nM vasopressin 
3. 
200nM ADP 
200nM ADP 
% Light 
Transmission 
0 
50 
tn 
123 
A 
B 
Time(min) 
Figure 3.8 The Aositive interaction of adrenaline, 
vasopressin and DP. 
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The PRP was anticoagulated with 1.3U/ml heparin (A+ H). 
21nM adrenaline did not cause aggregation by itself. These 
responses were obtained 70 mins after blood collection. 
Platelet count was 307,000/~1. Agonists were added at the 
times indicated by the arrows which are 15sec. apart. The 
order of addition was as indicated below. 
RD - reagent diluent 
A. 
B. 
1 • 
RD 
21nM adrenaline 
Agonists 
2. 
1.0nM vasopressin 
1 .OnM vasopressin 
3. 
200nM ADP 
200nM ADP 
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Figure 3.9 The positive interaction of adrenaline, 
noradrenaline, vasopressin and ADP. 
The PRP was anticoagulated with 10/ml heparin (CSL). 2.6nM 
adrenaline did not cause aggregation by itself. These 
responses were obtained 130 mins after blood collection. 
Platelet count was 319,000/µl. Agonists were added at the 
times indicated by the arrows which are 15sec. apart. The 
order of addition was as indicated below. 
RD - reagent diluent 
1 • 
A. RD 
B. 2. 6nM 
adrenaline 
Agonists 
2. 
4.3nM 
noradrenaline 
4.3nM 
noradrenaline 
3 . 
O. SnM 
vasopressin 
O.SnM 
vasopressin 
4 . 
400nM ADP 
400nM ADP 
% Light 
T ronsmission 
0 
50 
lttl 
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Time(min) 
Figure 3.10 The aositive interaction of adrenaline, 
vasopressin, 5-hy roxytryptamine and ADP. 
The PRP was anticoagulated with 1.3U/ml heparin (A+ H). 
4.3nM adrenaline did not cause aggregation by itself. 
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These responses were abtained 140 mins after blood 
collection. Platelet count was 291 ,000/~1. Agonists were 
added at the times indicated by the arrows which are 15sec. 
apart. The order of addition was as indicated in the right 
hand columns. 
RD - reagent diluent 
A. 
1 • 
RD 
B. 4.3nM 
adrenaline 
Agonists 
2. 
1 .OnM 
vasopressin 
1 .OnM 
vasopressin 
3 .. 
120nM SHT 
120nM SHT 
200nM ADP 
200nM ADP 
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3.4.3 DISCUSSION 
This study ?as demonstrated that enhancement of 
aggregatio~ of human _platelets is possible in vitro using 
concentrations of catecholamines which could be achieved in 
vivo. This is in contrast to previously published minimum 
levels (Grant an~ Scrutton, 1980a) which have been 
considerably higher than the levels which occur in 
pathological states. If the results using low 
concentrations of heparin can be extrapolated to the 
in vivo situation, then platelet aggregation may occur in 
certain states. An example may be the emotional stress of 
public speaking which is associated with a more than 
doubling of the plasma level of adrenaline (Dimsdale and 
Moss, 1980). The potentiating properties of adrenaline may 
provide a mechanism for facilitating platelet activation at 
sites of vascular injury. 
The method used here for examining agonist interaction 
differs from others in that a much lower concentration of 
heparin was used to anticoagulate blood. With this method 
of collection, platelets were at least as sensitive as 
those collected in citrate, and often more sensitive to 
aggregating agents. Those platelets which were found to be 
more sensitive responded to multiple agonists at 
concentrations obtained in physiological and pathological 
states. 
The reduction in the sensitivity of the heparinized 
PRP caused by hirudin, a specific inhibitor for thrombin, 
suggests that thrombin participates in the aggregatory 
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response. This has been suggested by earlier workers, 
Ardlie and Han (1974)and Huzoor-Akbar and Ardlie (1976; 
1977) who particularly emphasized a role for thrombin in 
the release reaction. The lack of difference in thrombin 
levels in PRP anticoagulated with either citrate or heparin 
seems to negate this theory. Nevertheless, a small amount 
of thrombin may act as an additional agonist, inhibitable 
by hirudin. MacIntyre et al.(1981) reported that heparin 
po~entiates aggregation, but in the present study heparin 
had to be increased 3-fold above the anticoagulant 
concentrations used to cause any enhancement of aggregation 
caused by three combined agonists. 
The reduced effectiveness of adrenaline in the 
presence of citrate is consistent with calcium fluxes being 
involved in the mechanism of adrenaline potentiation (Owen 
et al., 1980). Others have obtained evidence, however, to 
show that adrenaline does not cause net influx of calcium 
into human platelets unless secretion occurs(Brass and 
Shattil,1982; Clare and Scrutton,1984). An alternative 
explanation for the effect of citrate may have to be 
sought, not necessarily, however, excluding effects on 
membrane bound calcium. In addition, and consistent with 
observations made by Haslam and Rosson (1972), citrate 
appears to inhibit vasopressin which therefore, probably 
requires calcium for its action. 
There are possible similarities between the test 
system described for this study and physiological 
anticoagulation. Anti-thrombin is considered to be an 
important natural anticoagulant and its interaction with 
clotting factors is significantly enhanced by heparin 
(Rosenberg, 1977). Heparan sulphate, which is associated 
with endothelial cells, may be a normal cofactor for 
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antithrombin in regulating coagulation. In both the test 
system described in the present study and in the 
haemostatic response (Shattil and Bennett, 1980) platelet 
activation is enhanced by thrombin. Furthermore, the 
interaction of platelets with a combination of agonists 
probably more closely reflects platelet activation in vivo. 
CHAPTER 4 
MECHANISM OF THE FACILITATING EFFECTS OF 
ADRENALINE ON PLATELET AGGREGATION 
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4.0 SUMMARY 
Adrenaline, by itself, can aggregate human platelets 
in vitro, and also has the property of being able to 
potentiate the aggregation response to subthreshold concentr 
ations of other platelet agonists. Since it is largely 
inhibited by aspirin, the ability of adrenaline, alone, to 
cause platelet aggregation in citrated plasma is believed 
to depend on the cyclooxygenase pathway of arachidonic acid 
metabolism. This chapter examines whether the potentiating 
effects of adrenaline also depend on this mechanism. 
This report describes the effects of several 
inhibitors of arachidonate metabolism on adrenaline-
potentiated aggregation and TXB 2 production. It was shown 
that adrenaline stimulated a cyclooxygenase-independent 
pathway resulting in potentiation of platelet aggregation. 
Adrenaline also stimulated the cyclooxygenase pathway to an 
extent sufficient to generate TXB 2 when platelets were 
under the inhibitory influence of aspirin, but only upon 
the addition of large concentrations of arachidonate. 
Adrenaline was not able to cause this stimulation in the 
presence of indomethacin and BW755C, a dual cyclooxygenase 
and lipoxygenase inhibitor. At the concentrations of these 
inhibitors used, adrenaline was unable to potentiate 
arachidonate-induced aggregation, but was able to 
potentiate ADP-induced aggregation. There appears to be at 
least two mechanisms by which adrenaline can potentiat e 
platelet aggregation, one of these being cyclooxygenase-
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independent,the relative importance of which may depend on 
the function of this pathway in the aggregation response of 
the principal agonist. In the absence of thromboxanes, 
more adrenaline is required to potentiate aggregation. 
The facilitating effect of adrenaline on a 
cyclooxygenase-independent pathway was mimicked by 
clonidine, a partial a 2-receptor agonist but not by 
phenylephrine an a 1-agonist. This indicates that these 
effects of adrenaline on the platelet occur via stimulation 
of the a 2-receptor. Dibenamine and phenoxybenzamine, post-
receptor inhibitors, inhibited even high concentrations of 
adrenaline and inhibited the second phase of the ADP-
response. Not only did these inhibitors prevent adrenaline 
potentiation of ADP, but the response of the combined 
agonists in their presence, was less than the ADP response 
alone. The biochemical changes subsequent to receptor 
occupation are investigated further in later chapters. 
4.1 INTRODUCTION 
Potentiation of human platelet aggregation by 
adrenaline may possibly represent a prime role for 
this catecholamine in the haemostatic response to injury of 
a blood vessel. Increased levels of this catecholamine 
may enable platelets to aggregate more quickly and 
irreversibly to plug a wound. It is not known whether 
adrenaline, by itself, can cause aggregation in vivo and it 
is disputed whether the observed in vitro aggregation in 
citrated PRP is an artifact or not. Adrenaline has been 
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reported, however, by several workers as being able to 
potentiate the platelet aggregation response to other 
agonists in both citrated and heparinized plasma (O'Brien, 
1964; Ardlie et al., 1966; Mills and Roberts, 1967; Grant 
and Scrutton, 1980a). 
The ability of adrenaline alone to cause platelet 
aggregation in vitro, is reported by Best (1980) to be 
largely ~ependent on the metabolism of arachidonic acid via 
the cyclooxygenase pathway to thromboxane A2 (TXA 2),the 
first phase, which is independent of thromboxane, being 
very small. Both aspirin and n-butyl imidazole, which 
inhibit cyclooxygenase and thromboxane synthetase 
respectively, prevent the second phase of adrenaline-
induced aggregation. It is of interest to determine 
whether the ability of adrenaline to potentiate aggregation 
by other agonists also depends on the metabolism of 
arachidonic acid. 
Rao et al. (1980a) using a thin layer chromatography 
method, have previously shown that adrenaline can overcome 
aspirin inhibition of ADP-, and arachidonate-induced 
aggregation without utilizing the cyclooxygenase pathway, 
as shown by lack of TXA 2 production. This is not 
unexpected since aspirin is believed to irreversibly 
acetylate the enzyme cyclooxygenase, but the mechanism by 
which adrenaline achieves potentiation independently of 
prostaglandin synthesis remains largely unexplored. 
This study sought to verify first of all that the 
mechanism of adrenaline potentiation could, in part, be 
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thomboxane independent. The effects of different 
cyclooxygenase inhibitors on adrenaline potentiation of ADP-
and arachidonate-induced aggregation was examined. The 
effectiveness of these various inhibitory agents on 
thromboxane synthesis was determined using a 
radioimmunoassay technique. Clonidine, a partial 
a 2-receptor agonist, and phenylephrine (a partial 
a1 -agonist) were also studied to determine whether they were 
able to potentiate aggregation in a similar manner to 
adrenaline in the absence or presence of these inhibitors. 
Following the establishment of the involvement of a 
thromboxane-independent pathway in adrenaline potentiation, 
certain aspects of the a-receptor system itself were 
considered to be worthy of further study. Dibenamine and 
phenoxybenzamine are thought to be drugs which act on the 
a-receptor system but by a mechanism independent, to some 
extent, of agonist binding (Lullman et al., 1969; 
Mitchelson, 1975). Their actions have been found to be 
different, despite similarities in structure between the 
two drugs (Jafferji and Michell, 1976; Cockcroft et 
al.,1980). Dibenamine seems to inhibit calcium 
mobilization without altering phosphatidylinositol turnover 
which is, however, affected by phenoxybenzamine. It was 
thought, therefore, that the effects of these two drugs on 
the adrenaline-potentiated response in platelets might 
reveal more of the events following a-receptor activation 
by adrenaline. The results indicate that further attention 
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needs to be focussed on platelet membrane events sub
sequent 
to adrenaline a-receptor interaction. 
4.2. METHODS AND MATERIALS 
Platelet aggregation, release of ATP and TXB 2 
formation were assessed utilizing techniques describ
ed in 
Chapter 2. Blood was anticoagulated with citrate. 
The agonists used were adrenaline (Calbiochem), 
adenosine diphosphate (ADP)(Sigma), arachidonic acid 
(Sigma), clonidine (Boehringer-Ingelheim) and phenylephrine 
(Sigma). 
The inhibitors used were acetylsalicylic acid 
(ASA)(aspirin) (BDH), indomethacin (Sigma),3-amino-1-[m-
(tri-fluoromethyl)-phenyl]-2-pyrazoline (BW755C)(Wellcome), 
n-butyl-imidazole (Koch-Light), phenoxybenzamine and 
dibenamine (Smith, Kline and French). 
Aspirin,100µM, unless otherwise stated was 
preincubated with PRP in a tightly stoppered syringe
 at 
37°c for at least 10min prior to the test. The other
 
inhibitors were added to the PRP in the cuvette 1min
 prior 
to the addition of agonists. 
4.3. RESULTS 
4.3.1 Potentiation of ADP-induced Aggregation by 
Adrenaline 
The synergistic effect on agregation of subthreshold
 
concentrations of ADP and adrenaline was associated w
ith 
a small increase in TXB 2 (Fig 4.1). 
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The appearance of the potentiated aggregation response 
varied from donor to donor. The tracing took on the 
appearance of an adrenaline-induced aggregation response in 
some cases. That is, the "first phase" was small and there 
was a lag before a second phase. Nevertheless, there was 
also a shape change. This tended to occur when low 
concentrations of both ADP and adrenaline were used, with 
the order of addition being adrenaline before ADP. 
Pre-incubation with 100µM aspirin did not prevent 
adrenaline potentiation of ADP-induced aggregation but did 
prevent TXB 2 formation (Fig 4.2). In the presence of 
aspirin, higher concentrations of adrenaline were required 
to acheive a similar degree of potentiation observed 
without aspirin. For example, the addition of 0.8µM 
adrenaline and 1.6µM ADP in the presence of aspirin 
(Fig4.2,tracingD) resulted in the same extent of 
aggregation as 0.08µM adrenaline and 1.6µM ADP in the 
absence of aspirin in the same donor(not shown). 
Nonetheless, in the presence of aspirin, 0.08µM adrenaline 
clearly potentiated 1 .6µM ADP(Fig.4.2,tracingC). 
When PRP was pre-incubated with 10-100µM indomethacin 
for 1 min, potentiation of the first phase of the ADP 
response was also possible(Fig 4.3.) In the presence of 
100µM indomethacin, the addition of 8µM adrenaline was 
necessary to obtain marked potentiation of aggregation but 
without TXB 2 formation. Similarly, when the dual 
cyclooxygenase and lipoxygenase inhibitor, BW755C (38 µM) 
was used, enhancement of ADP-induced aggregation by 
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Figure 4.1 Potentiation of ADP-induced aggregation by 
adrenaline. 
A. RD+ 0.8µM ADP 
B. 0.08µM adrenaline+ RD 
C. 0.08µM adrenaline+ 0.8µM ADP. 
Aggregation tracings are shown for PRP prepared from 
citrated blood. The arrows indicate the points of addition 
of the agonists in the order given above. Similar results 
were obtained with four other donors whose TXB 2 levels were 
0.4-2.0 pmol/10 7 platelets for irreversible aggregation. 
ND= not detected. 
u 
0 
25 
% Light 
T ronsmission 
so 
A 
B 
C 
107 
TXB2(pmol/10
7 platelets) 
(N.D.} 
(ND.) 
(N.D.) 
D (ND.) 
75 ....__..,__...,_....._...._ ________ _ 
Time(min) 
Figure 4.2 The influence of as 
of ADP-induce aggregation 
on the otentiation 
ine 
Aggregation tracings for the responses in the presence of 
100µM ASA are shown. The synergistic effect of ADP and 
adrenaline in the presence of ASA was not associated with 
the production of TXB 2 • 
A. 0.08µM adrenaline+ RD. 
B. RD+ 1.6µM ADP. 
C. 0.08µM adrenaline+ 1 .6µM ADP. 
D. 0.8µM adrenaline + 1.6µM ADP. 
ND= not detected. 
0 TXSi(pmol/10 7 platelets) 
A (N.D.) 
B (N.D.) 
% Light 
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50 
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Figure 4.3 The influence of indomethacin on the 
potentiation of ADP-induced aggregation by adrenaline . 
PRP was pre-incubated for 1 min with 100µM indomethacin . 
A. RD+ 0.8µM ADP. 
B. 8µM adrenaline+ RD. 
C. 8µM adrenaline+ 0.8µM ADP. 
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Similar results were obtained with two other donors us i ng 
indomethacin concentrations as low as 10µM. ND= no t 
detected. 
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adrenaline occurred again with no increase in TXB 2 
formation. When the concentration of BW755C was decreased 
to 3.8µM, potentiation occurred with a small increase in 
TXB 2 formation. The thromboxane synthetase inhibitor, n-
butyl imidazole (SmM) also behaved like indomethacin and 
did not inhibit a prostaglandin-independent ADP-response. 
Adrenaline overcame the inhibition of ADP-induced 
aggregation by 1mM n-butyl imidazole with the production of 
a small amount of TXB 2 • 
In addition to the assay of thromboxane formation, 
aggregation and release of nucleotide were assessed 
simultaneously in a lumi-aggregometer. PRP was 
preincubated with each inhibitor of arachidonic acid 
metabolism and adrenaline was added at concentrations 
which, by itself, were insufficient to overcome the 
inhibitors alone. When ADP-induced aggregation was 
enhanced in this manner without an increase in TXB 2 
formation, there was no release of nucleotide. When TXB 2 
formation occurred, this was accompanied by release of 
nucleotide. 
4.3.2 Potentiation of Potassium Arachidonate (KA)-induced 
Aggregation 
Potentiation by adrenaline of KA-induced aggregation 
in the absence of inhibitors was associated with an 
increase in TXB 2 formation (Fig 4.4). 
When PRP was preincubated with aspirin (100µM) 
potentiation of KA-induced aggregation could only be 
achieved with high(45µM) concentrations of adrenaline(Fig 
0 
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T ronsmission 
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TXB2(pmol/10 
7 platelets) 
A 
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Time(min) 
Figure 4.4 The potentiation of KA-induced aggregation by 
adrenaline 
A. RD+ 160µM KA. 
B. O.OSµM adrenaline+ RD. 
C. O.OSµM adrenaline+ 160µM KA. 
In another experiment where 160µM KA was the subthreshold 
concentration, TXB 2 levels were 1.6 p mol/10
7 platelets fo r 
KA only and 6.6 p mol/10 7 platelets for adrenaline -
potentiated KA-induced aggregation. 
ND - not detected. 
% Light 
Transmission 
0 
50 
H 
Time(min) 
1 1 1 
TXB2{pmol/JO 7 platelets) 
A (ND.) 
8 (ND.) 
C (N.D.) 
Figure 4.5 The influence of aspirin on the potentiation of 
KA-induced aggregation by adrenaline. 
PRP was preincubated with lOOµM ASA as described. 
A. RD+ 400µM KA. 
B. 4SµM adrenaline+ RD. 
C. 4SµM adrenaline+ 400µM KA. 
ND= not detected. 
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4.5). This potentiation was small and occurred without any 
increase in TXB 2 • If the concentration of KA was increased 
approximately 10-fold, such that a small amount of 
aggregation occurred in the presence of 100µM aspirin, 
adrenaline could further increase this aggregation with an 
increase in TXB 2 (Table 4.1). This was possible even if the 
aspirin concentration was doubled, but again, only at high 
concentrations of KA. In addition, 5mM n-butylimidazole 
could not prevent adrenaline potentiation of arachidonate-
induced aggregation and TXB 2 formation if the arachidonate 
concentration was sufficiently high (Fig 4.6). 
Table 4.1 Aggregation and TXB 2levels associated with 
adrenaline potentiation of arachidonate-induced 
aggregation in the presence or absence of 
aspirin. 
No Inhibitor Aspirin 
TXB %a TXB 
II • R + 7 • 0 
45 µMadren + RD 0.37 0 
45µMadren+0.4mM KA 9.6 0 
RD + 5mM KA 35 0.26 
45 µMadren+ 5mM KA 35 4.0 
112. RD + 0.4mM KA 0 0.25 0 0 
45µMadren + RD 15 0.92 10 0 
45µMadren+0.4mM KA 90 29 10 0 
RD + 3.6mM KA 100 45 8 2.2 
45µMadren+3.6mM KA 100 45 50 7.2 
The data for two separate experiments are shown. 100µM 
aspirin was used for exp#1 and 200µM aspirin was used for 
exp#2. The abbreviations used are: KA= potassium 
arachidonate, adren = adrenaline, RD= reagent diluent, 
TXB 2 = thromboxane B2 (pmol/10 7platelets). 
When PRP was preincubated with 10-100µM indomethacin, 
however, potentiation of KA-induced aggregation by 
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Figure 4.6 The influence of n-but limidazole on the 
potentiation o 
PRP was preincubated with SmM n-butylimidazole for 1 min. 
A. 0.8µM adrenaline+ 400µM KA. 
B. 0.8µM adrenaline+ 600µM KA. 
Each agonist at these concentrations was inhibited when 
added separately. 
ND= not detected. 
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adrenaline (up to 8µM) was not achieved. Some potentiation 
by adrenaline was achieved with an increase in TXB 2 
formation when the concentration of indomethacin was 
decreased to SµM which was still sufficient to inhibit each 
agonist alone. Similarly, when PRP was pre-incubated with 
38µM BW755C, no potentiation was achieved, whereas a 
reduction in the concentration of BW755C to 3.8µM did allow 
adrenaline potentiation but not to the same extent as in 
the absence of the inhibitor. With each of these 
cyclooxygenase inhibitors, when adrenaline did overcome the 
inhibition of KA-induced aggregation, release of nucleotide 
was also observed. 
4.3.3 Potentiation of ADP-induced and Arachidonate-
induced Aggregation by the a-adrenoceptor Agonists, 
Clonidine and Phenylephrine 
Clonidine a partial a 2-agonist behaved in a similar 
way to adrenaline in being able to potentiate subthreshold 
concentrations of ADP and KA. Clonidine was able to 
potentiate responses to ADP in the presence of the 
cyclooxygenase inhibitors without TXB 2 formation. 
Clonidine, therefore, facilitated cyclooxygenase-
independent aggregation. 
Clonidine usually did not cause aggregation by itself 
even at concentrations as high as 800µM. However, two 
patients with thrombotic disorders were found to respond to 
0.8µM and 800µM clonidine respectively. The concentrations 
of clonidine which potentiated aggregation due to ADP 1n 
the presence of aspirin were comparable to those of 
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adrenaline, that is in the range 0.8 - 8µM. Nevertheless, 
in any one donor, a -concentration of clonidine which 
potentiated an ADP reponse was not as effective as the same 
concentration of adrenaline (Fig 4.7). 
Some donors exhibited potentiation of the ADP response 
by the a 1-agonist, phenylephrine. Those donors who did, 
also exhibited an additive response to the combination of 
clonidine and phenylephrine (Fig 4.7). Much higher 
concentrations of phenylephrine than of clonidine were 
required to potentiate ADP. For the donor illustrated in 
Fig 4.7, 8.0µM phenylephrine potentiated ' 0.4µM ADP with an 
associated TXB 2 production of 0.46 pmole/10
7platelets 
(2.4ng/ml). 
4.3.4 Post-Receptor Inhibitors 
As discussed previously, there is some evidence that 
dibenamine and_ phenoxybenzamine may be acting on the 
stimulus-response coupling sequence distal to the receptor. 
These drugs were therefore used to probe post-receptor 
events. Both dibenamine (0.2mM) and phenoxybenzamine 
(0.2mM) inhibited the aggregation response of platelets to 
adrenaline even when the concentration of adrenaline was 
increased to 80µM. Adrenaline induced TXB 2 formation was 
also inhibited by these drugs. These drugs also prevented 
the second phase of the ADP response with a reduction of 
the first phase, but had no effect on the ADP-induced shape 
change. Inhibition of the second phase of the ADP response 
was associated with an absence of TXB 2 formation. 
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Figure 4.7 Potentiation of ADP-induced aggregation~ 
adrenaline, clonidine and phenylephrine. 
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The concentration of ADP for all tracings was 0.4µM. The 
additional agonists (added at the first arrow) were : 
A. RD. 
B. 0.8µM phenylephrine. 
C. 0 . 008µM clonidine. 
D. 0.008µM adrenaline. 
E. 0.8µM phenylephrine + 0.008µM clonidine. 
This donor was one of a small percentage of donors whose 
ADP response was potentiated by phenylephrine in addition 
to clonidine. This donor is extremely sensitive to 
adrenaline as indicated by the very low concentration 
(0.008µM) which potentiated the ADP response. 
ND= not detected. 
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Phenoxybenzamine, and sometimes dibenamine, also 
prevented adrenaline potentiation of ADP. In some donors, 
the addition of either of these drugs with adrenaline 
actually diminished the aggregation response to ADP alone. 
There were no observable differences with these inhibitors 
when experiments were carried out with platelets from 
donors exhibiting a 1-receptors, as detected by the ability 
of phenylephrine to potentiate the ADP response, and 
platelets from donors that did not exhibit a 1-receptors. 
4.4 DISCUSSION 
These data support the theory that adrenaline can be 
pro-aggregatory through a thromboxane-independent 
mechanism. In the presence of cyclooxygenase inhibitors, 
adrenaline can potentiate aggregation due to other 
agonists. Adrenaline can also increase thromboxane 
production despite the presence of aspirin, when high 
concentrations of arachidonate are added. In the absence 
of cyclooxygenase inhibitors, adrenaline probably acts 
through both mechanisms and these are expected to involve 
activation of a 2-receptors which is supported by the 
potentiating effects of clonidine described in this 
chapter. 
Grant and Scrutton(1979) identified the a 2 -
adrenoceptor as being primarily responsible for mediating 
the response to adrenaline. They showed that the 
potentiation of ADP-induced aggregation by clonidine was 
inhibitable by yohimbine, a selective a 2 -antagonist. In 
contrast, indoramin, a selective a 1-antagonist, was 
relatively ineffectual as an inhibitor of clonidine-
11 8 
stimulated responses. Inhibition of responses to clonidine 
by yohimbine occurred over a range of concentrations signif-
icantly higher than that required for inhibition of adrenal-
ine-induced responses. Clonidine is therefore regarded as a 
partial a 2-agonist. Since the possible a 1-receptor is not 
exhibited on platelets from all donors as shown by 
methoxamine potentiation and specific [ 3H]-prazosin binding 
(Scrutton, 1982), it cannot be the predominant receptor 
involved in activation of platelets by adrenaline. 
Some conversion of arachidonate to TXB 2 is possible 
despite irreversible acetylation of cyclooxygenase by 
aspirin if sufficiently large amounts of exogenous 
arachidonate are added. Whatever the mechanism of this 
reaction, high concentrations of adrenaline can enhance it. 
Concentrations of indomethacin and BW755C less than that of 
aspirin, inhibited the cyclooxygenase pathway no matter how 
much adrenaline was added. The chemical nature of the 
interference of the inhibitor with the enzyme active site 
may determine whether adrenaline can increase 
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cyclooxygenase activity (Humes et al., 1981). Another 
explanation for the greater effectiveness of indomethacin 
may be that this inhibitor also reduces the amount of 
available endogenous arachidonate (Erman et al., 1980). 
Indomethacin was effective in preventing adrenaline 
potentiation of KA-induced aggregation but not when the 
inhibitor concentration was reduced to S~M. Similarly, 
BW755C, which inhibits both cyclooxygenase and 
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lipoxygenase, prevented adrenaline potentiation of KA-
induced aggregation at a concentration of 38µM, but not at 
one-tenth this concentration. Indomethacin(100µM) inhibits 
lipoxygenase by 20% (Higgs et al.,1979) and can therefore 
also be a dual inhibitor like BW75SC. It is possible that 
adrenaline achieves potentiation by overcoming inhibition 
of the lipoxygenase pathway of arachidonate acid 
metabolism, although no role has yet been assigned to the 
products of the lipoxygenase pathway in platelet 
activation. 
ADP-induced aggregation can still be enhanced by 
adrenaline or clonidine under the influence of these 
inhibitors at concentrations which completely prevent 
thromboxane production. Adrenaline promotes this 
thromboxane-independent pathway of ADP-induced aggregation 
without causing release of nucleotide. Higher 
concentrations of adrenaline were required to achieve the 
same extent of aggregation as in the absence of thromboxane 
inhibitors and much higher concentrations than found in 
vivo. Without the ampiifying effect of thromboxanes and 
nucleotide, a larger stimulus seems to be required to 
achieve platelet activation by the thromboxane-independent 
pathway. 
This thromboxane-independent aggregation is also 
irreversible and can appear indistinguishable from the 
pattern of irreversible aggregation which is accompanied by 
release, discerned from recorder tracings only. Additional 
information on thromboxane formation and the release 
reaction are needed to characterize the aggregation 
response in more detail. What is usually ref~rred to as 
first phase aggregation could also be referred to as 
cyclooxygenase-independent aggregation. 
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There could be several mechanisms by which adrenaline 
promotes thromboxane-independent aggregation. It has 
recently been proposed that adrenaline by binding to a-
receptors, enhances calcium (Ca 2+) mobilization and thereby 
promotes aggregation (Rao et al., 1981a). Stimulation of 
the a-receptor also increases Ca 2+ uptake (Owen et al., 
1980) but further work (Owen and Le Breton, 1980) showed 
that potentiation of the ADP response by subthreshold 
levels of adrenaline was not associated with measurable 
Ca 2+ uptake. Calcium redistribution was considered to be 
involved since the Ca 2+ channel blocker, verapamil, 
inhibited potentiation, but it is now acknowledged that 
verapamil achieves an inhibitory effect at the level of the+ 
a-adrenergic receptor (Barnathan et al.,1982). Brass and 
Shattil(1982) were unable to find an enhancement of net Ca 2 
uptake by ADP or adrenaline although both these agonists 
increased the extent of binding of Ca 2+ to the surface and 
also the rate of exchange into the intracellular pool. The 
biochemical changes leading to this possible redistribution. 
of Ca 2+ are not understood and probably only some of the 
many effects of Ca 2+ in platelets have been so far revea l ed 
Inositol-1,4,5-trisphosphate is a possible mediator of 
calcium redistribution(Berridge,1984). 
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a 2-receptor stimulation is thought to be universally 
associated with inhibition of adenylate cyclase (Fain and 
Garcia-Sainz, 1980), reducing c'AMP production which could 
be related to calcium redistribution (Kaser-Glanzman et 
al., 1977). Rao et al. (1981a) reported, however, that 
adrenaline can potentiate platelet responses without 
measurable changes in c'AMP levels. No net decrease in 
c'AMP results on exposure of resting platelets to 
adrenaline (Haslam,1978a,b). Furthermore, the induction 
of aggregation by adrenaline has been shown to be 
dissociated from its effect as an inhibitor of adenylate 
cyclase, by removal of extracellular Na+ (Connolly and 
Limbird,1983) or by the use of certain antagonists (Clare 
et al., 1984). 
There could also be other membrane changes in response 
to a-receptor stimulation. For other tissues, besides 
platelets, it has been suggested that a 1-receptors mediate 
phosphatidylinositol (PI) turnover and hence the release of 
bound intracellular Ca 2+, as well as the entry of 
extracellular Ca 2+ (Fain and Garcia-Sainz, 1980; Jafferji 
and Michell, 1976). These Ca 2+ responses are precisely the 
reported effects of adrenaline on platelets. The effects 
of adrenaline on platelets, however, are believed to be 
mediated by a 2-receptors, not a 1-receptors (Grant and 
Scrutton, 1979). It is also not known whether adrenaline , 
while potentiating ADP, affects PI turnover. Very 
recently, Clare and Scrutton(1984) failed to show PI 
breakdown due to adrenaline alone in the absence of 
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secretion. In either case polyphosphoinositides have not 
been examined. 
The fact that phenoxybenzamine totally inhibits the 
adrenaline response in the platelet is consistent with PI 
turnover being important in mediating the adrenergic 
effects. The results are obviously difficult to interpret, 
however, since phenoxybenzamine is an a-receptor(a 1greater 
thana 2)antagonist in addition to possessing post-receptor 
inhibitory activity (Jafferji and Michell, 1976). There is 
no need to necessarily assume that PI breakdown would 
depend on a 1-receptor activation since the particular 
effects associated with a particular receptor demonstrated 
in other tissues may not apply to the platelet. The 
effects of phenoxybenzamine on adrenaline stimulation and 
potentiation require further study, possibly in association 
with analysis of membrane phospholipids. 
The inhibition by dibenamine is consistent with 
Ca 2+ mobilization being a prerequisite for expression of 
adrenaline stimulation of a-receptors. Even though there 
is some evidence that calcium uptake may not to be involved 
in the mechanism of adrenal.ine activation, calcium movement 
within the membrane may still be involved. It is possible 
that effects on calcium may be independent of the PI 
effect, since dibenamine seems to act independently of PI 
turnover. The present findings concur with those of Rao et 
al.(1980a) in establishing the existence of a thromboxane-
independent pathway of adrenaline potentiation and both 
studies show the ability of adrenaline to influence the 
aggregation response of aspirin-treated platelets to 
arachidonate. Adrenaline, together with higher 
concentrations of arachidonate, partially restores the 
activity of cyclooxygenase, under conditions appropriate 
for total enzyme inhibition. 
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Following cyclooxygenase inhibition, much higher 
concentrations of adrenaline are required to achieve the 
same potentiation of ADP-induced aggregation as that 
observed when the thromboxane pathway is operating. It is 
unlikely that such concentrations would ever be achieved in 
the circulation, and therefore thromboxane formation is 
probably essential for the complete pro-aggregatory effect 
of adrenaline in vivo. The influence of other agonists 
present in the circulation on the pro-aggregatory effect of 
adrenaline has been shown(Chapter 3). Therefore the 
effective concentration of adrenaline with or without 
cyclooxygenase inhibition, in vivo is expected to be much 
lower than the concentrations used in vitro. A 
thromboxane-i~dependent pathway is involved in adrenaline 
potentiation the mechanism of which remains unresolved. 
CHAPTER 5 
THE INFLUENCE OF PHOSPHOLIPASE A2 INHIBITORS 
ON ADRENALINE POTENTIATION 
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5.0 SUMMARY 
To further characterize adrenaline potentiation of 
ADP-induced aggregation, the influence of phospholipase A2 
inhibitors was examined. The inhibitors chosen were 
bromophenacyl bromide (BPB), a widely reported inhibitor of 
phospholipase A2 ; tosylphenylalaninechloromethyl ketone 
(TPCK), a chymotrypsin inhibitor with reported 
phospholipase A2 inhibitory properties; and phenothiazines 
which inhibit several enzymes including calmodulin-
dependent enzymes and protein kinase C. 
BPB and TPCK shared in common the ability to enhance 
thromboxane production when adrenaline potentiated the ADP-
response. Adrenaline therefore enhances arachidonic acid 
release by a mechanism independent of phospholipase A2 
activity in the presence of these two inhibitors. The 
phenothiazines, chlorpromazine and trifluoperazine 
inhibited thromboxane production but adrenaline 
potentiation of thromboxane-independent aggregation was 
still observed. 
It is suggested that adrenaline promotes 
diacylglycerol production from which arachidonic acid 
release is promoted via lipase activity, in the presence of 
BPB or TPCK, but not in the presence of phenothiazines, in 
which case the kinase may be more active. 
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5.1 INTRODUCTION 
In the previous chapter, the mechanism of adrenaline 
potentiation of ADP and arachidonate-induced aggregation 
was examined. While adrenaline was found to stimulate a 
non-prostaglandin pathway there was also evidence of some 
stimulation of arachidonic acid metabolism. Perhaps 
adrenaline has a direct effect on cyclooxygenase or 
thromboxane synthetase activity. It was therefore decided 
to inhibit the prostaglandin pathway by inhibition of 
arachidonate release because it was thought that inhibition 
of arachidonate release might allow further 
characterization of the effects of adrenaline leading to 
both prostaglandin-dependent and independent pathways of 
activation. 
As discussed in Chapter 1, there are several ways in 
which arachidonate might be released from membrane 
phospholipids(Fig 5.1). Phospholipase A2 enzymes could 
release the fatty acid from phosphatidic acid or otherwise 
from the phospholipids, phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylserine or 
phosphatidylinositol(PI) (Billah et al., 1980; 1981). 
Alternatively, phospholipase C and diacylglycerol lipase 
activity can lead to the release of arachidonic acid from 
PI (Bell et al., 1979). The respective contributions of 
these different phospholipases to arachidonic acid release 
has not been resolved. 
It has been difficult to find specific inhibitors of 
either phospholipase A2 or phospholipase C. Vallee et al. 
POSSIBLE SOURCES OF ARACHIDONIC ACID 
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Figure 5.1 The release of arachidonic acid from platelet 
phospholipids. 
A simplified diagram of the reactions and enzymes involved 
in the possible mechanisms of arachidonate release. The 
proposed influence of adrenaline under conditions of 
potentiation of ADP-induced aggregation on these reactions 
is shown. 
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(1979) assessed four different phospholipase A2 inhibitors. 
Mepacrine and papaverine were found to be indirect 
inhibitors, probably inhibiting through effects on calcium, 
while bromophenacyl bromide (BPB) and 2,3-dibromo (4'-
cyclohexyl-3'chloro)-phenyl-4-oxo-butyric acid (CB874) were 
thought to have direct inhibitory properties. None of 
these inhibitors was found to be specific for phospholipase 
A2 • BPB was thought to alkylate the histidine residue of 
the active site of phospholipase A2 while the mechanism of 
action of CB874 is still under investigation. 
Phenothiazines have been shown to inhibit both 
phospholipase A2 and phospholipase Cat different 
concentrations. Wightman et al.(1981) studied several 
phenothiazines for their inhibition of phospholipase C in 
resident mouse macrophages. Chlorpromazine was found to 
have an 1 50 of 6.3µM for phospholipase C. This is in 
direct contrast to the observations of Walenga et al. 
(1981) who investigated platelets, and found that 10µM 
chlorpromazine caused a 57% increase in phosphatidic acid. 
Increasing the concentration of chlorpromazine to 30µM, 
however, decreased the amount of phosphatidic acid formed. 
Phenothiazines cannot be regarded as specific calmodulin 
antagonists since selective receptor blockade, or 
inhibition of a pathway stimulated by receptor activation, 
has also been shown by Cocks et al. (1981) for liver and 
smooth muscle. Chlorpromazine has been shown to inhibit 
protein kinase C in some circumstances(Mori et al.,1980). 
Lullman et al. (1981) reported that phenothiazines can 
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displace bound Ca 2+ from PI monolayers at an I 50 of 
approximately SOµM. Phospholipase C activity requires 
calcium (Billah et al.,1980) and at certain concentrations, 
phenothiazines provide calcium for phospholipase C in the 
cytosol. Receptor affinity and calcium availability could 
determine whether phenothiazines behave as inhibitors or 
stimulators. 
BPB and tosylphenylalanine-chloromethylketone (TPCK) 
were shown by Vargaftig et al. (1980b) to inhibit 
aggregation caused by thrombin or ionophore A23187. Both 
were shown to inhibit phospholipase A2 activity. BPB was 
not specific for phospholipase A2 since it also reduced the 
yield of thromboxane A2 from exogenously added arachidonic 
acid, indicating an inhibition of cyclooxygenase or 
synthetase. Short incubation times, however, showed a 
preferential inhibition of phospholipase A2 over 
cyclooxygenase or thromboxane synthetase. TPCK caused a 
reduction in thromboxane release but this was shown to not 
be significant. BPB can also inhibit acetyl and 
acyltransferases which could affect the synthesis of 
platelet activating factor (PAF) (Wykle et al., 1980). BPB 
can also presumably inhibit the putative acyltransferase 
enabling mobilization of arachidonic acid between membrane 
phospholipids (Billah et al., 1980). It has also been 
shown with crude platelet extracts that BPB is an inhibitor 
of the PI-specific phospholipase C-diglyceride lipase 
pathway (Hofmann et al., 1982). Another cautionary note in 
the use of BPB comes from the work of Smolen and Weissman 
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(1980) who showed that BPB also inhibits superoxide anion 
generation in human polymorphonuclear leucocytes, a normal 
response to surface stimuli. What effect such inhibition 
may have in the platelet is unknown. 
Serine esterase inhibitors have been shown to inhibit 
PI and phosphatidylcholine (PC) metabolism (Walenga et al., 
1980). These authors concluded that serine esterase 
inhibitors are therefore inhibitors of phospholipase C and 
possibly, of phospholipase A2 • Their evidence for 
inhibition of PI turnover induced by A23187 could actually 
be due to inhibition of phospholipase A2 • It has 
subsequently been shown by Rittenhouse-Simmons (1981) that 
the action of phospholipase A2 is responsible for the 
release of arachidonic acid from PI by A23187. Serine 
esterase inhibitors therefore appear to be inhibitors of 
both phospholipase C and A2 • 
In this chapter the effects of BPB, TPCK and 
phenothiazines on adrenaline potentiation of ADP is 
examined. 
5.2 METHODS AND MATERIALS 
Blood collection in citrate, platelet aggregation and 
thromboxane B2 assay were carried out as before. 
Bromophenacyl bromide (Koch Light) and tosylphenyl-
alaninechloromethylketone (Serval) were dissolved in 
di~ethylsulphoxide (DMSO) and added at one-hundredth of the 
plasma volume. The phenothiazines, clorpromazine and 
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trifluoperazine (Smith, Kline and French) were dissolved in 
reagent diluent (RD). 
5.3 RESULTS 
5.3.1 Potentiation of the ADP-response by Adrenaline 1n 
the Presence of Bromophenacyl Bromide (BPB). 
BPB(10µM) completely inhibited the response to 8µM 
adrenaline which would otherwise cause irreversible 
aggregation. BPB also inhibited thromboxane B2 formation 
caused by adrenaline. BPB did not completely inhibit the 
response to threshold ADP, but inhibited the second phase 
along with TXB 2 production and also reduced the first 
phase. BPB did not affect the shape change due to ADP. 
BPB also inhibited the response to threshold exogenous 
arachidonate, reducing but not totally inhibiting 
thromboxane formation. Table 5.1 summarizes an experiment 
exemplifying these properties of BPB. The amount of TXB 2 
formed when the arachidonate response was inhibited by BPB 
was still in excess of that produced in response to 
adrenaline. 
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Table 5.1 The ability of bromophenacyl bromide to inhibit 
aggregation due to adrenaline, ADP and potassium 
arachidonate. 
Agonist Inhibitor TXB 2 Aggregation 
Adrenaline ( 8 µM) DMSO 1 • 3 irreversible 
" " BPB ( 10 µM) 0 no aggregatio 
ADP(2.5µM) DMSO 0.3 biphasic 
" " BPB ( 10 µM) 0 shape change 
and small first 
phase 
Arachidonate(0.12µM) DMSO 1 1 complete 
" " BPB( 1 QµM) 1 • 9 no aggregatio 
The inhibitor was added 1min prior to each agonist. TXB 2 
levels are expressed as pmol/10 7platelets. 
DMSO = dimethylsulphoxide(1%). 
n 
n 
Despite these inhibitory effects on single agonists, 
BPB (10µM) did not inhibit the ability of adrenaline to 
potentiate ADP or arachidonate. Indeed, when potentiation 
occurred in the presence of BPB, thromboxane formation was 
increased (Fig 5.2). Not every donor exhibited the 
dramatic reduction in the first phase of aggregation in the 
presence of BPB as shown in Fig. 5.2. In all donors, 
however, there was a 2-3fold increase in TXB 2 • BPB (100µM) 
prevented adrenaline potentiation of the ADP response, as 
did 50µM BPB for some donors, but 20µM BPB did not inhibit 
potentiation nor TXB 2 formation. 
A time-course experiment revealed that the increase in 
TXB 2 in the presence of BPB commenced sooner than in the 
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Figure 5.2 Potentiation of the res onse to 
adrenaline int e presence o enacy (BPB). 
The agonist concentrations were 
1. 0.8µM adrenaline and 
2. 0. 8µM ADP. 
The PRP was prepared from blood anticoagulated with 10mM 
citrate and the platelet count was 516,000/µl. BPB or DMSO 
1% was added 1 min. before the first agonist, at one-
hundredth volume to achieve a concentration of 10µM. 
absence of this inhibitor. There was measurable TXB 2 
during the first phase of aggregation in the presence of 
BPB but not in its absence. 
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When high concentrations of ADP alone were used, a 
similar increase in TXB 2 was observed in the presence of 
BPB comparable to that observed when adrenaline potentiated 
a low concentration of ADP. 
5.3.2 Potentiation of the ADP-response by Selective a-
receptor Agonists in the Presence of Bromophenacyl 
Bromide. 
Clonidine, a partial a 2-receptor agonist, behaved in a 
similar manner to adrenaline and was able to potentiate the 
ADP-response in the presence of BPB. Thus, at 
concentrations of BPB, which were inhibitory for threshold 
concentrations of adrenaline alone, potentiation by 
clonidine was observed with an increase in TXB 2 • 
Phenylephrine, a partial a 1-agonist, in donors showing 
the capacity for a 1-potentiation, showed weak potentiation 
in the presence of BPB. Those donors who did not exhibit 
phenylephrine potentiation of the ADP-response in the 
absence of BPB, showed no potentiation in the presence of 
BPB. Adrenaline was able to potentiate TXB 2 formation in 
the presence of BPB in donors irrespective of platelet 
a 1-receptor status. 
5.3.3 A Comparison of the Effects of Tosylphenylalanine-
chloromethylketone (TPCK) and Bromophenacyl Bromide 
(BPB) on Adrenaline Potentiation. 
TPCK was also tested as an inhibitor of adrenaline 
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poentiation. TPCK was found to behave in a similar manner 
to BPB in that increased concentrations of TXB 2 were 
produced when adrenaline potentiated ADP in the presence of 
the inhibitor. The result differed in that, at the same 
concentrations of inhibitors in the same donor, more TXB 2 
was produced in the presence of TPCK than BPB (Fig 5.3). 
Comparable amounts of TXB 2 were produced in the presence 
of 20µM TPCK or 50µM BPB (in donors in whom this was not 
inhibitory). It can be seen that the extent of aggregation 
was not altered very much by these inhibitors at these 
concentrations, but the first phase of aggregation was 
decreased and this was associated with earlier TXB 2 
formation. 
As with BPB, increased TXB 2 production with high 
concentrations of ADP alone was observed in the presence of 
TPCK. 
5.3.4 Influence of Phenothiazines on the Potentiation of 
the ADP-response by Adrenaline. 
The phenothiazines, chlorpromazine, and 
trifluoperazine were examined for their influence on 
adrenaline potentiation. These phenothiazines inhibited 
thromboxa?e production d~~ to ADP in a dose-dependent 
fashion. Adrenaline potentiation of the ADP-response 
occurred with very _little increase in TXB 2 formation in the 
presence of these drugs; chlorpromazine did not inhibit 
adrenaline potentiation of the thromboxane-independent 
pathway (Fig 5.4). Aggregation by adrenaline alone at 
concentrations which potentiated ADP was completely 
0 
tl 
1 2 
% Light 50 TXBipmol/10 
7 platelets) 
T ronsmission 
A (3.7) 
B (3.6) 
C (2.0) 
D (4.9) 
100 
Time(min) 
Figure 5.3 Potentiation of the response to ADP by 
adrenaline in the presence of BPB or TPCK. 
The agonist concentrations were 
1. 0.8lJM adrenaline and 
2. 0. 8 µMADP. 
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The PRP was prepared from blood anticoagulated 
citrate and the platelet count was 448,000/lJl. 
results were obtained with five other donors. 
inhibitor concentrations were 
with 1 OmM 
Similar 
The 
A S0µM BPB 
B 20µM TPCK 
C DMSO1% 
D S0µM TPCK. 
0 
TXB2(pmol/10 7 platelets) 
A (0.27} 
% Light so 
T ronsmission 
B (0.20) 
Time(min) 
Figure 5.4 Influence of chlorpromazine (CPZ) on 
adrenaline potentiation of theADP-response. 
The agonist concentrations were 
A. RD + 4µMADP. 
B. 0.8µMadrenaline + 4µMADP. 
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The platelets were treated with SOµMCPZ for 1min prior to 
the addition of the agonists. The PRP was anticoagulated 
with 10mM citrate and the platelet count was 322,000/µ l . 
In the absence of CPZ the adrenaline potentiated response 
produced 3.8pmol TXB 2 /10 7 p1atelets. 
inhibited by chlorpromazine. In the presence of 
trifluoperazine, adrenaline also potentiated the ADP-
response independently of thromboxane formation. 
5.4 DISCUSSION 
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The observations reported in this chapter are based on 
the use of phospholipase A2 inhibitors none of which, 
however, are specific for this enzyme. Any conclusions 
therefore, must be tentative. BPB has been shown to have a 
preferential effect on phospholipase A2 over 
cyclooxygenase/synthetase when incubated for 10 minutes or 
less with the platelets (Vargaftig et al., 1980b). Fifteen 
minute incubations, however, significantly affect 
thromboxane _production from exogenously added arachidonic 
acid. In the present experiments however, TXA 2 production 
from arachidonic acid was shown to be reduced after less 
than 10 min incubation with BPB. The fact that the 
thromboxane production was still in excess of that produced 
by adrenaline, indicates that cyclooxygenase is far from 
completely inhibited by BPB and the reduction may be due to 
other effects of BPB. It is noteworthy also that despite 
this amount of TXA 2 produced, aggregation was completely 
inhibited by BPB. 
It is not known how preferential BPB might be for 
phospholipase A2 over other membrane effects at these 
incubation times. Hofmann et al. (1982) reported that BPB 
inhibits both PI-specific phospholipase C and diglyceride 
lipase. Maximum inhibition of phospholipase C was achieved 
with 100µM BPB after 15min incubation. After 1min 
incubation, approximately 20% inhibition was observed. 
S0µM BPB would presumably cause even less inhibition. 
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These workers used crude platelet extracts exposing 
phospholipase C, otherwise in the soluble fraction of 
intact platelets. The efficiency of BPB in inhibiting 
phospholipase C and diglyceride lipase would be expected to 
be reduced in intact platelets. On the other hand, 
phospholipase A2 , being in the membrane, may be more 
accessible to BPB. Experiments examining the effects of 
BPB on exogenous phospholipase Care presented and 
discussed in Chapter 6. Phenothiazines are not specific, 
and may also affect a-receptors or a-receptor linked events 
(Cocks et al., 1981) and thus other enzymes will be 
inhibited. 
Bearing these cautionary remarks in mind, it is of 
interest that BPB or TPCK not only did not prevent TXB 2 
formation, but rather, stimulated an even greater increase 
in thromboxane production when adrenaline potentiated the 
ADP response, or when high concentrations of ADP alone were 
used. According to other reports thromboxane production 
should be reduced in the presence of these concentrations 
of BPB since it affects cyclooxygenase and/or synthetase in 
addition to its direct action on phospholipase A2 • The 
assumption that phospholipase A2 is the only source of 
arachidonic acid would lead one to predict a complete 
inhibition of thromboxane production by BPB. 
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There is, however, more than one source of arachidonic 
acid in the platelet. PI breakdown by phospholipase C and 
the action of a lipase on the resultant diglyceride can 
produce arachidonic acid (Bell et al., 1979). Phosphatidic 
acid could also act as a source of arachidonic acid but 
would also require a phospholipase A2 for its release. It 
is possible that in the presence of BPB or TPCK, 
stimulation of phopholipase C and/or diglyceride lipase may 
still occur. This stimulation could be caused by 
potentiation of ADP by adrenaline, probably involving the 
a 2-receptor, or could be caused by high concentrations of 
ADP alone. With the blockade of other phospholipid 
changes, arachidonate release could actually be stimulated 
via the phospholipase C-diglyceride lipase pathway(FigS.1). 
Vargaftig et al. (1980b) noted that TPCK did not lower 
thromboxane production as expected and postulated an 
alternative pool of arachidonic acid. Vargaftig (1976; 
1977) also reported potentiation of TXA 2 formation by TPCK 
and by BPB under certain conditions. BPB and TPCK have 
similar chemical properties in that both can alkylate a 
histidine residue, accounting for the direct inhibition of 
phospholipase A2 • The two inhibitors may also share non-
specific effects. Nevertheless, it is interesting that 
they both have the same effect on adrenaline potentiation 
of ADP-induced aggregation. 
This chapter contributes the further information that 
the addition of adrenaline to subthreshold ADP lead s to 
potentiation of TXA 2 formation in the presence of TPCK or 
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BPB. Further, clonidine, a partial a 2-recepto r agonis t but 
not phenylephrine a partial a 1-receptor agonist, mimics 
this property of adrenaline. It could be argued that 
adrenaline might overcome the inhibition of phospholipase 
A2 directly by perhaps increasing Ca
2+ availability. 
However, as BPB is a direct enzyme inhibitor, binding to 
the active site, it would seem more likely that adrenaline 
stimulates an alternative mechanism for arachidonate 
release such as the phospholipase C/lipase pathway 
(Fig.5.1). The early formation of TXA 2 would support this 
theory since phospholipase C is thought to be more rapidly 
activated than phospholipase A2 (Billah et al., 1980). 
The phenothiazines, chlorpromazine and trifluoperazine 
exhibited characteristics which differed from BPB and TPCK 
with respect to adrenaline potentiation. The 
phenothiazines inhibited arachidonic acid release from all 
sources. At SOµM, chlorpromazine was expected to inhibit 
the second wave of aggregation stimulated by ADP or 
adrenaline and to inhibit thromboxane-dependent 
potentiation of ADP by adrenaline. Although this was 
indeed confirmed, thromboxane-independent potentiation was 
observed in the presence of these inhibitors. The 
mechanism of this thromboxane-independent aggregation would 
therefore seem to be independent of certain events s ub ject 
to a-receptor interaction and calmodulin-dependent enzymes. 
It is believed that the contribution of the d iglyceride 
lipase pathway for arachidonate release is minor while 
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phospholipase A2-activated release predominates in response 
to thrombin (Imai et al., 1982). While the predominant 
mechanism of arachidonate release caused by ADP is not 
known, it has been shown that ADP increases phosphatidic 
acid turnover (Lloyd et al., 1973a,b). In the presence of 
phenothiazines, it might be possible that adrenaline is able 
to potentiate diglyceride kinase activity, which would 
increase phosphatidic acid formation due to ADP, since there 
is no evidence of arachidonic acid release due to 
diglyceride lipase activity. This must await biochemical 
analysis to be confirmed. Alternately, effects of adrenaline 
on calcium influx or mobilization need to be considered. 
Rao et al. (198Gb) reported on the influence of 
trifluoperazine and BPB on platelet aggregation and 
disaggregation. They concluded that adrenaline could 
correct the inhibition of phospholipase A2 by BPB. They 
were, however, studying re-aggregation of dissociated 
platelets which is a different situation to an adrenaline-
potentiated ADP response as studied here. 
Despite the very different results obtained with 
different types of phospholipase A 2 inhibitors, some 
general conclusions can be drawn. Firstly, adrenaline has 
effects on ADP-induced aggregation which lead to increased 
thromboxane production, possibly through increased 
arachidonic acid release. Secondly, adrenaline enhances 
platelet responses by a pathway independent of thromboxane 
production as indicated in the previous chapter. In the 
presence of phenothiazines the potentiation was obviously 
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independent of thromboxane production. Stimulation of 
arachidonic acid release from diacylglycerol may be 
possible in the presence of BPB or TPCK. Diversion of 
diacylglycerol to arachidonic acid may account for the 
decrease in the extent of the primary phase and the early 
onset of the second phase. 
An association between adrenergic receptors and 
phospholipase C activation has been shown in other 
cells. Abdel-Latif(1974) for example, found that 
catecholamines caused a stimulation of 32Pi incorporation 
into PA and PI of the iris muscle of the rabbit. The 
relationship between a 1-receptor activation and the PI 
effect has been discussed in Chapter 4. It is, however, 
the a 2-receptor which seems to be involved in the 
adrenaline-platelet interaction. 
Adrenaline has been shown to cause changes in 
phospholipids in association with release (Deykin and 
Snyder,1973) and more specifically, adrenaline and ADP have 
been found to increase production of diacylglycerol, but 
only after 120sec (Kawahara et al.,1983b). Very recently, 
it has been found that adrenaline alone fails to cause 
breakdown of PI independently of release(Clare and 
Scrutton,1984) but the potentiating effects of adrenaline 
on ADP have yet to be analysed in this manner. Since ADP 
alone can stimulate the PI cycle, adrenaline may potentiate 
ADP by enhancing the effect of ADP on PI turnover or 
alternately, by enhancing events consequent upon PI 
metabolism caused by ADP. Finally, the combined effects of 
adrenaline and ADP on calcium fluxes may be involved and 
need to be investigated. 
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CHAPTER 6 
THE EFFECTS OF EXOGENOUS PHOSPHOLIPASE C 
ON PLATELETS. 
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6.0 SUMMARY 
Aggregation and release due to exogenous phospholipase 
C were examined in the presence of several inhibitors used 
in the previous studies of adrenaline potentiation. 
Aggregation was found to be prostaglandin-independent 
whereas a second wave of release was found to be 
thromboxane-dependent. Aggregation by exogenous 
phospholipase C in the presence of BPB, however, was 
inhibited by indomethacin. Calcium and c'AMP appear to 
regulate the response to phospholipase C. 
Phospholipid analysis of platelets treated with 
exogenous phospholipase C in the presence or absence of the 
inhibitors BPB or verapamil showed that PC could be broken 
down without an increase in PA production. It is possible 
that under these conditions, diglyceride lipase is more 
active, releasing arachidonic acid which accounts for 
increased TXB 2 production in the presence of BPB. 
Diacylglycerol could have a pivotal role in the release 
mechanism, and if unavailable for the protein 
phosphorylation reaction (Kawahara et al., 1980) release 
could be inhibited. The first phase of release caused by 
exogenous phospholipase C in resuspended platelets could be 
due to the formation of diacylglycerol from PC. 
Spermine was found to cause inhibition of the action 
of exogenous phospholipase C itself, preventing 
diacylglycerol production and hence phosphatidic acid 
production. Trimetoquinol did not inhibit phosphatidic 
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acid production but caused inhibition of phospholipase C-
induced aggregation. 
The results using exogenous phospholipase C in the 
presence of BPB or a combination of BPB and verapamil are 
consistent with diglyceride lipase being more active in the 
presence of BPB. It remains to be shown that this is the 
pathway by which ADP, and adrenaline potentiated ADP, 
trigger responses in the presence of BPB. 
6.1 INTRODUCTION 
The activity of endogenous phospholipase C in 
platelets is significant because of its role in the 
conversion of inositol phospholipid to diacylglycerol in 
stimulated platelets (Lloyd et al., 1972; 1973a,b; 1974; 
Lapetina and Cautracasas, 1979; Rittenhouse-Simmons, 
1979). Diacylglycerol may be metabolized by two 
alternative pathways and may also be involved in protein 
phosphorylation (Kawahara et al., 1980). Through the 
action of a kinase, diacylglycerol can be converted to 
phosphatidic acid. Alternatively, the action of a lipase 
can supply arachidonic acid from this same intermediary 
(Bell et al., 1979). The relative importance of these two 
enzymes in normal platelet function is under debate. 
Exogenous phospholipase C also increases the amount of 
phosphatidic acid in the platelet membrane (Chap et al., 
1979). The substrate is not inositol phospholipid as in 
thrombin-treated platelets, but is believed to be 
phosphatidylcholine (PC), the most predominant phospholipid 
after sphingomyelin. Platelet membrane phospholipids are 
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distributed asymmetrically. PS,PI and PE are present 
largely on the interior of the membrane of inactivated 
platelets. PC on the exterior of the membrane is an 
obvious site of attack. Although the phospholipid substr-
ates for endogenous and exogenous phospholipase differ, 
investigation of the action of exogenous phospholipase Con 
platelets could still be worthwhile because of its ability 
to produce diacylglycerol and phosphatidic acid. 
Chap et al. (1971) reported that phospholipase C 
derived from Clostridium welchii induces aggregation of 
human platelets with the production of ceramides and 
diaclyglycerols. Cell lysis follows slowly as indicated by 
lactate dehydrogenase release. Schick and Yu (1974) also 
studied the effects of this phosph~lipase Con platelets. 
They showed that PC and SPH were hydrolyzed, and platelet 
release of serotonin, ADP and platelet factor 4 occurred. 
These platelets were found to be intact by ultrastructural 
analysis after treatment with phospholipase C. It was also 
verified that the enzyme hydrolysis was due to the 
phospholipase and not due to any bacterial contaminant. PE 
and PS were degraded when more extensive hydrolysis 
occurred but PI was not found to be affected. 
It is difficult to investigate endogenous 
phospholipase C activity since agonists known to stimulate 
phospholipase C also stimulate phospholipase A2 • Thrombin 
(Lapetina et al., 1981a) and collagen (Broekman et al., 
1980) for example, stimulate both phospholipases. ADP has 
also been shown to stimulate phospholipase C activity 
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within 30sec of contact with platelets (Lloyd _et al., 1972) 
with the activation of phospholipase A2 occurring 
secondarily (Best et al., 1980). The calcium ionophore 
A23187 also stimulates both phospholipases but is an 
inefficient stimulus for diacylglycerol generation, and in 
fact requires the formation of cyclooxygenase products and 
ADP to stimulate phospholipase C (Rittenhouse,1984). 
Another method of examining the role of phospholipase 
C activity involves the use of specific inhibitors. 
Unfortunately, no such specific inhibitor has been found to 
date. Walenga et al. (1980) demonstrated that several 
serine esterase inhibitors did, in fact, inhibit PI-
specific phospholipase C, but also inhibited phospholipase 
A2 • Since the serine esterase inhibitors blocked 
arachidonic acid release by A23187, an enzymatic step 
beyond calcium mobilization is inhibited, which in the case 
of A23187 is likely to be phospholipase A2 (Rittenhouse-
Simmons, 1981). Phenothiazines may inhibit phospholipase C 
but they also inhibit phospholipase A2 (Rao et al., 1980b). 
Trimetoquinol has recently been reported to be a 
phospholipase C inhibitor (Huzoor-Akbar et al., 1982) as 
have some polyamines (Nahas and Graff, 1982) but the 
specificity of these compounds is yet to be determined. 
The following studies were carried out to characterize 
the aggregation of platelets and associated release 
achieved with exogenous phospholipase C, and examine the 
effect of several inhibitors which have been previously 
used with adrenaline. The effects of inhibitors on 
phospholipase C treated platelets and adrenaline 
potentiated responses of platelets are compared. 
6.2 METHODS AND MATERIALS 
6.2.1 Preparation of Platelets 
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Blood was obtained and plasma prepared as decribed in 
Chapter 2, with citrate as the anticoagulant for the 
preparation of platelet rich plasma (PRP) or acid-citrate-
dextrose for the preparation of washed platelets and 
resuspended platelets. Some studies were performed with 
PRP and some with unwashed platelets suspended in a 
modified Tyrode's solution. This resuspension method was 
essentially the same as the washing procedure described 
except that the wash step consisted of rinsing the top 
layer of the platelet pellet, instead of resuspending the 
whole pellet in washing fluid, thus eliminating one 
centrifugation step. The modified Tyrode's solution had 
the following composition:NaCl 8.0g/1, KCl 0.2g/l, NaHC0 3 
1.0g/1, NaH 2P0 4 O.OSg/1, MgC1 2 0.009g/l, CaC1 2 0.022g/l, 
albumin 3.Sg/1, glucose 1g/l; pH 7.4, 37°C. 
6.2.2 Platelet Studies 
Aggregation, measurement of ATP release, TXB 2 
radioimmunoassay and phospholipid analyses were undertaken 
according to the methods described in Chapter 2. 
6.2.3 Materials 
Phospholipase C, Type I was obtained from Sigma and 
had a specific activity of 8.1U/mg solid. Thrombin(Parke-
Davis, bovine origin) was also used as an aggregating 
agent. 
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The inhibitors used were aspirin, indomethacin, 
BW75SC, verapamil (Isoptin), p-bromophenacyl bromide, 
phenoxybenzamine, dibenamine, spermine, chlorpromazine, 
promethazine and trifluoperazine. Their sources and usage 
were as described in Chapter 2. 
6.3 RESULTS 
6.3.1 Characteristics of the Response to Phospholipase C 
Exogenous phospholipase C (0.1 mg/ml) caused 
aggregation in PRP after a · variable delay of up to Smin 
(Fig. 6.1). Resuspended platelets were more sensitive to 
phospholipase C with a threshold of 5-10µg/ml, and the 
aggregation response was faster (Fig. 6.1). Release of 
nucleotides in PRP commenced slowly and reached a peak 
after aggregation was almost complete (Fig. 6.1). In 
contrast to PRP, the release reaction in resuspended 
platelets occurred in two phases. The first phase was very 
rapid, coinciding with the shape change, and the second 
phase appeared about one minute after, or later if the 
overall reaction was slow for that particular donor. The 
release reaction was more extensive in resuspended 
platelets than in PRP (Fig 6.1). Aggregation of platelets 
due to phospholipase C in either medium was associated with 
the formation of small amounts of TXB 2 • For example , in 
PRP, phospholipase C (0.1mg/ml) caused the formatio n of 
0.2-2.0 pmol TXB 2/10 7 platelets. 
0 
% Light 
T ronsmission 
50 
t 
A 
A B 
lime(min) 
150 
75 
µmole 
ATP 
50 
25 
Figure 6.1 Platelet aggregation and release caused by 
exogenous phospholipase C. 
Platelets were suspended in platelet rich plasma(B) or in 
modified Tyrode's solution (see Methods)(A). 
Aggregation(upper traces) was acheived with 0.1mg/ml 
(0.8U/ml)(B) and 0.01mg/ml(0.08U/ml)(A) of phospholipase C 
Release of nucleotide was assessed in comparison to ATP 
standards using a lumiaggregometer(lower traces). TXB 2 
levels obtained on completion of aggregation were 
A,0.6pmol/10 7 platelets and B,1.0pmol/10 7 platelets ~ 
6.3.1 .1 The Effects of Cyclooxygenase / Synthe t ase 
Inhibitors. 
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Neither aspirin (SmM) nor indomethacin (10- 4 M) nor 
BW755C (10µg/ml) by themselves had any effect on 
aggregation caused by exogenous phospholipase C (0.1mg/ml ). 
These inhibitors were found to be effective in preventing 
formation of TXB 2 • Following the inhibition of 
cyclooxygenase, however, other inhibitors were found to be 
more effective as described below for BPB. Indomethacin 
inhibited the second peak of nucleotide release from 
resuspended platelets. The first peak was slightly 
reduced. 
6.3.1.2 The Effects of Verapamil, a Calcium Channel 
Blocker. 
In PRP, verapamil (SSµM) did not inhibit aggregation 
due to exogenous phospholipase C (0.1mg/ml), but reduced 
the amount of TXB 2 formed. Higher concentrations of 
verapamil(110µM and 165µM) decreased the rate of 
aggregation and reduced TXB 2 formation. In PRP, verapamil 
(165µM) inhibited the release of nucleotide. With 
resuspended platelets, the first phase of release was 
markedly reduced, while the second was increased ( Fig 6.2 ) . 
Nifedipine (10µM) had a similar effect to verapami l 
(165µM) (results not shown). 
6.3.1.3 The Effects of Bromophenacyl Bromide ( BPB) 
In both resuspended platelets and PRP, BPB (100µM) 
partially inhibited aggregation caused by exogenous 
phospholipase C while increasing TXB 2 format i on (Fig 6.3). 
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Figure 6.2 The effects of verahamil on aggregation and 
release due to exogenous phosp olipase C. 
Platelets were suspended in modified Tyrode's solution and 
were aggregated with O.OSmg/ml phospholipase C without 
inhibitor(A) or with 75~g/ml verapamil(B)(upper traces). 
Release of nucleotide was assessed in comparison to 
standard ATP using a lumiaggregometer(lower traces). TXB 2 
levels were A,0.Spmol/10 7 platelets and B,0.3pmol/10 7 
platelets. 
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Figure 6.3 The additive inhibitory effect of BPB and 
indomethacin on aggregation due to phospholipase C. 
Platelet rich plasma (400,000 platelets/~l)prepared from 
citrated blood was incubated for 1min with (A) 10-~M 
indomethacin + 100~M BPB, (B) 100~M BPB and (C) DMSO. 
Phospholipase C(0.1mg/ml) was added at the arrow. 
ND=not detected. 
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Preincubation with a combination of indomethacin' and BPB 
completely inhibited TXB 2 formation(Fig.6.3). The 
combination of verapamil and BPB, however, did not inhibit 
TXB 2 formation even though verapamil, by itself, reduced 
TXB 2 formation caused by exogenous phospholipase C. This 
is in contrast to indomethacin which invariably prevented 
TXB 2 formation. 
BPB decreased the release of nucleotide from 
resuspended platelets, and altered the pattern of release 
(Fig 6.4). Only one phase of release occurred and the 
larger the extent of inhibition of aggregation, the larger 
was the inhibition of the release reaction. 
6.3.1.4 Other Inhibitors 
Several inhibitors known to affect calcium dependent 
reactions were tested for their effects on aggregation 
caused by exogenous phospholipase C. Mepacrine 
(quinacrine)(3OµM) caused a slight inhibition of 
aggregation with a complete inhibition of TXB 2 formation. 
The phenothiazines, chlorpromazine, promethazine and 
trifluoperazine were not inhibitory at 1OOµM. There was, 
however, some reduction in release of nucleotide in PRP in 
the presence of phenothiazines. Phenoxybenzamine(4OµM) and 
dibenamine (4OµM) also reduced release but not aggregation. 
In resuspended platelets, this reduced release of 
nucleotide occurred in one peak only, well after the shape 
change, as aggregation was proceeding. Prostacyclin 
(1Oµg/ml) and theophylline(1mM) partly inhibited 
aggregation if the concentration of phospholipase C was s o 
0 
% Light 
Transmission 
50 
t 
A 
100-"-.___.___..__ _____ __..._ __________ _ 
Time(min) 
Figure 6.4 The effects of bromo henac 1 bromide on 
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aggregation an ue to exogenous p osp o ipase C. 
Platelets were suspended in modified Tyrode's solution and 
were -aggregated with 0.05mg/ml phospholipase C without 
inhibitor(A) and with 50~M BPB(B)(upper traces). Release of 
nucleotide was assessed in comparison to standard ATP using 
a lumiaggregometer(lower traces). TXB 2 levels were 
O.Spmol/10 7 platelets for both traces. 
reduced that aggregation only occured after a delay of 
about 4min. The inhibitory effects of these agents, 
although small when used singly, were additive when 
combined. 
6.3.1.5 Spermine and s-Trimetoquinol 
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s-Trimetoquinol (1mM) inhibited aggregation due to 
exogenous phospholipase C (10µg/ml). The polyamine, 
spermine (10mM) also completely inhibited phospholipase C 
mediated aggregation. These observations were examined 
further by the analysis of the changes in phospholipids 
caused by phospholipase C in the presence of these 
inhibitors (see below). Both s-trimetoquinol and spermine 
inhibited thrombin-induced aggregation and the accompanying 
phospholipid changes caused by thrombin in the presence of 
these inhibitors were also analyzed. 
6.3.2 Phospholipid Changes Due to Exogenous Phospholipase C 
Washed platelets were aggregated with phospholipase C 
and membrane phospholipids were extracted. The 
phospholipids were separated by paper chromatography and 
estimated by phosphorus analysis and sometimes following 
3H-arachidonic acid incorporation. The phospholipids 
analyzed were PC, SPH, PI, PE, PS and PA. The distribution 
of these lipids on a typical chromatogram is given in Fig 
6.5. The lysolipids, lysophosphatidylcholine (LPC) and 
lysophosphatidylethanolamine (LPE) were tentatively 
identified in addition to these. 
The major change caused by phospholipase C was an 
increase in PA. A typical phospholipid analysis is given 
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and 
Chro_~atograms were run on Whatman SG-81 paper, first in 
chloroform:methanol:SN ammonia(64:34:4) and then in 
chloroform:diisobuylketone:pyridine:methanol :acetic 
acid:formic acid:water(23:20:25:20:8:1 :3). The 
phospholipids are identified(see Ch.7) as : 1.sphingomyel in 
SPH 2.phosphatidylcholine PC 3.phosphatidylserine PS 
4.phosphatidylinositol PI 5.phosphatidylethanolamine PE 
6.phosphatidic acid PA 7.lysoPC 8.lysoPE. 
158 
in Table 6.1. PA increased 10-fold in 3min compared with 
the area (unstained) in a corresponding control 
chromatogram of unstimulated platelets. PC is the lipid 
measurably hydrolyzed while the other lipids appear 
unaffected. Mean PA production at 3min and 5min for three 
experiments is shown _ in Fig 6. 6. 
Table 6.1 Phospholipid Analysis by Phosphorus Content for 
Unstimulated and Phospholipase C-treated Platelets. 
Phospholipid 
SPH 
PC 
PS 
PI 
PE 
PA 
LPC 
LPE 
% TOTAL PHOSPHORUS 
Unstimulated 
16.5 
32.3 
9. 1 
2.9 
17.9 
0.34 
1 • 7 
2.3 
Phospholipase C 
16.3 
27.3 
9.0 
3.6 
19.3 
3.8 
1 • 0 
2.8 
These are the results of a single experiment in which 
5.7x10 9 platelets in 1500µ1 were treated with phospholipase 
C(10µg/ml,0.08U/ml) for 90 sec. Phospholipids were 
extracted and chromatographed according to the methods 
described. 
6.3.3 The Effects of Inhibitors on Phospholipid Changes 
due to Exogenous Phospholipase C 
The effects of BPB and verapamil on changes in PC and 
PA changes caused by phospholipase Care shown in Table 
6.2. Only PC and PA are shown as there were no detectable 
changes in the other phospholipids. The data includes 
estimation of phospholipids by 3H-arachidonic acid 
incorporation (2 experiments) and by phosphorus assay (4 
experiments). Changes caused by phospholipase C in the 
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Figure 6.6 _Production of phosphatidic acid during platelet 
aggregation due to phospholipase C. 
Platelets were washed (methodB) and resuspended at 2-3x109 
platelets/ml. PA was estimated by phosphorus assay of the 
spot separated on two-dimensional chromatography and shown 
in terms of %total phosphorus as the mean of three 
experiments ±SD depicted as bars. 
presence of BPB (50\JM) or verapamil (S0µg/ml) or a 
combination of these two inhibitors are shown. 
Table 6.2 Changes in PC and PA due to Exogenous 
Phospholipase C(PLC) in the Presence of BPB and/or 
verapamil. 
% TOTAL PHOSPHORUS 
Unstim. PLC PLC PLC 
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PLC 
+BPB +verap. +BPB/verap 
Exp. PL C 3 5 3 5 3 5 3 Smin 
1 PC 47.4 36. 27.6 36.8 
PA 0.28 1 0 9 4 1 • 9 3.2 
t2 PC 44.3 41 • 0 40.0 38.3 35.9 1 • 7 32.0 2.5 33.S 
PA o.os 2.17 5.81 2.3 3.90 2.56 2.84 2.35 3.70 
#3 PC 45.0 44.2 40. 1 40.3 33.7 38.2 39.7 34.6 33.0 
PA 1 • 1 0 4.15 7.81 4. 1 9.98 4.56 5.60 6.83 
14 PC 40.0 38.0 37.4 32.9 29.2 30.8 42.3 35.4 -3 4. 2 
PA 0.46 1 • 06 5.4 4.8 s.21 2. 1 5.03 3.80 4.73 
MEAN PC 4 3. 1 41 • 1 39.2 37.2 32.9 36.9 38.0 37.5 33.6 
±SD 2.1 3. 1 1 • 5 3.8 3.4 5.6 5.4 4.3 0.6 
MEAN PA 0.54 2.4 6.3 3.7 6.3 3. 1 3.92 4.89 
±SD 0.53 1 • 5 6 1 • 26 1 • 29 3.20 1 • 30 2.30 1 • 7 0 
,
3H-ARACHID NIC A ID 
13 PC 43.5 43.0 40.0 3.0 35.0 , • 0 34.0 6.0 32.0 
PA 0.13 1 • 26 2.90 1 • 5 0 3.00 1 • 7 2.00 1 • 60 2.20 
14 PC 41 • 6 51 • 0 2 9. 1 2.0 31 • 0 7.0 33.7 3 • 1 
PA 0.12 0.97 3.64 1 • 7 0 3.68 1 • 6 3.21 1 • 88 
MEAN PC 42.6 47.0 34.6 7.5 33.0 9.0 33.8 0. 1 7.6 
±so l • 3 5.7 7.7 6.4 2.8 , • 3 0.21 8.3 7.0 
MEAN PA 0. 1 2 1 • 2 3.27 1 • 60 3.34 1 • 7 2.61 1 • 1 0 2.04 
±SD 0.06 0.21 3.27 0. 1 4 0.48 0.07 0.86 0.72 0.23 
In each experiment, 2-3x10 9platelets/ml were treated with 
phospholipase ·C(l0µg/ml) for 3 or 5min. The last two 
experiments were analyzed for 3H-arachidonic acid 
incorporation in addition to phosphorus analysis. Exp.#1 
is excluded from the mean±SD because of limited data. 
BPB(S0µM) and verapamil(50µg/ml) were added lmin before 
phospholipase C. 
Using phosphorus estimation, it was found that 
exogenous phospholipase C achieved a greater hydrolysis of 
PC in the presence of BPB than in the absence of this 
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inhibitor. This was found in each experiment and is 
reflected in the mean. The large standard deviations are 
due to wide differences in responsiveness of different 
platelet preparations used in each experiment. PA 
production does not appear to account for this reduction in 
PC. Breakdown of PC by exogenous phospholipase C was also 
increased in the presence of verapamil, but not by as much 
as in the presence of BPB. PA production was not always 
increased in the presence of verapamil or BPB. In the 
presence of a combination of BPB and verapamil, a similar 
pattern emerged as in the presence of each inhibitor alone, 
namely, increased breakdown of PC but no further increase 
of PA production. 
With 3H-arachidonic acid incorporation, however, it 
was found that, in the presence of the combination of BPB 
and verapamil there was a greater loss of arachidonic acid 
from PC which did not appear in PA, compared to the effects 
of exogenous phospholipase C in the presence of each 
inhibitor singly. The changes in 3H-arachidonic acid 
incorporation due to exogenous phospholipase C in the 
presence of these inhibitors, in general, revealed a 
different pattern to the results obtained using phosphorus 
estimation. No change in 3H-arachidonic acid incorporation 
in PC was evident after 3min and there was only a small 
decrease in radioactivity by 5min. Changes in the presence 
of inhibitors were, therefore more difficult to detec t . 
Phospholipid analysis of phospholipase C-treated 
platelets in the presence of trimetoquinol or spermin e is 
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shown in Table 6.3. Spermine, and to a lesser extent, 
trimetoquinol, inhibited the breakdown of PC by exogenous 
phospholipase C. The two inhibitors differed in their 
effect on PA production in that spermine (10mM) inhibited 
PA production while trimetoquinol (2mM) did not. 
Table 6.3 Changes in PC and PA due to Exogenous 
Phospholipase C in the presence of Trimetoquinol or 
Spermine. 
% TOTAL PHOSPHORUS 
PL Unstimulated Phospholipase C 
(PLC) 
PC 31.4 18.2 
PA 0.60 4.9 
PLC+ 
trimetoquinol 
(2mM) 
24.6 
5.3 
PLC+ 
spermine 
(10mM) 
34.4 
0.40 
The results shown are from one experiment, and were 
confirmed in another. 3.4x10 9platelets were treated with 
phospholipase C(100µg/ml) for 8min in the presence or 
absence of each inhibitor, preincubated for 1min. 
6.3.4 The Effects of Inhibitors on Phospholipid Changes 
due to Thrombin 
Washed platelets (method A) were aggregated with 
thrombin in the presence of the same inhibitors previously 
examined for their effects on phospholipase C-induced 
phospholipid changes. Two experiments were performed, one 
with 0.14U thrombin/10 8 platelets and another with 0.08U 
thrombin/10 8 platelets. Phospholipids were quantitated by 
3H-arachidonic acid incorporation and by phosphorus assay. 
BPB partially inhibited aggregation and verapamil almost 
totally inhibited aggregation by thrombin. Total 
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inhibition of aggregation by thrombin was achieved with the 
combination of BPB and verapamil. In Table 6.4 it can be 
seen that PA production due to thrombin was not prevented 
by BPB nor by verapamil. Also PI breakdown due to thrombin 
was not greatly affected by these inhibitors. Since only 
two experiments were performed, this data cannot be 
analyzed further. 
Table 6.4 Changes in PC,PI and PA due to Thrombin in the 
Presence of BPB and/or Verapamil. 
%3H-ARACHIDONIC ACID 
PL Unstimulated Thrombin Thrombin Thrombin Thrombin 
+BPB +verap. +BPB/verap. 
3 5 3 5 3 5 3 
PC 55.9 62.0 50.3 55.8 58. 1 59.0 51.0 58.4 
PI 8.73 5.6 3.7 6.8 5.9 5.4 4.9 6.8 
PA 0.21 3.6 4.2 2.2 4.2 3.8 4.3 2.6 
%TOTAL PHOSPHORUS 
PC 43.0 44.8 38.9 45.5 39.7 38.8 38.6 42.8 
PI 5.0 3.0 3.5 3.4 2.6 3.4 4.4 3. 1 
PA 0.47 1 • 9 2.5 2.7 2.0 3.9 2.9 1 • 8 
3.5x10 9platelets/ml were treated with thrombin(5U/750µl) 
and incubated for 3 or 5min, in the presence or absence of 
BPB(50µM) or verapamil(50µg/ml) or a combination of the 
two. 
Phospholipid analysis was also performed on thrombin-
activated platelets (0.4 U/10 8 platelets) in the presence 
of trimetoquinol or spermine. The results are shown in 
Table 6.5. With phosphorus analysis, 100mM spermine 
prevented PI breakdown and PA formation, whereas 10mM 
trimetoquinol did not inhibit PI breakdown nor PA 
formation, even though both caused inhibition of 
aggregation. 
Table 6.5 Changes in PI and PA due to Thrombin in the 
Presence of Trimetoquinol or Spermine. 
% TOTAL PHOSPHORUS 
PL Unstimulated Thrombin Thrombin + 
trimetoquinol 
(10mM) 
PI 6.8 5.3 5.2 
PA 0.38 1 .9 2s5 
Thrombin + 
spermine 
(100mM) 
6.3 
0.56 
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2.4x10 9 platelets/ml were treated with thrombin(SU/750µ1) 
and incubated for 3min in the presence of 
trimetoquinol(10mM) or spermine (100mM). 
6.4 DISCUSSION 
There have been several reports on the effects of 
phospholipase C (derived from Clostridium welchii) on human 
platelets in vitro (Sc~ick and Yu, 1974; Chap et al., 1977; 
Kawahara et al., 1980; Huzoor-Akbar et al., 1982). In 
agreement with these reports, the present data shows that 
phospholipase C causes aggregation and release of 
nucleotides from platelets. Aggregation was independent of 
prostaglandin synthesis but was partially inhibited by 
verapamil, mepacrine, phenothiazines and agents which 
increase c'AMP. It is suggested, therefore, that calcium 
and c'AMP may regulate the platelet response to 
phospholipase C. 
Phospholipase C caused aggregation and release in both 
PRP and resuspended platelets although higher 
concentrations of the enzyme were required in PRP, and the 
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pattern of release in PRP differed from that in modified 
Tyrode's solution. The reduced sensitivity of PRP may be 
attributable to the presence of other lipids and to protein 
in the plasma. The first and more rapid phase of release 
of nucleotide from resuspended platelets corresponds in 
time with 5-hydroxytryptamine release by phospholipase C 
reported by Schick and Yu (1974). This first phase of 
nucleotide release was inhibited by verapamil (165µM) or by 
BPB (50µM). It could be speculated that, in the presence 
of BPB, diacylglycerol is diverted, possibly by the lipase 
(Bell et al., 1979) such that it is unable to be linked to 
protein phosphorylation for the release reaction (Kawahara 
et al., 1980). This is supported by the data showing 
increased breakdown of PC in the presence of BPB, without 
conversion to PA. 
If diacylglycerol is involved in the action of 
exogenous phospholipase Cit would have to enter the 
platelet after the action of phospholipase Con externally 
located PC. Phospholipase C does not enter the cell but 
instead utilizes the externally located substrate as 
indicated by the experiments with 3H-arachidonic acid. 
Phospholipase C caused very little change in 3H-arachidonic 
acid in PC, while phosphorus analysis indicated significant 
hydrolysis of PC. These observations indicate that the 
substrate for phospholipase C is PC located in the outer 
membrane leaflet. Inner membrane PC contains a higher 
proportion of arachidonic acid while PC in the outer 
membrane leaflet contains oleate and linoleate 
(Rittenhouse-Simmons and Deykin, 1981). 
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Both calcium mobilization and diacylglycerol 
production seem to be necessary for the full physiological 
response of the platelet(Kaibuchi et al.,1983). Verapamil 
may inhibit the release reaction by acting as a calcium 
antagonist which inhibits calcium-dependent reactions 
including protein phosphorylation. 
The second phase of nucleotide release from 
resuspended platelets is thromboxane-dependent since it was 
inhibited by indomethacin. Aggregation is not thromboxane-
dependent. Nevertheless, small amounts produced may 
contribute towards aggregation associated with the second 
phase of release. Thromboxane seems to contribute more to 
aggregation occurring in the presence of BPB since this was 
more sensitive to inhibition by indomethacin. 
Nevertheless, increases in TXB 2 observed in the presence of 
BPB or BPB and verapamil combined, were not able to 
overcome the inhibition of aggregation. A step beyond the 
formation of thromboxane therefore seems to be inhibited. 
If diacylglycerol lipase is indeed more active than the 
kinase in the presence of BPB, with resultant release of 
arachidonic acid, then the present observations can be 
explained. 
The effects of BPB and verapamil on phospholipid 
changes caused by thrombin differ from their effects on 
phospholipid changes caused by exogenous phospholipase C. 
Thrombin activates endogenous phospholipase C in platelets, 
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forming diacylgly'cerol from phosphatidylinositol-4,5-
bisphosphate (Broekman, 1984). Whereas exogenous 
phospholipase C was more active in the presence of BPB than 
in its absence, the activity of endogenous phospholipase C 
following thrombin activation was unaffected by BPB. The 
two phospholipases in question act on different substrates: 
PC in the case of the exogenous enzyme and PI in the case 
of thrombin activated phospholipase C. Thus there may be 
important differences in diacylglycerol formation and 
metabolism when platelets are activated by thrombin or 
exogenous phospholipase C, the latter enzyme requiring 
entry of diacylglycerol into the platelet. 
Most of the agents examined for their ability to 
inhibit exogenous phospholipase C were only partially 
effective. Spermine(10mM) and trimetoquinol(1mM) were the 
only agents found to be completely inhibitory for exogenous 
phospholipase C. These two inhibitors differed in their 
effects on phospholipids. Spermine, but not trimetoquinol 
inhibited PA formation due to exogenous phospholipase C. 
Perhaps trimetoquinol inhibits a step in the activation 
pathway beyond diacylglycerol and PA formation. An 
interesting possibility is that trimetoquinol inhibits 
protein kinase C, since it does not inhibit diacylglycerol 
formation. Inhibition by spermine can be attributed to 
inhibition of diacylglycerol formation which is important 
for aggregation and release by phospholipase C. 
The results of this chapter suggest that BPB could 
indeed, be affecting the phospholipase C pathway, perhaps 
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enabling diacylglycerol lipase to be more active. It would 
be interesting to examine the effects of BPB on the 
adrenaline potentiated response to ADP by platelets in 
terms of such phospholipid changes. If adrenaline can 
influence this pathway, it may well be of considerable 
physiological and pathological significance. 
Chapter 7 
THE EFFECT OF ADRENALINE ON PLATELET 
MEMBRANE PHOSPHOLIPIDS. 
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7.0 SUMMARY 
The mechanism of prostaglandin-independent adrenaline 
potentiation may involve phospholipid changes, ~r 
alternately, could be associated with increased calcium 
uptake due to adrenaline. Since PI metabolism has been 
found to alter as a result of stimulation by other 
agonists, it was thought that adrenaline effects on PI 
metabolism should be examined. 
Two solvent systems for a paper chromatographic 
technique for the separation and quantitation of PA and PI 
were compared. The second system was found to give a well 
resolved, compact spot compared to the more diffuse spot of 
the first system. This method was used for some 
preliminary experiments, examining adrenaline potentiation 
of ADP and thrombin. 
The results are preliminary and therefore inconclusive 
but focus on the PI cycle and mobility within the different 
polyphosphoinositides as areas worthy of further 
investigation. 
7.1 INTRODUCTION 
Adrenaline potentiation of other platelet agonists in 
vitro may reflect the proposed important biological role of 
adrenaline in the preparation of platelets to react 
efficiently where required in wound repair. Besides an 
effect on arachidonic acid metabolism, the present work 
indicates that adrenaline potentiation can be independent 
of prostaglandin synthesis. Adrenaline, by its binding to 
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a 2-receptors (Grant and Scrutton,1979) possibly causes some 
kind of membrane change involving calcium mobilization(Rao 
et al., 1981a; Brass and Shattil, 1982). This calcium 
movement could be associated with phospholipid changes 
(Michell, 1975) or could be independent of phospholipids. 
Alterations to phospholipids have been observed during 
aggregation of human, horse and rabbit platelets induced by 
thrombin, collagen and ADP(Lloyd et al., 1973b; 1974; 
Broekman et al., 1980; Lapetina et al., 1981a). 
Adrenaline has been found to increase PI synthesis in 
platelets, but only following completion of the release 
reaction (Deykin and Snyder,1973) and not in the presence 
of aspirin (Clare and Scrutton,1984). It is, however, the 
immediate post-receptor events in adrenaline activation 
which are of interest in the potentiation mechanism since 
potentiation can be acheived after only fifteen seconds or 
less prior contact with adrenaline. Both phospholipid 
turnover and changes in phospholipid proportions need to be 
assessed. Since PI is capable of cycling (Lapetina et 
al., 1981b) resynthesis is possible so that while PI can • 
participate in a platelet reaction, its overall level may 
not alter, as was found for ADP (Lloyd et al.,1972). The 
evidence reported so far in this thesis indicates that 
adrenaline may affect phospholipase C-mediated PI 
metabolism when the ADP response is potentiated and this 
chapter focusses on the effects of adrenaline on this 
aspect. These investigations, however, are only of a 
preliminary nature. Details of the development of the 
chromatographic procedure employed are also included. 
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A paper chromatographic method was chosen for the 
separation of phospholipids. With this technique, PI and 
PA could be separated and quantitated, but diacylglycerol 
could not. PI was considered to be important to assay for 
reasons which have been discussed previously. PA is a 
product of PI breakdown and its accumulation has been shown 
to be important in the response to thrombin (Lapetina et 
al., 1981). Increases in PA indicate that the enzyme 
diglyceride kinase is active as opposed to digyceride 
lipase. Silica gel-loaded paper has been reported to be 
suitable for separation of lipids from tissue 
extracts (Wuthier, 1966). 
7.2 METHODS AND MATERIALS 
Platelet preparation, aggregation, chromatography, 3H-
arachidonic acid incorporation and phosphorus assay were 
carried out according to the methods described in Chapter 
2. The platelets were washed using method B with the 
inclusion of prostacyclin in each centrifugation. 
Aggregation was performed in a large cuvette in the 
aggregation module so that a sufficient number of platelets 
could be used to obtain measurable amounts of phosph o li p i d. 
At least 1x10 9 platelets(approx.30µg P) were required per 
incubate. For most experiments, 750µ1 platelet suspension 
containing approximately 3x10 9 platelets was employed. 
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The lipid extraction procedure was modified from Bligh 
and Dyer(1959) to allow for the small volumes of each 
incubate. SG-81 paper from Whatman was used for two-
dimensional chromatography to separate the phospholipids. 
The first pair of solvent mixtures employed (System A) used 
by Kramer et al.(1982), and modified from Wuthier(1966), 
was found to be unsuitable, especially for the recovery of 
measurable phosphatidic acid and was later substituted with 
a second pair of solvent mixtures (System B). A full 
comparison of chromatograms obtained with both pairs is 
reported in the Results section of this Chapter(7.3). 
Phospholipids were quantitated by phosphorus assay 
(Rouser et al.,1966) and expressed as a percentage of total 
phosphorus extracted from the platelet incubate. 
Phospholipid turnover was assessed by determining the 
incorporation of 3H-arachidonic acid. 
The aggregating agents employed were adrenaline, ADP, 
and thrombin. The inhibitor used was BPB. Phosphatidic 
acid standards used included synthetic dioleoyl 
phosphatidic acid-Na salt(Sigma), dipalmitoyl phosphatidic 
acid-free acid(Sigma), lecithin-derived phosphatidic 
acid(Serdary) and phosphatidic acid(Supelco). Other 
standard phospholipids,PI(Supelco), PC, PE, PS and 
SPH(Sigma) were also used to identify chromatographic 
spots. 
7.3 RESULTS 
7.3.1 Chromatography with Solvent System A. 
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Two different solvent systems for two-dimensional 
chromatography on SG-81 paper were tested. The first 
system(A) separated platelet membrane lipids according to 
the pattern shown in Fig 7.1. PI resolved well in this 
system, but PA could not be observed, presumably because it 
constitutes such a small proportion of total phospholipids. 
The maximum lipid phosphorus load of this system is 
10µg(Wuthier,1966) of which less than 0.1%(0.01µg) would be 
PA. This amount would not stain with rhodamine 6G, 
especially if the spot was diffuse. The localization of PA 
was therefore attempted with the use of commercial 
standards in quantities which would stain. Even so, the 
localization of platelet PA would not necessarily be 
coincident with PA derived from a source other than 
platelets(Wuthier,1976). 
The mobilities of PA from three different sources in 
each phase of the solvent system are shown in Fig 7.2. All 
of these standards were unsatisfactory. The Serdary sample 
separated into three different spots in the second 
dimension. Dipalmitoyl-PA showed no movement at all in the 
second dimension and dioleoyl~PA moved high in both phases. 
PA moving rapidly in the second phase would overlap with 
cardiolipin and PE. Platelet PA could not be localized by 
this method. 
Washed platelets(6x10 9 /ml) were treated with thrombin 
(0.2U/10 8platelets) for 2min, extracted and chromatograph ed 
in parallel with an extract from unstimulated platelets. 
The PI content of control and thrombin-stimulated platelets 
174 
First Solvent Front 
_,,,,.---
/ ' I \ 
I 6 I 
\ 
' 
- -
X 
Figure 7.1 Chromatogram of platelet membrane lipids using 
solvent system A. 
The lipids were extracted by a modification of Bligh and 
Dyer(1959). The chromatogram was run on Whatman SG-81 paper 
first in chloroform:diisobutylketone:methanol:acetic acid: 
water(45:30:15:20:4) for the long phase, and secondly in 
chloroform:diisobutylketone:pyridine:methanol :water(30:25 : 
35:25:8). The spots were stained with rhodamine 6G and 
identified as 1.SPH 2.PC 3.PS 4.PI 5.PE and 6.?PA by their 
colour under UV light and their comparison to standards. 
x=origin. 
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Figure 7.2 The mobilities of standard phosphatidic acids in 
each phase -· of solvent system A. 
The PA samples were: A. synthetic dioleoyl PA-Na salt 
(Sigma) B. synthetic dipalmitoyl PA-free acid(Sigma) and 
C. egg lecithin derived PA(Serdary). The effect of the 
first phase solvents are shown in the upper chromatogram 
and the effect of the second phase solvents are shown in 
the lower chromatogram, run separately. The solvents of the 
two phases are as given for Fig 7.1. 
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is shown in Table 7.1 together with SPH and PC, and a 
possible PA. The results for the suspected PA spot were 
highly variable and the expected increase due to thromb i n 
stimulation was not observed. The amount of supposed PA 
- was also much higher than the expected levels. 
Phospholipase C treated platelets were then used as a 
source of standard PA together with an alternative solvent 
system which was expected to yield a more compact, well 
resolved spot for PA. 
Table 7.1 Phospholipid Content of Unstimulated and 
Thrombin-stimulated Platelets. 
Solvent System A 
Phospholipid Unstimulated Stimulated 
SPH 18.8%(1.6) 15.5%(2.4) 
PC 36.9%(0.78) 37.8%(1.8) 
PI 3.8%(0.32) 2.2%(0.71) 
?PA 1.2%(1.7) 1.4%(1.2) 
Results are expressed as percentage total phosphorus 
and are the mean(±SD) of three experiments. 
7.3.2 Chromatography with Solvent System B. 
The chromatograms of platelet membrane phospholipids 
using solvent system Bare shown in Fig 7.3 and Fig 7.4. 
Chromatography of phospholipids of both thrombin-
stimulated(Fig 7.3) and exogenous phospholipase C-
stimulated platelets(Fig 7.4) revealed the appearance o f a 
spot on the lower right hand corner not present in 
unstimulated platelets. This spot(numbered 6 in t h e Fig) 
is consistent with the position of PA in a chromatogram of 
rat tissue phospholipids illustrated by Wuthier ( 1976 ) . A 
PA standard(Supelco) was subsequently found to 
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latelet membrane li ids from 
Washed platelets (3X10 9 /ml) were treated with thrombin 
(0.1U/10 8 platelets) for Smin. The chromatograms were run on 
Whatman SG-81 paper, first in chloroform:methanol:5N NH~OH 
(64:34:4) and secondly in chloroform:diisobutylketone: 
pyridine:methanol:acetic acid:formic acid:water(23:20:25: 
20:8:1 :3). The spots were stained with rhodamine 6G and 
identified as 1.SPH 2.PC 3.PS 4.PI S.PE 6.PA 7.lysoPC 
8.lysoPE. x=origin. 
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Washed platelets(3X10 9 /ml) were treated with phospholipase 
C(lO~g/ml) for 2min. The chromatograms were prepared as 
described for Fig 7.3. x=origin. 
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chromatograph in this position also. Thrombin treatment 
gave rise to two additional spots(7,8) considered to be 
lysolipids:lysoPC and lysoPE resulting from phospholipase 
A2 activity. 
This solvent system therefore produced a chromatogram 
with well separated PI and PA spots. The PA spot had the 
advantage of being compact with little chance of overlap 
with any other phospholipids. The solvent system B was 
therefore considered the method of choice. The 
chromatographs of SPH, PC, PS, PE and PI standards using 
solvent system Bare shown in Fig 7.5 and the 
identification of each platelet phospholipid was thus 
verified. 
7.3.3 The Effects of Adrenaline on ADP-induced Metabolism 
of PI. 
The results of three experiments, in which 
phospholipids were analyzed for 3H-arachidonic acid 
incorporation and phosphorus content, in response to a 
combination of adrenaline and ADP both in the presence and 
absence of BPB are shown in Table 7.2. These results are 
difficult to analyze for several reasons. First of all, 
the degree of incorporation of arachidonic acid in PA in 
unstimulated platelets is highly variable and stimulation 
by agonists causes variable effects. Stimulation may 
either decrease or increase this basal level of 
incorporation, or remain much the same, as in experiment 
If 1 • 
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Figure 7.5 Chromatograms of standard phospholipids using 
solvent system B. 
The standard phospholipids were chromatographed as 
described for Fig 7.3. The samples were: 
Pl(Supelco)S~g PA(Supelco)S~g PC,SPH,PS,PE,(Sigma)10~gea. 
x=origin. 
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Secondly, there is no consistent pattern of changes in 
PA nor PI. The first two experiments indicate a small 
increase in 3H-arachidonic acid incorporation in response 
to a combination of adrenaline and ADP. Experiment #3, on 
the other hand, shows a decrease, but, in this experiment, 
the degree of incorporation was high in the unstimulated 
platelets. Experiments #2 and #3 show an increase in 
incorporation by adrenaline in the presence of BPB, a 
result paralleled by increases in amount of PA as estimated 
by phosphorus content. There is very little change in 
incorporation in PI, except for a general trend toward 
increased incorporation in platelets in the presence of 
BPB, especially when incubated with ADP or adrenaline 
combined with ADP. Two experiments also showed a small 
increase in 3H-arachidonic acid incorporation in PI in 
platelets aggregated with adrenaline combined with ADP in 
the absence of inhibitor. 
The phosphorus estimations for PA are also variable. 
One experiment showed an increase in PA while the other 
showed no change, when the platelets were treated with ADP 
for 30 sec. The phosphorus estimations for PI are difficult 
to interpret. 
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Table 7.2 Phos!holipid Changes Durin& Adrenaline 
Potentiation o ADP-induced aggregation in the Presence or 
Absence of BPB. 
%3H-ARACHIDONIC ACID 
No inhibitor BPB(50µM) 
Exp.No. PL C Adr. Adr. ADP Adr/ADP Adr. Adr. ADP Adr/ADP 
15s 45s 30s 15/30s 15s 45s 30s 15/30s 
#1 PA 0.23 0.27 0.32 0.25 0.40 0.19 0.21 0.32 0.38 
PI 6.64 6.57 6.48 6.82 6.32 6.93 7. 14 7.82 9.30 
#2 PA 0.69 0.57 - 1 .40 1 • 55 2. 13 - 0.40 1 • 55 
PI 6.03 5.98 - 5.71 7 • 1 1 6.30 - 6.08 7. 1 3 
113 PA 2.34 0.99 0.45 0.90 0.49 2.86 0.59 1 • 45 0.41 
PI 6.38 6.80 7.21 5.98 7.38 7. 12 6. 17 8.34 7.01 
%Phosphorus 
112 PA 1 .82 0. 14 - 5. 10 0.65 2.03 - 0.38 1 • 40 
PI 3.47 1. 4 7 - 3.30 2.68 2. 1 8 - 3.80 7.20 
113 PA 0. 10 0. 11 0.09 0.07 0. 1 0 0.60 0. 10 0.08 0 .• 09 
PI 2.32 1 • 88 1 • 82 2.96 2.69 2. 18 2.37 2.54 2.89 
%3H-arachidonic acid incorporation is shown for three 
experiments and %phosphorus for the last two experiments. 
1-2x10 9platelets/ml were treated with adrenaline(Adr.) 
and/or ADP as indicated at the following concentrations: 
#1 adrenaline 10- 5M ADP 10- 5M. 
#2 adrenaline SX10-~M, ADP 10- 5M. 
#3 adrenaline 10- 4M, ADP 10- 4M. 
Fibrinogen(0.3mg/ml) was added 1min prior to the agonists. 
Each figure is the result of a single estimation. 
PL=phospholipid, s=sec, C=unstimulated platelets. 
7.4 DISCUSSION 
The results of this chapter, while of a preliminary 
nature, indicate that it is unlikely that adrenaline 
influences the total amounts of PI or PA. Some aspects of 
the data are conflicting, indicating that some aspects of 
the method could be improved. 
183 
Separation of PA and PI on Whatman SG-81 paper, using 
solvent system B, was adequate, provided excessive amounts 
were not applied, but was subject to variations in 
behaviour between different batches and small cnanges in 
climatic conditions. Platelet preparations were obtained 
from platelet-rich plasma supplied by the Red Cross Blood 
Bank. Variability in donors and in handling may have been 
responsible for the widely different unstimulated levels of 
arachidonic acid incorporation in PA. Other stimuli 
associated with handling procedures could account for high 
incorporation of arachidonic acid observed in PA in 
apparently unstimulated platelets. 
ADP was expected to induce increased PA turnover, 
without altering the amount of PA (Lloyd et al.,1972), 
whereas thrombin was expected to increase the amount of PA. 
In the experiment where there was increased incorporation 
of arachidonic acid due to exposure to ADP for 30sec, there 
was also an increase in the amount of PA. On the other 
hand, where a large incorporation was observed in 
unstimulated platelets, ADP reduced this incorporation, 
possibly due to increased turnover. Further experiments 
are obviously needed to compare a wider range of platelet 
preparations. 
Equally confusing results were obtained in experiments 
where adrenaline and ADP were added to platelets. It 
should be noted, however, that the two experiments which 
did show a rise in arachidonic acid incorporation were 
performed with platelets in which there was a low initial 
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incorporation. In the third experiment, where ADP reduced 
incorporation, adrenaline and ADP in combination reduced 
this incorporation further. All experiments therefore, 
show that adrenaline affects phospholipid metabolism, even 
if only to a small extent. Further replication of all 
experiments is necessary. 
Phospholipase C may be activated in at least two 
different ways. Thrombin and other agonists interact with 
their receptors to directly activate phospholipase C which 
degrades PI (Lapetina et al., 1978) while the ionophore 
A23187 stimulates phospholipase C via thromboxane and 
ADP (Rittenhouse, 1984). A23187 mobilizes calcium which 
activates phospholipase A2 to release arachidonic acid for 
thromboxane formation. If adrenaline could be shown to 
affect calcium mobilization, this may lead to activation of 
phospholipase C following secretion. When adrenaline 
potentiates another agonist, the effects of adrenaline on 
calcium may be sufficient to act synergistically with 
whatever pathways are triggered by the second agonist. 
Increased labelling of PI, which seems to occur in the 
presence of BPB may indicate an increase in activity of the 
PI cycle (Lapetina et al., 1981b). Previous work, reported 
in Chapters 5 and 6, has indicated that BPB may inhibit 
diglyceride kinase, providing conditions suitable for 
increased lipase activity if diaclyglycerol production is 
increased. 
The PI spot assayed by this technique may provide 
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insufficient evidence to determine the effects of 
adrenaline. It has been shown that both thrombin (Billah 
and Lapetina, 1982) and ADP (Vickers et al . , 1982) cause 
rapid changes in amounts of phosphatidylinositol-4,5-
bisphosphate which may chromatograph differently from PI, 
while the different pools of inositides could participate 
in reactions necessary for platelet activation in different 
ways. ADP did not cause any increase in the amount of PA 
associated with the decrease in PI. It was suggested by 
these authors that decreases in phosphatidylinositol-4,5-
bisphosphate result in the mobilization of membrane-bound 
calcium. An alternative method which could differentiate 
between the different inositide classes in stimulated 
platelets might be more revealing in analyses of the 
effects of adrenaline on platelets. 
Recently, adrenaline alone has been shown to not cause 
breakdown of PI in aspirin-treated platelets (Clare and 
Scrutton, 1984). The results presented here are 
inconclusive. The difficulty in observing measurable 
changes in phospholipids due to adrenaline stimulation may 
indeed arise because the potentiating effects of adrenaline 
are not attributable to breakdown of PI. The ability of 
adrenaline to stimulate calcium redistribution has not been 
excluded by recent work and adrenaline may influence 
calcium mobilization independently of the PI-effect. 
CHAPTER 8 
GENERAL DISCUSSION 
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8.1 DISCUSSION 
Platelets make a vital contribution to the normal 
haemostatic process. There is also a great deal of 
evidence that increased platelet reactivity is important in 
the development of atherosclerosis, thrombosis and coronary 
artery disease. Vascular intimal thickenings have been 
shown to contain thrombus material (Mustard and Packham, 
1975). Platelets adhere to exposed connective tissue 
following injury to the endothelium and subsequently 
release granule contents (Stemerman and Ross, 1972; 
Baumgartner et al., 1967; White, 1972b). Platelet derived 
growth factor stored in a-granules has been found to be an 
absolute requirement for the proliferation of smooth muscle 
cells and to promote migration of endothelial cells in 
vitro (Ross et al., 1974; Wall et al., 1978). It has thus 
been proposed that platelets participate in atherosclerotic 
plaque formation according to the Response-to-Injury 
Hypothesis (Ross and Glomset, 1976). 
Increases in the rate or degree of response of the 
platelet can be brought about by the catecholamines, 
adrenaline and noradrenaline. Catecholamines may prepare 
platelets to respond more readily to other agonists. 
Adrenaline levels rise during even mild stress (Dimsdale 
and Moss, 1980) and this in part prompted the study of 
adrenaline interaction with platelets, since stress may be 
a major risk factor for coronary artery disease. 
Catecholamines are also increased in other risk factor 
conditions including cigarette smoking and hypertension. 
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Adrenaline may increase platelet reactivity, and thus 
contribute to atherogenesis and its complications. The 
mechanisms by which adrenaline increases the responsiveness 
of platelets has been the subject of this thesis. It is 
known that adrenaline interacts with its own specific 
cellular receptor on the platelet and this appears to be an 
a 2-adrenoreceptor(Grant and Scrutton,1979). The immediate 
post-receptor events in the platelet have not, so far, been 
determined. 
The differing choices of anticoagulant necessary for 
in vitro studies of platelet reactivity has lead to 
difficulties in interpreting the two phases of the platelet 
response to adrenaline. The response in heparin, and only 
to a small extent in citrate, has previously been reported 
to be of the 'primary' type (O'Brien et al.,1969). Primary 
aggregation is prostaglandin-independent, while the major 
response in citrate is prostaglandin-dependent (Best et 
al., 1980). It has been suggested that this 'secondary' 
aggregation is an artifact of citrated plasma (Mustard et 
al., 1975) but the findings reported here in Chapter 3 
indicate that secondary aggregation in response to ADP can 
occur if the heparin concentration is lowered sufficiently. 
The calcium chelating effects of an anticoagulant such as 
citrate are therefore not a prerequisite for prostaglandin-
dependent or second phase aggregation. 
Another criticism of the use of citrate as 
anticoagulant arises from the belief that it is the 
reduction in available calcium which reduces the primary 
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phase of adrenaline-induced aggregation. This may be so, 
but the presence of citrate does not, however, prevent 
adrenaline potentiating the response to other agonists 
(Grant and Scrutton, 1980a). Furthermore, this ability to 
potentiate is not inhibitable by aspirin (Rao et al.,1980a) 
and is therefore achieved by a prostaglandin-independent 
mechanism, which is expected to involve calcium 
redistribution without decreases in intra-platelet c'AMP 
(Rao et al., 1980b; 1981a). Citrated plasma was used in 
their experiments and in the experiments reported here in 
Chapters 4 to 7. Owen and Le Breton (1981) used a 
chlortetracycline probe to observe a release of 
intraplatelet membrane-bound calcium after adrenaline 
stimulation which was partially inhibited by indomethacin. 
Further evidence that calcium redistribution is involved in 
the thromboxane-independent mechanism has been obtained by 
Brass and Shattil(1982). These authors found that both ADP 
and adrenaline increased the number of surface membrane 
affinity sites for calcium in aspirin treated platelets. 
These agonists also increased the rate of calcium exchange 
into the intracellular pool without increasing the net 
amount of calcium. 
Several authors have studied adrenaline potentiation 
of other agonists since it was first demonstrated by Ardlie 
et al.(1966). Chapter 3 reports on the extension of these 
1n vitro studies to three or four agonists in combinat ion, 
instead of the paired combinations employed previously. 
Circulating blood obviously contains several possible 
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platelet agonists albeit at low concentrations. For the 
multiple agonist experiments, heparin was chosen as the 
anticoagulant to more closely reflect the in vivo 
situation. The study demonstrated that aggregation of 
platelets was possible in vitro using concentrations of 
catecholamines which could be achieved in vivo. The 
previously published lowest levels achieving aggregation in 
vitro were still higher than in pathological states (Grant 
and Scrutton, 1980a). The reduced sensitivity to multiple 
agonists in citrate compared to heparin suggests that 
calcium may be involved in the potentiation mechanism. 
The mechanism of adrenaline potentiation was explored 
in Chapter 4. The findings are in agreement with those of 
Rao et al.(1980a) to the extent that adrenaline stimulates 
b~th prostaglandin dependent and independent pathways when 
potentiating ADP. The results differed in being able to 
show by radioimmunoassay, small increases in cyclooxygenase 
activity due to adrenaline despite the presence of the 
cyclooxygenase inhibitor, aspirin, but only when high 
concentrations of arachidonate were used. In the presence 
of thromboxane inhibitors, higher concentrations of 
adrenaline are required to achieve the same extent of 
aggregation as in the absence of these inhibitors. 
Therefore, the thromboxane-dependent pathway represents the 
more efficient mechanism of adrenaline potentiation. 
It is suspected that both the prostaglandin-dependent 
mechanism and prostaglandin-independent mechanism of 
adrenaline potentiation occur via stimulation of the a 2 -
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receptor since the activity of adrenaline can be mimicked by 
clonidine, a partial a 2-receptor agonist. The experiments 
using phenoxybenzamine and dibenamine are difficult to 
interpret, but do not preclude post-receptor events 
involving calcium mobilization. 
Arachidonic acid release by adrenaline may involve 
activation of phospholipase A2. The effects of putative 
phospholipase A2 inhibitors were therefore examined and the 
findings are reported in Chapter 5. The surprising result 
with the use of BPB or TPCK was that, rather than enabling a 
prostaglandin-independent pathway to be examined, these 
inhibitors revealed that an alternative source of 
arachidonic acid could be released for thomboxane 
production. Despite the awareness of the lack of 
specificity of phospholipase A2 inhibitors, which has been 
well documented in the case of BPB, it is nevertheless 
suggested that adrenaline stimulates the release of 
arachidonic acid via diglyceride lipase. This pathway is 
the only known source not involving phospholipase A2 enzymes 
(Bell et al., 1979). BPB has been shown to inhibit 
diglyceride lipase in platelet extracts but not in intact 
platelets (Hofmann et al., 1982). The potentiation of 
thromboxane production in the presence of BPB or TPCK is in 
agreement with the work of Vargaftig (1976). 
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Thromboxane-independent potentiation of ADP-induced 
aggregation by adrenaline was shown to be possible in the 
presence of phenothiazines, inhibitors of several enzymes, 
including calmodulin-dependent enzymes. Because it has 
been shown that ADP increases PA turnover(Lloyd et al., 
1972) it is conceivable that adrenaline increases kinase 
activity and thus PA formation, in the presence of 
phenothiazines, rather than stimulating arachidonic acid 
release. The findings of Chapter 5 are therefore 
consistent with those of Chapter 4 in that adrenaline may 
influence PI metabolism. This remains to be confirmed by 
biochemical analysis. It is also possible that adrenaline 
in the presence of other agonists may promote calcium 
mobilization independently of PI metabolism. 
Since there was some doubt about the possibility of 
diglyceride lipase being active in the presence of BPB 
(Hofmann et al., 1982) the effects of exogenous 
phospholipase C in the presence of BPB were examined. 
Aggregation, release of nucleotide and phospholipid 
metabolism due to exogenous phospholipase Care the subject 
of Chapter 6. This Chapter also includes an investigation 
of possible inhibitors of phospholipase C and the effects 
of these on thrombin-induced aggregation and phospholipid 
metabolism. 
Exogenous phospholipase C caused the formation of a 
small amount of TXA 2 associated with aggregation. In the 
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presence of BPB, TXA 2 formation increased while aggregation 
was partially inhibited. This parallels the increase in 
TXA 2 observed when adrenaline potentiates ADP. In 
the 
presence of BPB, release of nucleotide due to exogenous 
phospholipase C was largely inhibited but a small 
indomethacin-sensitive peak of release still occurred. 
Phospholipid analysis indicated increased external PC 
breakdown without a corresponding conversion to PA in the 
presence of BPB. In addition, phospholipase C-induced 
aggregation in the presence of BPB was inhibited by 
indomethacin. These data are consistent with diglyceride 
lipase being more active in the presence of BPB. This 
would increase arachidonic acid release from diacylglcerol 
and thus increase TXA 2 formation. It could also divert 
diacylglycerol away from PA production, providing a 
mechanism for the inhibition of threshold phospholipase C-
induced aggregation by BPB. Interference at this level 
could alter phosphorylation reactions essential for release 
and aggregation. 
Similar experiments were performed with thrombin 
replacing exogenous phospholipase C. Thrombin activates 
endogenous phospholipase C, forming diacylglycerol from 
phosphatidylinositol-4,5-bisphosphate (Broekman, 1984) 
Since it was found that BPB did not affect PI breakdown due 
to thrombin, and TXA 2 was not estimated, these experimen t s 
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neither confirmed nor denied that the lipase could be more 
active in the presence of BPB. 
Inhibitors of phospholipase C-induced aggregation may 
have different mechanisms of action. For example, spermine 
prevented phosphatidic acid production but trimetoquinol 
did not. Perhaps trimetoquinol inhibits a step in the 
activation pathway beyond diacylglycerol and PA formation. 
The above evidence, based on aggregation studies with 
associated TXA 2 formation and nucleotide release required 
support from biochemical analyses of membrane 
phospholipids which were subsequently undertaken. The 
important question of adrenaline effects on phospholipid 
metabolism, and in particular, PI turnover, in the presence 
or absence of certain inhibitors could only be answered by 
quantitation of the relevant phospholipids. Chapter 7 
reports on the development of a paper chromatographic 
method for the separation of phospholipids. This method 
has the particular advantage of separating PA with good 
resolution for assay by phosphorus content or radioactive 
label. PI can also be quantitated but different 
polyphosphoinositides could not be distinguished. 
Adrenaline has been shown to increase 32Pi 
incorporation in PI and PA of the rabbit iris muscle 
(Abdel-Latif, 1974), while ADP causes a decrease in 
phosphatidylinositol-4,5-bisphosphate associated also with 
increased turnover of PA(Vickers et al.,1982). The results 
reported in Chapter 7 are inconclusive but certainly 
indicate that adrenaline behaves in a different manner to 
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either ADP or thrombin with respect to phospholipid 
metabolism. The preliminary results obtained indicated 
that, when adrenaline potentiates ADP-induced aggregation, 
increased turnover of PI and PA is difficult to observe. 
Previous Chapters indicated that BPB may inhibit 
diacylglycerol kinase but this was not supported, since the 
amount of PA and the turnover of PA did not alter in the 
presence of BPB. In the presence of BPB, however, 
adrenaline and ADP seemed to increase incorporation of 3H-
arachidonic acid in PI, without increasing the amount of 
PI. Further investigation of PI metabolism with respect to 
changes among the different inositide classes should be 
undertaken. In the presence of BPB an exaggeration of the 
adrenaline effects on PI cycling may occur. Some evidence 
for the involvment of calcium in the potentiation mechanism 
has been presented in this thesis, and if, indeed, 
adrenaline does not alter PI metabolism in the initial 
stages of platelet interaction, then calcium mobilization 
could occur independently of the PI-effect. 
8.2 CONCLUSIONS 
1. With low concentrations of heparin as anticoagulant, 
adrenaline can cause potentiation of aggregation in vitro 
at concentrations which can be found in the circulation, 
supporting the theory that adrenaline plays a role in 
facilitating platelet activation at sites of vascular 
injury. 
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2. The calcium chelating effects of citrate are not a 
prerequisite for prostaglandin-dependent aggregation due to 
adrenaline. Citrate indeed may reduce the potentiating 
effects of both vasopressin and adrenaline, indicating the 
importance of calcium availability. 
3 There must be at least two mechanisms by which 
adrenaline can potentiate platelet aggregation, firstly by 
causing increases in cyclooxygenase activity, and secondly, 
by a cyclooxygenase-independent mechanism, probably both 
involving a 2-receptor interaction. The cylcooxygenase-
dependent pathway is the more efficient mechanism of 
adrenaline potentiation. 
4. In the presence of certain phospholipase A2 
inhibitors, namely BPB and TPCK, adrenaline increases TXB 2 
formation due to ADP, possibly due to increased release of 
arachidonic acid. This increased release, via a non-
phospholipase A2 pathway, may be due to stimulation of 
diacylglycerol lipase by adrenaline. 
5. The immediate post-receptor events in the adrenaline 
response, may involve changes in phospholipids caused by 
other agonists and in particular, changes in the PI cycle. 
Adrenaline may influence diacylglycerol production or 
metabolism by ADP and thus influence a calcium-independent 
pathway via protein kinase C. 
6. Further examination of the effects of dibenamine on 
adrenaline activation may reveal any possible influence of 
adrenaline on membrane calcium distribution independent of 
the PI-cycle. 
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7. The response to exogenous phospholipase C does not 
mimic the response to endogenous PI-specific phospholipase 
C. This may be because outer leaflet PC, the substrate for 
exogenous phospholipase C, does not participate in the 
cycling series of reactions. Nevertheless, the rapid 
formation of diacylglycerol by exogenous phospholipase C 
could be exploited for examining the importance of this 
compound. 
8. Since phospholipase C induced aggregation in the 
presence of BPB occurs with an increased production of 
TXB 2 , it is tempting to believe that diacylglycerol lipase 
is active while other routes for diacylglycerol metabolism 
are inhibited by BPB. This could not however, be 
confirmed with thrombin-induced aggregation. 
9. The indication that adrenaline promotes 
diacylglycerol formation, but not PA formation should be 
examined further with respect to polyphosphoinositides. 
Changes in phospholipids due to adrenaline as measured by 
paper chromatography are difficult to observe. 
10. The evidence from other workers that adrenaline by 
itself does not influence PI turnover, nor calcium uptake, 
in the initial interaction with platelets, should not 
deter investigation of these possibilities in relation to 
the mechanism of adrenaline potentiation of other agonists. 
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